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Abstract: This study examined the effects of prenatal exposure to methadone on clinical and 
neurobehavioural outcomes of infants between 40 and 42 weeks gestation. The aims of this study were: 
(a) to describe clinical and neurobehavioural outcomes of infants exposed to methadone during 
pregnancy, (b) to examine the effects of maternal methadone dose during pregnancy on infant clinical 
and neurobehavioural measures, and (c) to examine the extent to which associations between exposure 
to methadone during pregnancy and infant outcomes persisted after statistical control for a range of 
confounding variables. Two groups of study infants were recruited. These consisted of 51 consecutively 
recruited infants born to mothers maintained on methadone during their pregnancy and 42 randomly 
identified non-methadone exposed comparison infants. Prior to her child‟s birth, each pregnant woman 
completed a comprehensive maternal interview. At birth and during the infant‟s hospital stay a broad 
perinatal data-base was collected. At 42 weeks gestation infants underwent a neurobehavioural 
assessment including the NICU Network Neurobehavioural Scale (NNNS; Lester & Tronick, 2004) and 
infant cry analysis. Study results showed significant differences across several clinical and 
neurobehavioural measures. Infants exposed to methadone in utero were found to be significantly 
lighter (p<.0001), have smaller head circumferences (p=.001), and spend longer in hospital (p<.0001). 
Neurobehaviourally, they were significantly less well regulated (p<.0001), less attentive (p=.004), more 
easily aroused (p=.001), more excitable (p<.0001), and more hypertonic (p=.001). In addition, they 
exhibited less motor maturity (p<.0001), displayed more stress abstinence symptomatology (p<.0001), 
and required more support from the assessor in order to remain in an appropriate state (p=.031). 
Concurrent analysis of infant cry characteristics revealed no significant differences between the 
fundamental frequencies (p=.764) or the melody contours (p=.453) of the two groups. However, infants 
prenatally exposed to methadone did display higher levels of frequency perturbation in their cries, as 
evidenced by analysis of their jitter factor (p=.012) and percentage of directional jitter (p=.015). 
Analysis of the effects of maternal dose during pregnancy suggested that maternal dose levels above 
60mg/day were general indicative of poorer infant outcomes than those below 60mg/day, with 
significant linear trends occurring across a number of measures. The extent to which associations 
between methadone exposure during pregnancy and infant outcomes reflected either a) the direct effects 
of methadone exposure and/or b) the effects of confounding factors correlated with maternal methadone 
use was examined using regression analysis. The results of this analysis for infant clinical outcomes 
showed confounding variables attenuated the effects of methadone exposure on infant birth length and, 
to some degree, infant head circumference. In contrast, associations between methadone exposure 
during pregnancy and most neurobehavioural outcomes remained significant, suggesting that maternal 
methadone use during pregnancy is an important, independent predictor of infant neurobehavioural 
functioning. These findings support the view that prenatal exposure to methadone has at least short term 
impacts on the infant‟s central nervous system (CNS) development. Important implications of possible 
vulnerabilities faced by these infants and their families are discussed. 
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The Effects of Prenatal Exposure to Methadone on Clinical and 
Neurobehavioural Outcomes of Infants Measured at Term 
 
Introduction 
 
1.1 Setting the Scene – An Overview of the Area of Opiate Abuse 
 
1.1.1 The International Cost of Opiate Abuse  
 
The social and economic costs of drug abuse and addiction are enormous. In the United 
States an estimated 10% of people suffer from alcohol or drug abuse or dependence, with 
over 7.5 million requiring treatment for a diagnosable drug problem and 18.6 million 
needing treatment for a serious alcohol problem. (U.S. Dept of Health & Human Services, 
2003) 
 
Similar statistics in New Zealand indicate that approximately 6% of people will meet 
clinical criteria for drug or alcohol abuse or dependence in their lifetime, with around 
45,000 people receiving drug and alcohol assessment and treatment services each year 
(New Zealand Country Report, 2001).  
 
Among the most used and abused of all illicit drugs are opiates. Naturally occurring 
opiates are derived from the resin of the opium poppy and have been used medicinally for 
centuries (Terry & Pellens, 1970). Opiates provide the user with an intense feeling of 
pleasure and wellbeing (commonly known as a “rush”), while feelings of pain, hunger, and 
sexual desire are diminished. However, opiates are highly addictive both psychologically 
and physically. The most commonly abused opiate derivative is the illicit drug heroin. 
Recent estimates suggest that as many as nine million people worldwide are dependent on 
heroin (United Nations Office for Drug Control and Crime Prevention as cited in Crandall, 
Crosby, & Carlson, 2004). 
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1.1.2 Treatment of Opiate Abuse  
 
Both in New Zealand and internationally, the primary method of treatment for opiate 
addiction is methadone maintenance (Kandall, Doberczak, Jantunen, & Stein, 1999; 
Preston, 1999). Methadone (6-dimethylamino-4, 4-diphenyl-3-hepatone-hydrochloride) is 
a synthetically manufactured opioid agonist. Its properties are similar to those of other 
opiates in that it affects both the central and peripheral nervous systems. Methadone binds 
to the same peptides as other opiates, thereby reducing the cravings and withdrawal 
symptoms for those dependent on opiates. However, because it has a much longer half life, 
it does not provide the same peaks and troughs and is therefore considered a more “stable” 
drug (Preston, 1999). Hence, methadone substitution is used as a licit and controlled means 
of treating opiate dependence in order to help the user abstain from criminal activity and to 
facilitate a more productive and stable lifestyle.  
 
Methadone maintenance treatment in New Zealand was first established in Christchurch 
during the early 1970s. In the late 1980s the evidence base for this maintenance modality, 
coupled with a greater awareness of the public cost of opiate addiction, led to an 
exponential increase in methadone maintenance enrolments, from 567 in 1990 to over 
3,600 in 1999 (Preston, 1999). Waiting lists for methadone maintenance treatment 
programmes remain long.  
 
1.1.3 Opiate Abuse and the Use of Methadone Maintenance Treatment During 
Pregnancy 
 
Currently, women of childbearing age make up approximately half of all methadone 
maintenance enrolments in New Zealand (Fallowfield & Hood, 2004; Preston, 1999). In 
1997, the National Institute of Health recommended methadone maintenance as the 
standard of care for pregnant women dependant on opiates (Berghella et al., 2003), despite 
pregnant women having been excluded from all randomized trails of methadone 
maintenance (Berghella et al., 2003). Growing enrolments, coupled with New Zealand‟s 
policy of considering pregnant women a priority group for methadone maintenance 
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treatment (Protocol for Methadone Maintenance Treatment in New Zealand, 2001), has 
resulted in increasing numbers of children being born to women maintained on methadone 
during their pregnancy. 
 
Furthermore, the average methadone dose being prescribed to pregnant women also 
appears to be on the rise. Although earlier international guidelines recommended dose 
ranges of 20 -40 mg per day be used with pregnant women (Chasnoff, Hatcher, & Burns, 
1982; Ostrea, Chavez, & Strauss, 1976; Rosen & Pippenger, 1976), more recently reported 
maternal doses are much higher (Berghella et al., 2003; Choo, Huestis, Schroeder, Shin, & 
Jones, 2004; McCarthy, Leamon, Parr, & Anania, 2005). To date there have been no 
empirically supported guidelines to aid clinicians in their decisions about the appropriate 
dosage and safe use of methadone maintenance during pregnancy. 
 
Although research has generally demonstrated that methadone maintenance during 
pregnancy is associated with a significant number of benefits in comparison to illicit drug 
use, the teratogenic effects of methadone maintenance upon the developing foetus continue 
to be an issue of debate (Finnegan, 1991). In particular, given the apparent trends of 
increasing maternal dose, the possible implications of this is large. Both socially and 
economically there is a pressing need to empirically evaluate the newborn child and gain a 
better understanding of the effects of prenatal exposure to methadone.   
 
1.2 Understanding the Effects of Methadone Exposure on the Developing Foetus 
 
In order to better understand the implications of findings of methadone exposure at birth it 
is pertinent to first understand the possible mechanisms by which exposure in utero takes 
place. The following section provides a synopsis of how methadone affects the foetus in 
utero. It concludes with a section on the impact of methadone on the foetal brain and 
central nervous system (CNS). 
  
In a simplified manner, the impact of methadone exposure on the developing foetus can be 
classified under pathways. Szeto (1995) described the impact of methadone exposure on 
the developing foetus as taking effect via two pathways: direct and indirect. 
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1.2.1 The Direct Pathway 
 
The direct pathway primarily delineates the potential bio-pharmacological effects that 
occur via placental transfer of methadone from the mother to the opiate binding sites of the 
foetus. Given ethical boundaries, much of what is known about the pharmacology of the 
direct pathway comes from animal studies. It is known that methadone is transferred across 
the placenta, with this occurring as early as 14 to 16 weeks gestation (Blinick, Inturrisi, 
Jerez, & Wallach, 1975, cited in Rosen & Johnson, 1993). It is also evident that transfer 
occurs at increasing levels over the gestation period (Kandall et al., 1999). Research has 
shown that, at low doses, prenatal methadone exposure is associated with behavioural 
excitation of the foetus, tachycardia, EEG activation, and respiratory stimulation. In 
contrast, higher doses of methadone cause behavioural sedation, EEG slowing, and 
respiratory depression in the foetus (Szeto, 1995).  
 
In recent years a small number of bio-medical studies have utilised human placental tissue 
to examine the circulation and metabolism of methadone in the foetus. Findings of one 
such study showed that although methadone is transferred very rapidly to the human foetus 
(with the majority of transfer occurring within the first hour), clearance of methadone 
occurs at a significantly higher rate from the foetus back to the mother (Nanovskaya et al., 
2004). 
 
1.2.2 The Indirect Pathway 
 
The second pathway, known as the indirect pathway, encompasses all other methods by 
which maternal methadone might affect the developing foetus. This includes influences 
such as changes in maternal physiology and sociological factors related with maternal 
methadone use. This pathway exemplifies the need for a comprehensive understanding of 
the maternal pregnancy history and the need for a multidisciplinary approach to 
understanding the effects of methadone exposure on the developing foetus. 
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Indirect effects of methadone on the foetus via maternal physiology include depression in 
maternal respiration and reduction of uterine blood flow. These, in turn, alter the delivery 
of oxygen and substrates to the foetus which can result in foetal hypoxia or 
hypoglycaemia, both of which have been shown to affect foetal EEG and foetal breathing 
activity (Szeto, 1995) 
 
Sociological factors implicated in the indirect pathway include factors related to 
environment and lifestyle choices. These include maternal health, prenatal care, and 
maternal nutritional intake, all of which need to be acknowledged as confounding the 
effects of methadone transferred via the direct pathway.  
 
1.2.3 Impact on the Foetal Brain and Central Nervous System 
 
The action of both pathways (direct and indirect) raises important concerns about the 
effects that prenatal exposure to methadone may have on the developing CNS in particular 
the foetal brain. A number of studies have examined this area more specifically. First, it 
has been shown that the brain is one of the primary organs used to store methadone during 
the gestation period (Kandall et al., 1999). Second, exposure to methadone has been shown 
to have disruptive effects on several neurotransmitter systems, including dopamine, 
norepinephrine, and serotonin within the brain (Malanga & Kosofsky, 1999; Robinson, 
Maher, Wallace, & Kunko, 1997). Third, both animal and human studies suggest that while 
methadone exposed infants may show relatively normal brain cytoarchitecture, they have 
been found to have smaller intracranial hemidiameter measurements and smaller lateral 
ventricle measurements, implying slower cortical cerebral growth (Nassogne, Gressens, 
Evrard, & Courtoy, 1998; Pasto et al., 1989). For example, Pasto et al. (1989) studied the 
sonographic characteristics of the cerebral ventricles, the transverse measurements of 
intracranial hemidiameter, right and left lateral ventricles, and temporal lobe and thalamic 
area measurements in 46 infants born to opiate dependent mothers and 31 controls. They 
found significantly different cerebral ventricle measures and smaller intracranial 
hemidiameter measures in the two groups. In a review of the mechanism of action of drugs 
of abuse, Malanga et al. (1999) argued that research has consistently shown that gestational 
opiate exposure results in a decrease in nucleic acid synthesis and protein production, both 
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of which are factors shown to impair brain growth. Robinson (2000) gave a thorough 
explanation as to how gestational methadone exposure may delay and disrupt cholinergic 
development, particularly in the striatum, which has been hypothesized to result in 
neuronal changes. Finally, Lester et al. (2003), examining the auditory brain stem response 
of one-month-old opiate exposed infants, found evidence for exposure affecting neural 
transmission. These findings suggest that there are likely to be both transient and persistent 
structural changes in the neurological development of infants prenatally exposed to 
methadone, raising important concerns about the neurodevelopmental effects that these 
changes may have on the child‟s future development.  
 
1.3 Review of Previous Research on the Effects of Prenatal Methadone Exposure 
When Measured at Birth 
 
The effects of methadone exposure on the CNS system of a developing human foetus 
discussed above can be understood as decreased neurodevelopmental integrity of the 
newborn infant, leaving the developing infant vulnerable to later difficulties. For instance, 
the findings of previous animal based research have suggested that prenatal exposure to 
methadone may result in both an increase in sensitivity to novel or reinforcing stimuli 
(Malanga & Kosofsky, 1999) and an impairment in directed motor co-ordination 
(Robinson, 2000). In order to have the least disruption to development it is important to 
identify and address potential vulnerabilities as early as possible. Therefore, it is essential 
to employ assessment techniques at birth to gain a better understanding of how these 
vulnerabilities may manifest in the newborn infant.  
   
The following section reviews the findings of some of the more recent research on the 
effects of methadone exposure during pregnancy on the developing infant as measured at 
birth. A comprehensive review of earlier studies was undertaken by Householder, Hatcher, 
Burns, and Chasnoff (1982). For functionality and ease of understanding, this review will 
be divided into three sections: 
 
1. Clinical outcomes associated with prenatal methadone exposure when measured at 
birth. 
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2. Neurobehavioural outcomes associated with prenatal methadone exposure when 
measured at birth, including discussion of neurobehavioural assessments and cry 
analysis. 
3. Review of infant outcomes in relation to maternal methadone dose when measured at 
birth. 
 
Appendix 1 provides a tabular overview of a number of studies relevant to the area.  
 
1.3.1 Clinical Outcomes Associated with Prenatal Methadone Exposure When 
Measured at Birth 
 
The simplest and possibly most rudimentary means of examining the effects of prenatal 
methadone exposure on the developing infant is via clinical measurements taken at the 
infant‟s birth. Clinical measurements include gestational age, weight, length, and head 
circumference. Almost all studies examining the effects of prenatal exposure to methadone 
at birth have provided at least two of these measurements. In many cases duration of 
hospital stay and infant APGAR scores are also considered as part of the infant‟s clinical 
outcome profile. APGAR scores are a popular quick and efficient measure of newborn 
health taken directly after birth (Apgar, 1953). The infant is assessed and scored across five 
measures: skin colour (Appearance), heart rate (Pulse), reflex irritability (Grimace), 
muscle tone (Activity) and respiration (Respiration). Scores range between zero and ten. A 
repeatedly low score is indicative of an infant that requires immediate medical attention. 
 
Previous research suggests that methadone exposed infants are at an increased risk for 
early delivery. A number of studies have calculated the mean delivery of methadone 
exposed infants as being around 38 weeks gestation (Jeremy & Hans, 1985; Kuschel, 
Austerberry, Cornwell, Couch, & Rowley, 2004; Lejeune, Simmat-Durand, Gourarier, & 
Aubisson, 2006; McCarthy et al., 2005; Rosen & Johnson, 1988; Sinha et al., 2001). 
Although this may not be considered premature (conventionally accepted as below 37 
weeks), it is still lower than the typically accepted average of 40 weeks, and in conjunction 
with other clinical outcomes it is notable.  
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Several studies have found infants exposed to methadone in utero have lower birth 
weights; most typically citing mean weights around 2,700 gm (Berghella et al., 2003; 
Blinick, Jezez, & Walach, 1973; Hagopian et al., 1996; Kuschel et al., 2004; Lejeune et al., 
2005; McCarthy et al., 2005; Rosen & Johnson, 1988; Sinha et al., 2001; Sharpe & 
Kuschel, 2003). Given the substantial lack of control groups and typically low sample sizes 
in these studies, significance levels relating to these lower birth weights are frequently not 
provided, but they are often notably lower than the New Zealand average of 3,410 gm 
(New Zealand Health Information Service, 2003). 
 
Surprisingly few of the studies reviewed have provided information on infant birth length, 
and those that have recorded length have generated a mixture of outcomes. Chasnoff, 
Burns, Burns, and Schnoll (1986) found a significant difference between the birth lengths 
of infants prenatally exposed to methadone (n = 51) in comparison to non-exposed controls 
(n = 27). However, Lester et al. (2002) reported no significant differences in birth length 
between 119 opiate exposed infants and a large sample of infants not exposed to opiates (n 
= 1,273). Sharpe and Kuschel (2003) found no significant difference between the birth 
lengths of 24 infants born to women on methadone maintenance treatment and birth 
lengths of children of 19 women prescribed methadone for the management of maternal 
pain, but did not compare either group to a non-exposed comparison group.  
 
Several previous studies conducted with infants exposed to methadone have noted that they 
have smaller head circumferences at birth (Bada et al., 2002; McCarthy et al., 2005; Rosen 
& Johnson, 1988; Sharpe & Kuschel, 2003). This is an important finding because head 
circumference has been directly correlated with IQ (Rushton & Ankney, 1996).  
 
Taken together, the clinical findings listed above may provide an indication of early 
vulnerability in these infants. Several studies of premature and/or low birth weight infants 
acknowledge a strong correlation between decreasing gestational age and birth weight and 
increasing rates of disability, including social, behavioural and learning problems (Davis, 
2003; Hack & Fanaroff, 2000; Taylor, Klien, & Hack, 2000), with one article stating that, 
“the relation between birth weight and IQ is usually linear in low birth weight groups – that 
is, the smaller the newborn the lower the IQ” (Wolke, 1998, p. 567). 
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Duration of hospital stays of these infants have been measured in a variety of ways. With 
some authors providing information on time in Neonatal Intensive Care Unit (Hagopian et 
al., 1996; Lejeune et al., 2006; Sinha et al., 2001) while others provide total time in 
hospital (Blinick & Jerez, 1973; Choo et al., 2004). Those studies that have provided 
information on the duration of infant hospital stay have cited means ranging from four days 
in NICU (Hagopian et al., 1996) to 23 days in NICU (Lejeune et al., 2006). For those that 
have provided information on total duration of stay, days in hospital have ranged as high as 
80 days (Choo et al., 2004). One study that specifically examined maternal drug use and 
the length of neonatal hospital stay reported that duration of stay was longest for infants 
exposed to methadone and other drugs (Johnson, Greenough, & Gerada, 2003). However, 
it should be remembered that caution needs to be taken when interpreting mean duration of 
infant hospital stay due to the variation in management and regulations of different 
hospitals across countries and regions. 
 
Finally, the only reported difference on APGAR scores at term was located in an older 
study in which ten percent of methadone exposed infants had depressed APGAR scores at 
birth (Blinick, Jezez, & Walach, 1973).  
 
1.3.2 Neurobehavioural Outcomes Associated with Prenatal Methadone Exposure 
When Measured at Birth     
 
1.3.2.1 Neonatal Neurobehavioual Assessments Outcomes 
 
A more sophisticated means of gauging the effects of prenatal methadone exposure at birth 
is via neurobehavioural assessments. These assessments determine the medical status of an 
infant via behavioural manifestation of the structural changes in CNS hypothesized to 
occur during foetal development (Mayes & Ward, 2003). In more simple terms, these 
assessments utilise the bi-directional nature of behaviour and neurological functioning to 
assess the infant on behavioural signs of neurological impairment. This provides a 
functional understanding of the nature of neurological impairments that can then be used to 
identify at risk infants and develop strategies to minimise areas of vulnerability. 
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The use of neonatal neurobehavioural assessments began in the mid 1900s, with early 
assessments utilising muscle tone and early reflexes to gauge an understanding of the 
infant‟s neurological status. From the later 1950s to the 1970s assessments advanced 
through the addition of more behavioural and attention-interactional components. One of 
the most well known newborn neurobehavioural assessments, the Neonatal Behavioral 
Assessment Scale (NBAS), developed by T. Berry Bazelton (1973), was developed around 
this time. More recently, neurobehavioural measures have been designed to assess specific 
populations. In neonates this includes areas such as prematurity (Premie-Neuro by Daily & 
Ellison, 2005) or neonatal drug exposure (NICU Network Neurobehavioural Scale, NNNS 
by Lester & Tronick, 2004).  
 
Typically, neurobehavioural assessments of infants exposed to drugs in utero have 
considered the behavioural symptomatology of neonatal abstinence syndrome (NAS). 
Studies suggests that as many as 48 to 95% of infants exposed to methadone in utero will 
show signs of neonatal abstinence (Preston, 1999; Sinha et al., 2001; Sarkar & Donn, 
2006). Evidence suggests that the incidence and severity of neonatal abstinence from 
methadone may be greater than in infants exposed to heroin and other opiates (Johnson et 
al., 2003). The combination of previous bio-medical and neurobehavioural research posits 
that although methadone may leave the blood stream within a few days of birth (Rosen & 
Pippenger, 1976, cited in Jeremy & Hans, 1985) it is excreted much more slowly from the 
body tissue to which it binds (Jaffe & Martin, 1980, cited in Jeremy & Hans, 1985). This 
delay results in the later onset of NAS, typically beginning between the second and fourth 
day (Sinha et al., 2001) with previous researchers finding that drug-free urine usually 
occurs around 7 to 21 days (Rosen & Johnson, 1993). As stated by Jeremy and Hans 
(1985), “while we are not able to answer questions about the biochemical status of 
withdrawal in these infants, their behavioural recovery is likely to be a good reflection of 
their status” (p. 325).  
 
Chasnoff, Schnoll, Burns, and Burns (1984) and Jeremy and Hans (1985) both utilised the 
NBAS to examine the neurobehavioural differences between newborn infants exposed to 
methadone during pregnancy and non-exposed controls. Relative to controls, infants 
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exposed to methadone were jerkier, tenser, more active, more irritable, and had difficulty 
with state control. 
 
Other studies utilising neurobehavioural measures have found evidence that infants 
exposed to methadone in utero have higher levels of irritability, lower levels of 
consolability, poorer state regulation, increased levels of overall activity coupled with 
decreased motor maturity, and reduced interacting responsiveness than comparison infants 
(Berghella et al., 2003; Blinick, Jezez, & Walach, 1973; Hagopian et al., 1996; Kuschel et 
al., 2004; Lejeune et al., 2006; McCarthy et al., 2005; Rosen & Johnson, 1988). Others 
have noted infant tremors, abnormal and ineffectual sucking, irregular postures, and sleep 
disturbances in exposed infants (Kaltenbach et al., 1987; Moore, Negrusz, & Lewis, 1998; 
Rosen & Johnson, 1993). 
 
Although many of these studies have demonstrated a consistent neurobehavioural profile, 
the majority have a number of methodological shortcomings. Primarily, the majority have 
used older neurobehavioural measures not specifically designed for use with infants 
exposed to maternal drug use during pregnancy and have failed to consider the influence of 
confounding variables. A more detailed discussion of the limitations of previous research 
is included in a later section. 
 
1.3.2.2 Acoustic Cry Analysis Findings 
 
Another form of neurobehavioural assessment is acoustical cry analysis. Since the early 
1960s, acoustical analysis of infant crying has been used as an inferential gage of a child‟s 
neurodevelopmental integrity. Because cry represents a combination of respiratory, 
laryngeal, and vocal tract functions, any unusual or deviant cry patterns are likely to be a 
reflection of poor organisation in either parasympathetic or sympathetic strands of the 
nervous system. In the early 1980s, Golub and Corwin (1985) developed a bio-behavioural 
model (known as the physioacoustic model) of infant crying that includes various acoustic 
parameters of crying and how they relate to the physiology and CNS of the infant. 
Appendix 2 provides the visual conceptualisation of the model offered by Golub and 
Corwin. The most common acoustic features examined in infant crying are fundamental 
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frequency (F0), cry duration, and the first and second formant frequencies (F1 and F2). 
Measurement of F0 is used to infer laryngeal behaviour, namely vocal fold vibration (i.e., 
pitch). Measurement of cry duration is used to infer respiratory effort, with respiratory 
capacity correlated with the overall length of infant crying. Measurement of F1 and F2 
frequencies is used to infer vocal tract articulation, namely vocal resonance. 
 
Although acoustic cry studies have been performed for some time, there are still 
surprisingly few studies of newborn cries, and the sample sizes used are typically quite low 
(Michelsson, Eklund, Leppanen, & Lyytinen, 2002). However, studies have successfully 
used acoustic cry analysis to detect subclinical effects in a variety of medical conditions 
and potential nervous system insults. A comprehensive listing of these, as summarized in 
Cacace, Robb, Saxman, Risemberg, and Koltai (1995), included “infants with 
chromosomal abnormalities, metabolic disorders, asphyxia, meningitis, cleft palate, 
laryngitis, unilateral vocal chord paralysis, sudden infant death syndrome, as well as 
infants that were premature, malnourished and whose mothers were addicted to heroin or 
who had used marijuana, cocaine or alcohol excessively” (p. 214). Additionally, a more 
recent review of the cry literature also included infants with the medical conditions of 
Krabbe‟s disease, hypothyroidism, hydrocephalus, Down syndrome, and cri-du-chat as 
well as infants prenatally exposed to methamphetamines, tobacco, and lead (LaGasse, 
Neal, & Lester, 2005). 
 
Laryngeal behaviour appears to be influenced by abnormalities of CNS functioning. Such 
being the case, the acoustic parameter of F0 is often revealing of differences between 
healthy term babies and those of at-risk babies (Michelsson, Eklund, Leppanen, & 
Lyytinen, 2002). For example, Michelsson and Michelsson (1999) performed an acoustic 
analysis of pain cries on low birth weight and typical birth weight infants at 10 days of age 
and found that low birth weight infants were more likely to have a higher F0, display more 
rapid changes in F0 (gliding), and have more biphonation (evidence of two simultaneous F0 
patterns). Similarly, Zeskind, Platzman, Coles, and Schuetze (1996) examined the effects 
of prenatal alcohol exposure and found that at 14 days of age, exposed infants had reliably 
higher peak F0. The perceptual aspects of F0 (i.e., voice pitch) have also provided 
confirmation of cry abnormality. Studies reviewing the perceptions of high pitched cries 
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from vulnerable or ill infants have found that they are generally rated as more aversive and 
sick sounding (LaGasse et al., 2005; Ziefman, 2004) 
 
Another related, albeit less frequently used, cry measure of F0 is that of frequency 
perturbation. More commonly referred to as jitter or vibrato, frequency perturbation 
reflects the microfluctuations present in cycle-to-cycle differences in the F0 over time. In 
simple terms, jitter can be interpreted as an indicator of vocal stability. Given the premise 
that perfect control of the phonatory system would reflect no jitter, increased levels of jitter 
can be viewed as reduced control of the phonatory system (Baken, 1987). This is 
confirmed by findings that jitter tends to increase in vocal pathology (Orlikoff & Baken, 
1993). As a reflection of this, an earlier study by Graul, Hock, and Rothenger (1990) 
postulated that the jitter index of a pain cry yielded the best discriminatory parameter for 
the characterization of “normal” versus “disturbed” crying behaviour.  
 
Within the cry literature to date there has been a small amount of research into the cry 
characteristics of infants exposed to maternal opiate use during pregnancy (Blinick et al., 
1971 and Corwin et al. 1987 cited in LaGasse et al., 2005; Lester et al., 2002). Results 
from these studies parallel results obtained from infants known to demonstrate central 
nervous system insults. In general, the cries are characterised by a high F0 and short cry 
duration in comparison to controls. To date there appears to be only one study examining 
the cry characteristics of infants exposed to methadone in utero, that done by Huntington, 
Hans, and Zeskind, 1990. This study examined the average F0, F0 variability, peak F0, and 
duration of the first expiratory cry in eight infants prenatally exposed to methadone in 
comparison with 12 control infants matched for socio-economic status at two to three days 
old. As opposed to the findings of those that examined other opiate exposure, the results of 
this study found no difference across the measures of F0, and found that only the duration 
of the first cry differentiated the two groups. However, across both groups they found that 
cry characteristics did relate to later measures of developmental functioning. 
 
The review of literature in the area of infant cry provides a strong rationale as to why there 
is further need to investigate the cry characteristics of infants exposed to methadone during 
pregnancy. First, given the growing rates of prenatal methadone exposure and the uses of 
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infant cry analysis as a neurobehavioural gage of infant integrity it is surprising there has 
been only one study in this area. Such being the case, a clear profile of the cry behaviour in 
methadone exposed infants has yet to be established. Second, the conflict between the 
findings of Huntington et al. (1990) and those from studies examining other opiate 
exposure (Blinick et al, 1971 and Corwin et al, 1987 cited in LaGasse et al., 2005; Lester et 
al., 2002) indicates the need for further exploration utilising a more fine-grained measure 
of analysis, such as the use of F0 perturbation.  
 
1.3.3 Review of Infant Outcomes in Relation to Maternal Methadone Dose When 
Measured at Birth  
 
Another means of examining the effects of exposure to maternal methadone during 
pregnancy is to consider the impact of maternal methadone dose. However, a dose 
response relationship between maternal methadone dose and infant outcome has been 
difficult to establish (Finnegan, 1991; Kaltenbach, 1994). Some researchers have found 
evidence for a relationship (Dashe, Sheffield, Olscher, Todd, Jackson, & Wendel, 2002; 
Malpas, Darlow, Lennox, & Horwood, 1995; Sharpe & Kuschel, 2003; Sinha et al., 2001), 
while others have not (Brown, Bakeman, Coles, Sexson, & Demi, 1998; Jeremy & Hans, 
1985; Kuschel, et al., 2004; McCarthy et al., 2005). 
 
A study by Dashe et al. (2002) is typical of those finding a dose response relationship. 
They undertook a retrospective study of 70 women between the years of 1990 and 2001. 
They showed that methadone dose (based on maximum daily intake over the last week of 
pregnancy) correlated with the duration of neonatal hospitalisation, the neonatal abstinence 
score, and treatment for withdrawal (median dose 20 mg, range 0-150 mg). Both the 
maternal dose and the extent of infant treatment increased over the time period, with those 
on a higher methadone dose more likely to have been using illicit heroin as well. Similarly, 
a local Christchurch study by Malpas et al. (1995), again using a retrospective design, 
covering the period from 1987 to 1991, showed strong correlation between maternal 
methadone dose and both length of hospital stay and duration of neonatal treatment across 
the 40 mother-infant dyads studied. 
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In contrast, another retrospective (1996-1999) study of 100 mother/infant pairs around the 
same period found no evidence for a dose response relationship. Berghella et al. (2003) 
examined both average methadone dose during last 12 weeks of pregnancy and last 
methadone dose before delivery with a high/low cut-off of 80 mg/day. Highest neonatal 
abstinence syndrome scores and length of neonatal abstinence syndrome were similar for 
both groups across both methods of comparison. These authors suggested that a 
confounding variable, benzodiazepine use, may have been responsible for greater 
symptomatology of neonatal withdrawal. 
 
Despite the lack of overwhelming evidence for either side of the dose argument, trends in 
the administration of maternal methadone doses appear to be increasing over time 
(Wouldes & Woodward, submitted). This is possibly a reflection of current policy coupled 
with the natural increase in metabolism of methadone during pregnancy. Current policy in 
regards to both New Zealand and the United States suggests increasing methadone doses in 
pregnant women in accordance with the woman remaining symptom free with either 
arbitrary or no limits (Berghella et al., 2003; McCarthy et al, 2005). Despite the fact that 
optimum serum trough levels (between 150-600 ng/mL) have been established for non-
pregnant users of methadone maintenance treatment, there appears little or no attempt to 
adhere to these levels (Mccarthy et al., 2005). Likewise, despite the fact early international 
guidelines (although never empirically validated) recommended methadone dose levels of 
between 20-40 mg/day (Chasnoff et al., 1982) the reality is that these are often exceeded 
today and for example, the mean dose levels currently reported in New Zealand literature 
are closer to 65 mg/day (Wouldes, 2004). 
 
1.4 Methodological Issues and Limitations of Previous Research  
 
The following section outlines in more detail the methodological issues and limitations of 
the past research. These shortcomings provide further rationale in regards to the need for 
the current study. 
 
1.4.1 Age of Previous Studies 
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A large number of the studies which initially examined the effects of prenatal exposure to 
methadone were conducted in the 1970s. Now, more than a quarter of a century later, there 
have been several changes and advances in both medical knowledge and neonatal intensive 
care procedures. This is likely to have influenced findings as neonatal mortality rates have 
been significantly reduced (Preston, 1999) and more refined measurements for testing and 
data collection are now available.  
 
Furthermore, as already stated, there has been a general rise in maternal dose over the past 
three decades. One recent study by McCarthy et al. (2005) used 100 mg/day as the cut-off 
between high and low maternal doses. When compared with the earlier studies such as 
Chasnoff et al. (1984) or Jeremy and Hans (1985) who quote maternal ranges between 3-
40 mg/day this trend is quite apparent. Average maternal dose in New Zealand also 
appears to be above the early international recommendations. For example Wouldes (2004) 
reported the mean dose prescribed in Auckland drug treatment centres at 64.8 mg/day 
(range: 4-125 mg).  
 
1.4.2 Lack of Control Groups  
 
A fairly comprehensive review of the earlier studies by Householder et al. (1982) lamented 
a general lack of control groups in this area of research and stated that in “the majority of 
the studies that do report control groups, populations are frequently poorly defined or are 
not well balanced in terms of important demographic variables”, (p. 463) citing differences 
in racial breakdown as a prime example. Despite this, newer studies have continued to lack 
control groups (Choo et al., 2004; Kuschel et al., 2004; McCarthy et al., 2005) or only 
provided selective comparison groups making findings harder to generalise (Fajemirokun-
Odudeyi et al, 2006; Lejeune et al., 2006; Sharpe & Kuschel, 2003). 
 
1.4.3 Procedural Inadequacies  
 
Several criticisms can be made of the procedural methods used in many of the studies in 
this area. In particular, a substantial majority of studies in this area are approached as a 
retrospective study of hospital or clinic records (Berghella et al., 2003; Fajemirokun-
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Odudeyi et al, 2006; McCarthy et al., 2005; Sharpe & Kuschel, 2003). Although useful, 
this type of research has been criticised for using what are known as “post hoc” analyses. 
That is, the hypotheses to be tested and interpretations of causality are made after the data 
has already been collected. This can lead to an increased probability that results will be 
statistically significant (a Type I error). In order to examine a true association, hypotheses 
should be established first. Hypotheses should then be tested via manipulation of the 
independent variable on a target population. Finally, this target population should be 
evaluated against a randomly selected control population and differences between the two 
measured.  
 
A further criticism is the use of routine and changing hospital staff, for example nurses, in 
order to gather data. This is the case for almost all retrospective studies but also a number 
of prospective studies. (Choo et al., 2004; Hagopian et al., 1996; Sinha et al., 2001). This 
has several methodological drawbacks. First, subjective differences from utilising multiple 
assessors may have increased measurement inconsistency and error. Second, training 
requirements and inter-rater reliability of different raters are generally not documented. 
Third, the accuracy of measures may not have been as precise as are required in research. 
For instance, when measuring infants‟ head circumferences a matter of millimetres may 
make no functional difference for hospital staff but may reflect significant differences in 
research populations.  
 
1.4.4 Measurement Inadequacies and the Role of Confounding Variables  
 
Inadequacies can also be found in regards to the measurement tools used in this area of 
research. A number of earlier studies examining the neurobehavioural implications of drug 
exposure in utero used assessment measures that were not designed specifically for use 
with substance-exposed infants, such as the Brazelton Neonatal Behavior Assessment 
Scales (NBAS) (Jeremy & Hans, 1985; Rosen & Johnson, 1988). It is therefore likely that 
data gathered may not be as comprehensive or useful as is currently possible. Other 
frequently used assessment scales, such as Finnegan‟s Neonatal Abstinence Scoring 
System (Finnegan, Kron, Connaughton & Emich, 1975), offer a subjectively interpretable 
checklist of items, therefore limiting the value of the information. In addition, the use of 
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the Finnegan‟s Neonatal Abstinence Scoring System has been criticised in regards to its 
complexity and questioned as to the appropriateness of its use in busy clinical settings 
(Sarkar & Donn, 2006). Worse still, a few studies have provided little or no information at 
all on what measure(s) were used (Fajemirokun-Odudeyi et al., 2006; Hagopian et al., 
1996; Sinha et al., 2001). This can be particularly complicated given the lack of 
consistency and diversity of quality of tools used across this area of research. 
 
Similarly, in the area of cry analysis, there have been improvements in the technology 
related to signal processing that should be noted. In the past sound spectrography involved 
hand measures of spectrograms. Therefore, there has been a shift in the literature from the 
use of sound spectrography to newer computer aided digitisation of infant cries (often 
referred to as fast Fourier Transform or FFT). However, FFT has significantly reduced the 
finer detail of information gleaned from infant cries. It has been acknowledged by others 
(Berge et al., 1984 cited in Hopkins, 2000) that these computerised systems are not good at 
adequately identifying the components of a sound signal, for example, differentiating adult 
talking from an infant cry and FFT typically ignores more fine grained changes in the F0 
over time. Although computerised systems may provide a fast and efficient means of 
analysing basic components of infant cry (for example, maximum and minimum F0) some 
of the most sensitive measures such as F0 frequency perturbation (jitter) are lost. Given the 
advances in computerisation of sound spectrography use of this method is likely to provide 
more accurate results of infant cry.  
 
Two additional areas of measurement inadequacy in regards to cry research should also be 
noted. These are: 1.) sampling differences across infant crying and 2.) differences in the 
method of eliciting cries and types of cry elicited. First, previous researchers have sampled 
infant cry in a variety of different ways. While some have focused on the beginning of the 
infant cry and the first few utterance (Huntington et al., 1990; Lester et al., 2002) others 
have argued that information across the entire cry bout is pertinent (Gobermann & Robb, 
1999). Similarly, as explained by Hopkins (2000) while some researchers have included all 
sounds including fuss and whimpers as cry others have more narrow definitions. Second, 
infant cries have been elicited in a variety of ways and to date there remains no 
standardised procedure. As discussed in Cacace et al., (1995) techniques have ranged from 
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rubber bands to the infants heal, to vaccinations, to removal of electrodes used to monitor 
the infant‟s heart and respiration. Alternative methods have also included physical 
manipulation of the infant or the use of newborn reflexes. The aim of all these methods is 
to fully activate the infant‟s CNS yet little detail is often given as to why a procedure was 
chosen. Relatedly, the use of noxious stimuli to elicit infant cries has been criticised in 
regards to the detrimental loss of information of spontaneous, more naturally occurring 
cries (Green, Irwin & Gustafson, 2000). 
 
Finally, an important measurement shortcoming that has been repeatedly raised in regards 
to understanding the effects of prenatal methadone exposure is the lack of consideration of 
confounding variables (Householder et al., 1982; Jacobson & Jacobson, 2005; Kaltenbach, 
1994). This is a well acknowledged and difficult aspect in regards to any research 
examining the effects of drug exposure in utero. The most significant of these confounding 
variables is that of poly drug use and abuse. Indeed, single drug use is considered relatively 
rare with a large proportion of women acknowledging multiple drug use during pregnancy 
(Lester et al., 2001 cited in Coles and Black, 2006). This is difficult to take into account on 
several levels. First, given the illegality of most drug use women are frequently reluctant or 
unwilling to disclose information about personal use because of both legal and social 
consequences (Schuetze & Eiden, 2006). Second, alternative methods of verifying poly 
drug use, such as meconium or hair analysis, may be costly or difficult to arrange and are 
therefore often under utilised. Although most studies acknowledge the high probability of 
poly drug use in these pregnant women, few have run analyses that factor out the effects of 
poly drug use thereby making the influence of methadone itself difficult to extract from the 
related, often well established, risk factors (for example cigarette use or alcohol use during 
pregnancy). Studies that have considered confounding variables often suggest these have a 
strong influence on newborn outcomes. For example, Choo et al., (2004) suggested that 
maternal tobacco use during pregnancy may influence the timing and severity of NAS 
exhibited by infants prenatally exposed to methadone.  
 
Other confounding variables that are often less considered but have also been raised as 
important variables to consider are sociological variables (Kaltenbach, 1994). These 
include, but are not limited to, maternal age, maternal health, ethnicity and socio-economic 
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status. Although a skewedness in many of these variables may be a realistic representation 
and considered part and parcel of a drug abusing population a number of these factors are 
also proven risk factors that have been shown to influence foetal development and should 
therefore be considered or at least presented as maternal background data alongside the 
pregnant woman‟s drug use. Indeed, Cole and Black (2006) suggest that “the interaction 
between the effects of the teratogen and the effects of the environment is probably the most 
interesting scientific question in the field at this time” (p. 3).  
 
1.5 Synopsis of Previous Findings and their Limitations 
 
The majority of studies already conducted in the area of infant exposure to methadone in 
utero have utilised both clinical and neurobehavioural measures. Clinical measures 
commonly include gestational age, birth weight, head circumference, APGAR scores and 
duration of hospital stay. Findings have shown that infants exposed to methadone in utero 
are often born earlier, are lighter, have smaller head circumferences and longer stays in 
hospital. 
 
A variety of neurobehavioural measures have been used assess infants outcome. Findings 
have shown that infants exposed to methadone often show signs of withdrawal, may be 
easily upset, exhibit poorer but often more hypertonic muscle control  and display 
difficulty in ability to self-regulate. However, the complexity, design and sophistication of 
the measures vary considerably. Additionally, one study used infant cry analysis as a 
means of establishing the neurodevelopmental integrity of these infants. In contrast to 
other neurobehavioural measures this method found very few indications of difference 
between infants prenatally exposed to methadone and controls.  
 
However, previous research has several methodological limitations. Research is generally 
outdated, either having been conducted several decades ago, or utilising dated or unrefined 
measures. Few studies have utilised appropriate control groups, many have procedural 
inadequacies and the majority have not adequately considered the role of confounding 
variables.  
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1.6 The Current Study – Research Questions and Hypotheses 
 
The current study examines the effects of prenatal exposure to methadone on the clinical 
and neurobehavioural outcomes of infants at term. It addresses a number of the drawbacks 
of previous studies by utilising a prospective, between groups approach in combination 
with a number of comprehensive and up-to-date measures. Furthermore, it addresses the 
current debate of whether or not maternal methadone dose influences the outcome these 
infants and examines the much neglected issue of confounding variables.  
 
This final section explicitly outlines the aims and hypotheses of the current research. 
 
Specific Aim One 
To compare the effects of prenatal exposure to methadone on the clinical and 
neurobehavioural outcomes of infants at term. Infants born to mothers maintained on 
methadone during their pregnancy are compared with a sample of randomly identified non-
exposed infants. Clinical outcomes include birth weight (gms), birth length (cm), head 
circumference (cm), infant APGAR scores and duration of hospital stays. 
Neurobehavioural outcomes include the NNNS assessment and infant cry acoustics. 
 
Hypothesis One 
At term, infants born to methadone maintained women will have lower birth weights, 
smaller head circumferences and longer hospital stays than the comparison infants. 
 
Hypothesis Two 
At term, infants born to methadone maintained women will perform less well on a 
standardised neurobehavioural assessment compared to the randomly identified, non-
exposed infants. Specifically, infants exposed to methadone in utero will display poorer 
quality of movement, poorer regulation capacities and decreased attentional abilities, while 
demonstrating higher levels of non-optimal reflexes, muscle tone and stress/abstinence 
symptomatology in comparison to the non-methadone exposed infants.  
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Hypothesis Three  
At term, the cry acoustics of infants born to methadone maintained women will have a 
higher and more variable F0, shorter cry utterances and abnormal cry configurations when 
compared to the cries of non-methadone exposed infants. 
 
Specific Aim Two 
To examine whether higher maternal doses of methadone during pregnancy are associated 
with poorer clinical and neurobehavioural (NNNS) outcomes of these infants at term. 
 
Hypothesis Four  
Higher maternal methadone dose will correlate with lower infant birth weight, reduced 
infant head circumference and increased symptomatology of neonatal abstinence. 
 
Specific Aim Three 
To examine the role of confounding variables in relation to the findings reported in regards 
to the previous aims. Using statistical techniques, models outlining the role of confounding 
variables and their relationship to the impact of prenatal methadone exposure are 
constructed and interpreted.  
 
Hypothesis Five 
Confounding variables will reduce but not eliminate the effects of methadone exposure on 
the developing foetus. Certain confounding variables, such as cigarette use during 
pregnancy, will have an important role in accounting for any variance found between the 
infant‟s exposed to methadone in utero and the comparison non-exposed infants.  
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Methodology 
 
 
2.1 Ethical Approval of the Current Study 
 
The current study was undertaken as part of a larger multi-site study run by the Child 
Development Research Group at Canterbury University. Ethical approval for the current 
study was obtained by the senior investigator, Dr. Lianne Woodward under an umbrella 
application for the complete term assessment for the larger study (Woodward, Inder, 
McKie, Wouldes & Kuschel, 2002). Ethical approval was obtained from the Canterbury 
Ethics Committee.  
 
2.2 Participants and Recruitment 
 
The methodology of the current study used a prospective, between groups approach.  
The following two groups were included in this study. 
 
2.2.1 Group 1 – Methadone Maintenance Group 
 
Fifty pregnant women consecutively enrolled in the Christchurch Methadone Maintenance 
Programme were recruited via the Methadone in Pregnancy Clinic provided by the 
Women‟s Health Division of the Canterbury District Health Board (CDHB). These women 
were referred via the Community Alcohol and Drug Service (CADS) Methadone 
Maintenance Programme between November 2002 and December 2005. Recruitment of 
this group was conducted by a research nurse from Christchurch Women‟s Hospital as part 
of the larger study. The research nurse attended the methadone clinics and the antenatal 
classes that all methadone maintained women attended as part of their treatment. At these 
meetings she offered information on the study, answered women‟s questions and obtained 
consent from those women who agreed to participate. On a number of occasions the 
research nurse was also accompanied by the research group‟s Maori cultural health advisor 
to ensure that any cultural needs were being met and to ameliorate any culturally-based 
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biases that may have been occurring at the recruitment stage. All women involved with the 
CADS Methadone Maintenance Programme give birth at Christchurch Women‟s Hospital. 
This enabled the research nurse to be available for these women and also to inform 
members of the research group when a recruited infant was born.  
 
Exclusion criteria for this group included infants born with serious congenital 
abnormalities, still births and premature deliveries of less than 33 weeks gestation. For 
pragmatic reasons, pregnant women who were unable to speak or understand English 
sufficiently to give informed consent and those outside the Canterbury region were also 
excluded from the study. In addition, three pregnant women on the methadone 
maintenance programme who did not regularly attend the methadone maintenance 
programme and therefore whose methadone dose records were incomplete were excluded.  
 
Table 1 displays the recruitment statistics for the methadone exposed group. A total of 76 
pregnant women were approached of which, 50 agreed to participate. This equates to a 
recruitment rate of 66%. However, of the 26 that did not agree to participate, over half 
were not recruited due to ineligibility criteria for instance living outside of the recruitment 
area, lack of consistent attendance at the methadone clinic or termination of pregnancy. 
The remaining ten ineligible cases were refusals to consent, either by the pregnant women 
herself (n = 7) or refusal by her partner (n = 3). After factoring out ineligible cases (n = 
16), the recruitment rate for this group can be considered 82%. 
 
Table 1  
Recruitment Statistics of the Women Enrolled in Methadone Maintenance Treatment 
Recruitment type Number of participants % of total contacted 
Contacted 76 100 
Recruited and Consented 50 66 
Not recruited 26 34 
 
Ineligibility Criteria Number of participants  % of total not recruited 
Participant refused 7 27 
Partner of participant refused   3 12 
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Foetus ineligible* 8 31 
Other ineligibility** 8 31 
*congenital abnormalities, still birth, miscarriage, termination, born less than 30 weeks 
gestation 
**out of catchment area, irregular attendance of methadone programme, not able to 
understand English sufficiently 
 
2.2.2 Group 2 – Non-Methadone Exposed Control Group 
 
Over the same period, 42 pregnant women used for control comparisons were recruited at 
random from the Christchurch Women‟s Hospital delivery database. Randomisation was 
used to identify control participants in order to provide a representative sample of non-
methadone exposed comparison infants. A randomized method of recruitment was chosen 
because previous experience attempting to match for factors such as cigarette smoking 
have proved to be extremely difficult to achieve due to low rates of disclosure (Wouldes, 
2004). Furthermore, by using random recruitment it was anticipated that the disclosed rates 
of cigarette smoking and other drug use would more accurately represent national/regional 
rates, thus allowing these factors to be included as covariates in the multivariate analyses 
of the relationship between methadone exposure and infant outcome. 
 
The recruitment of the control mother-infant dyads was conducted by the author of the 
study with aid from the research co-ordinator of the larger study. A database including 
names, addresses and expected dates of delivery of all women listed to give birth at 
Christchurch Women‟s Hospital was obtained via the hospital affiliated research nurse. A 
random number generator (www.randomizer.org) was then used to decide which women to 
contact. Women were selected approximately two months before delivery to allow for 
larger numbers on the database while enabling enough time to complete study enrolment 
prior to delivery. The number selected each month varied depending on the number of 
methadone infants due. Once selected, names and hospital numbers were sent back to the 
research nurse in order to cross-check eligibility. Information letters were then mailed out 
to all randomly selected women along with a contact number to call if interested. Follow 
up calls were made approximately a week later to all women who had called over the 
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previous week. For those women who did not return the invitation to participate, a follow 
up telephone call or visit in person was made to enquire if they were interested. On several 
occasions where no phone number was available the author door knocked at the addresses 
provided to try to enlist those randomly selected. Thus, several endeavours were 
undertaken to ensure that those randomly selected were provided with a number of 
opportunities to participate. At follow-up phone calls or home visits, further information 
was provided regarding the study and pertinent questions were answered. Consent from 
this group of women was obtained upon initial physical contact prior to being interviewed.  
 
As with the women in the methadone maintenance group, exclusion criteria for those in the 
control group included, infants born with serious congenital abnormalities, still births and 
premature deliveries of less than 33 weeks gestation. Pregnant women who were unable to 
speak or understand English sufficiently to give informed consent and those outside the 
Canterbury region were also excluded from the study. 
 
Recruitment statistics relating to the control women are presented in Table 2. Of the 92 
letters posted out 42 women were successfully recruited. This equates to a recruitment rate 
of 46%. After factoring out those women that were ineligible for instance, due to 
congenital birth defects of the foetus or lack of sufficient understanding of English to 
provide informed consent, the recruitment percentage increased to 51%. Of those in the 
control group the majority of women not recruited were due to participant refusals (n = 25) 
as opposed to partner refusals. However, a sizeable number (n = 12) were also not 
recruited due to the fact they could not be located from the contact information provided 
despite multiple endeavours from the research recruiters. 
 
Table 2  
Recruitment Statistics of the Non-Methadone Exposed Control Group 
Recruitment type Number of participants % of total contacted 
Contacted 92 100 
Recruited and Consented 42 46 
Not recruited 50 54 
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Ineligibility Criteria Number of participants   % of total not recruited 
Participant refused 25 50 
Partner of participant refused   3 6 
Un-locatable* 12 24 
Other ineligibility** 10 20 
*addresses of women were incorrect and no forwarding address or alternative address was 
available 
**congenital abnormalities in foetus, pulled out after consenting, not able to understand 
English sufficiently, moved out of area 
 
2.2.3 Analyses of Maternal Background Characteristics  
 
Table 3 describes the maternal and family background characteristics of women enrolled in 
the methadone maintenance programme and women in the non-methadone exposed group. 
A range of characteristics across several domains were examined including, maternal age, 
marital status, ethnicity, schooling and living circumstances. Each comparison was tested 
for significance using the chi squared test of independence for dichotomous measures 
(presented in percentages) or independent samples t-tests for continually distributed 
variables (presented with means and standard deviations). The information provided on 
this table was based on questions included in the maternal interviews which were 
completed by each pregnant woman prior to their infant‟s birth and was supplemented with 
data from hospital records.  
 
The results in Table 3 show significant differences between the two groups occurred across 
the areas of relationships, schooling, finances and accommodation. In regards to 
relationships, women in the methadone maintenance group were significantly more likely 
to be un-married (p < .0001) and have been in the current relationship for approximately 
half as long as the comparison group (43 versus 80 months in a relationship). They were 
also significantly more likely to have received no formal schooling (p < .0001), be 
unemployed (p < .0001) and to be receiving a social welfare benefit (p < .0001). The most 
frequently endorsed type of accommodation for women in the methadone maintenance 
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group was “living in rented accommodation” (55%) while the equivalent for the 
comparison women was “living in own home” (48%).  
 
No significant between group differences were found on measures of maternal age and 
ethnicity. As shown, across both groups the ethnicity primarily identified with was New 
Zealand European. This was the case for 66% of the methadone maintenance group and 
60% of the control comparison group. When combined with those that endorsed “Other 
European” the totals for the two groups are 72% and 67% respectively. The second most 
commonly identified ethnicity, also across both groups, was New Zealand Maori. Eighteen 
percent of the methadone maintenance group and 14% of the control group identified 
themselves as NZ Maori. These figures are relatively consistent with details gathered from 
New Zealand Census information. The 2001 New Zealand Census reported that Europeans 
constituted 79% of the ethnic share of New Zealand population while Maori constituted 
15% (Statistics New Zealand, 2005). 
 
Table 3  
Comparisons of Maternal Background Characteristics 
 
Measure 
MM 
(n = 50) 
Control 
(n = 42) 
T/2 df p 
 
Maternal Age  M (SD) 
 
29.75 (4.63) 
 
30.69 (5.90) 
 
-0.87 
 
91 
 
0.389 
 
Marital  Status 
   
40.31 
 
3 
 
<.0001 
   % Married 2 62    
   % Co-habiting partner 49 21    
   % Non-co-habiting partner 35 12    
   % No partner 14 5    
 
Length of current 
relationship 
in months M (SD) 
 
42.67 (47.58) 
 
80.33 
(57.09) 
 
-3.47 
 
91 
 
.001 
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Ethnicity 5.26 5 .385 
   % NZ European 66 60    
   % Maori 18 14    
   % Other European 6 7    
   % Asian 0 7    
   % Pacific Island 0 2    
   % Mixed Ethnicity / Other 10 10    
 
Schooling 
     
   % Without formal 
schooling 
78 33 28.39 6 <.0001 
 
Finances 
     
   % Unemployed 98 60 21.89 1 <.0001 
   % In receipt of a benefit 94 31 40.72 1 <.0001 
 
Accommodation 
   
13.55 
 
5 
 
.019 
   % Own home 16 48    
   % Rented Private landlord 55 34    
   % State owned house / flat 21 9    
   % Living with family 8 9    
 
 
2.3 Procedures 
 
A flow diagram is presented below to help illustrate the procedure and timing of measures 
used in the current study. 
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* One woman in the Methadone Maintenance Group gave birth to twins 
** Three methadone exposed infants unable to be assessed 
 
Figure 1 
Timeline of Procedures and Measures Used in the Current Study 
 
2.3.1 Recruitment and Consent 
 
As described in the earlier section, recruitment of women in the methadone group was 
completed by the research nurse during the women‟s routine antenatal visits at the hospital 
Methadone in Pregnancy Clinic while recruitment of control women was completed with 
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randomly selected controls during their third trimester of pregnancy. Additional 
information was provided and consent sheets were signed at recruitment. A copy of the 
written information package provided for the pregnant women being recruited and the 
consent form used is attached in Appendix 3.  
 
2.3.2 Maternal Interviews 
 
Following recruitment and consent a comprehensive maternal interview was conducted 
with each pregnant woman towards the end of the third trimester of her pregnancy (post 33 
weeks gestation). Interviews of the women involved in the methadone maintenance group 
were primarily conducted by the research nurse during the women‟s routine antenatal visits 
while pregnant women in the control group were interviewed by the author in the women‟s 
own homes. Maternal interviews took approximately one hour to one and a half hours to 
complete. A copy of the complete Maternal Interview is attached as Appendix 4. 
 
2.3.3 Collection of Infant Clinical Characteristics 
 
At the birth, clinical data on the newborn infant was collected. These measures were 
initially taken by the delivery team attending the birth and then validated by the team‟s 
research nurse. Further clinical information such as duration of stay in hospital and 
treatment for neonatal abstinence syndrome were collected throughout the infant‟s hospital 
stay. 
 
2.3.4 Neurobehavioural Assessment 
 
2.3.4.1 NNNS Assessment 
  
Following delivery, mothers were contacted by the neurobehavioural assessor in order to 
arrange a time and place suitable to administer the assessment. Neurobehavioural 
assessments were scheduled to be conducted on all infants between 39 and 46 weeks 
gestation using the NICU Network Neurobehavioural Scale (NNNS). As much as possible 
assessments occurred around 42 weeks gestation (i.e. two weeks of age if the infant was 
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born at term). Experienced assessors have recommended that earlier assessments may 
prove difficult to administer and do not necessarily provide as clear an indication of the 
infant‟s best performance while elements of later assessments (e.g. primitive reflexes) may 
be skewed by the natural development of the infant. On occasions where an infant was 
totally unable to be assessed (for example, the infant was unable to regulate his/herself and 
maintain an appropriately responsive state), the assessors would reschedule with the 
infant‟s caregiver, up to three (and occasionally four) attempts in order to complete the 
assessment and as far as possible to elicit the infant‟s “best performance”. This persistence 
means that a small number of infants were assessed after 43 weeks (n = 11). If an infant 
was still unable to be assessed after several separate attempts, endeavours to complete the 
NNNS assessment were abandoned and the infant was deemed “unable to be tested” (n = 
3). 
 
2.3.4.2 Cry Collection 
 
In addition to administering the NNNS, a recording of a sub-sample of infant cries was 
collected during the NNNS assessment. At the conclusion of Section C of the NNNS exam 
(“Unwrap and Supine”) infants were administered the NNNS item referred to as “tactile 
stimulation of the foot”. While the infant was in the supine position a lapel microphone 
(Sony ECM-T145) was positioned approximately 15cm from the infant‟s mouth. The 
microphone was attached to a minidisk recorder (Sony M2 N710). If the administration of 
this item did not elicit a cry, the recording device was left running and a note was taken 
regarding when the infant began to cry. The current sampling methodology has similarities 
to past acoustic studies of infant crying (Nugent, Lester, Greene, Wieczorek-Deering & 
O‟Mahony, 1996). In part, this procedure was chosen because it was less-invasive and 
therefore less likely to elicit refusal from parents or impact retention rates for follow-up 
studies. 
 
2.4 Measures Used in the Current Study 
 
2.4.1 Prenatal Drug Exposure  
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2.4.1.1 Methadone Exposure  
 
Information on maternal methadone dose was gathered from the Methadone in Pregnancy 
Clinic of the CADS Methadone Maintenance Programme. Consent obtained from each 
woman enabled charts from the clinic to be photocopied and used by the research group. 
Using this information, average dose per trimester and average dose per total period 
enrolled in the Methadone Maintenance Programme were calculated for each woman. 
Figure 2 provides a histogram illustrating the distribution of methadone dosages from all 
three trimesters and overall mean methadone doses (calculated across all three trimesters) 
taken by the women in the methadone maintenance group during pregnancy.  
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Figure 2  
Maternal Methadone Dose Distributions 
 
In order to examine the role of maternal methadone dose on infant outcome, study infants 
were divided into three groups based on maternal methadone dose during trimester three. 
Dose at trimester three was chosen for several reasons. First, it has been frequently used as 
the defining dose variable in previous literature (Chasnoff et al., 1984; Hagopian et al., 
1996). Second, information on dose at trimester three was available for all women (where 
some women were not enrolled in the methadone maintenance programme for trimester 
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one). Third, although it is still unclear exactly how early methadone transfer begins to 
occur to the foetus it is known that transfer occurs at increasing levels over the gestation 
period (Kandall et al., 1999). Therefore, it has been suggested that dose levels during 
trimester three may be particularly important.  
 
The mean dose across the group at trimester three was slightly higher at 62.28 mg/day (SD 
= 32.07) than the overall mean of 58.98 mg/day (SD = 33.33), with a median of 60 mg/day 
and a range of 11.2 mg/day to 195 mg/day. Further analysis suggested that overall dose 
measures and dose at trimester three were highly and significantly correlated (p < .0001).  
 
For dose comparisons the methadone exposed group was divided using a median split with 
infants born to those women on 60 mg/day and below being grouped as “Low Dose” (n = 
26), and above 60 mg/day being grouped as “High Dose” (n = 25). This dose level is 
relatively close to the mean dosages discussed in more recent New Zealand and 
international studies (Kuschel et al., 2004; McCarthy et al., 2005; Wouldes, 2004).  
 
2.4.1.2 Exposure to Other Drugs 
 
Prenatal exposure to other drugs was collected via self report during the Maternal 
Interview. A comprehensive section on maternal drug use, both licit and illicit was 
included. The questions around drug use utilised in the current study were based on those 
previously used in the widely acknowledged long-term epidemiological Christchurch 
Health and Development Study (Bowden, Fergusson & Horwood, 2006). The information 
in the drug use section focused mainly on use during the current pregnancy (broken down 
across the three trimesters) but also covered maternal use prior to the current pregnancy. 
Detailed questions regarding use were asked about cigarettes, cannabis, alcohol, 
benzodiazepines, heroin and other opiates (excluding methadone) and stimulants (e.g. 
speed, amphetamines, cocaine). For example, participants were asked how many cigarettes 
they smoked per day prior to pregnancy, during the first three months of pregnancy, during 
the second three months of pregnancy and during the final three months of pregnancy. The 
complete breakdown of questions is provided in Sections E and G of the Maternal 
Interview attached in Appendix 4.  
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2.4.2 Infant Clinical Measures 
 
Clinical information collected at the infant‟s health and well being at birth included: 
1. Infant gender. 
2. Gestational age (provided in weeks/days and converted to a decimal system for 
analysis). 
3. Birth weight (gms). 
4. Birth length (cm). 
5. Head circumference (cm). 
6. Total length of stay in hospital following delivery (days). Information on this was also 
collected in finer detail for instance in regards to length of stay in Neonatal Intensive Care 
Unit (NICU). 
7. Infant APGAR Scores (at one, five and ten minutes).  
 
Additionally, for those infants born to women on the methadone maintenance programme 
and for those infants that required treatment for neonatal abstinence syndrome:- 
8. Finnegan scores (Finnegan, Kron, Connaughton & Emich, 1975). This is a brief semi-
objective assessment measure which examines the newborn for symptoms of NAS. (A 
copy of the exact measure used in the current study is attached in Appendix 5.)  
9. Number of days on treatment  
10. The type of treatment used. 
 
2.4.3 Neurobehavioural Measures 
 
2.4.3.1 NICU Network Neurobehavioural Scale 
 
The NICU Network Neurobehavioural Scale (NNNS) is a relatively new measure 
developed by the National Institute of Health (NIH) specifically designed to evaluate the 
neurobehavioural profiles of at-risk infants, in particular infants prenatally exposed to 
drugs (Lester & Tronick, 2004). Developed through a process of revisions, amalgamations 
and additions to earlier neurobehavioral assessments such as Brazelton‟s Neonatal 
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Behavioural Assessment Scale (NBAS) and Finnegan‟s Neonatal Abstinence Scoring 
System, the NNNS is a comprehensive assessment of neurological integrity, which utilises 
a combination of observed and elicited behavioural functioning, and stress/abstinence 
symptomatology. Neurobehavioural functioning is examined using empirically validated 
methods such as assessing the infants muscle tone (both passive and active), primitive 
reflexes (for example the rooting and stepping reflexes), orientation abilities (both animate 
and inanimate) and ability to self regulate, while the stress/abstinence scale comprises 
symptoms that have been clinically documented as signs of neonatal abstinence.  
 
Procedurally the NNNS assessment is a non-invasive measure that takes approximately 30 
minutes to administer and can be used to assess any infant between the ages of 30-46 
weeks gestation. The infant is assessed and scored on 115 individual items across three 
components: the examination itself (items 1-45), examiner observations of the infant (items 
46-65) and a stress/abstinence scale (items 66-115). The physical examination itself 
follows a relatively invariant administration order, with items administered in eleven 
focused, state-dependent “packages” that the infant is moved through, for example, 
package “E” examines the infant‟s “upper extremities and face” while package “F” 
examines the infant‟s “upright responses”. Packages are designed to reduce unnecessary 
manipulation while steadily moving the infant through the assessment following the 
infant‟s natural progression of state changes from sleep to wake. Standardised directions 
are also provided in regards to the context in which the assessment should take place and 
procedures to be followed in difficult situations, for example, a set procedure is outlined 
and required to be followed if or when an infant begins to cry.  
 
In order to facilitate interpretation and enhance objectivity a detailed scoring guide 
accompanies the assessment. This includes descriptions, pictures, asymmetrical options 
and optimal scores (for the examination component). The assessor must choose the score 
that represents the infant‟s best performance on each item. In the event that an item is not 
administered specific codes are used to identify the reasons that the item was unable to be 
scored. For example a “99” represents examiner error while a “98” indicates that the infant 
was in an inappropriate state to complete the item. Observed stress/abstinence symptoms 
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are scored on a comprehensive “yes/no” checklist. For further details the complete scoring 
guide to the NNNS is available online at http://pediatrics.aappublications.org. 
 
Tallied scoring of the NNNS provides information on twelve summary scores that can then 
be used for interpretation purposes. These include measures of: Habituation, Attention, 
Handling, Quality of Movement, Regulation, Non-optimal Reflexes, Stress/Abstinence, 
Arousal, Excitability, Hypertonicity, Hypotonicity and Lethargy. Development of themed 
summary scores was undertaken by the authors of the NNNS using a “combined 
conceptual and statistical (co-efficient alphas) aggregation of items and scores” (p. 185, 
Lester & Tronick, 2004). Basing summary scores over several items throughout the 
assessment is considered to enhance the reliability of the summary scores.  
 
Initial reliability and validity of the NNNS was checked during the development of the 
Maternal Lifestyles Study in which 12 examiners across four sites assessed 1,400 one-
month old infants from a variety of substance exposures, ethnicity, regions and social 
classes. Results showed that the NNNS reliably differentiated between drug exposed and 
control infants. Since its development several other studies have also used the NNNS, 
confirming both its reliability and validity (Boukydis, Brigsby, & Lester, 2004; Tronick et 
al., 2004). Reliability evaluation of the summary scores has shown adequate to good 
internal consistency, with alpha co-efficients ranging from 0.56 to 0.85 (Lester et al., 
2004). 
    
The majority (80%) of NNNS assessments were administered by one of two trained 
assessors (the author and the neonatal physiotherapist from Christchurch Women‟s 
Hospital). For most of these assessments the assessors worked together with one 
administering the assessment while the other observed. This kept procedures consistent 
across the assessors and was felt to enhance scoring validity as both assessors were able to 
report on what they observed. Whenever possible the NNNS assessment was performed 
within the hospital setting. When this was not possible assessments were performed at the 
infant‟s home. In order to avoid scoring biases, both NNNS administers were blind to 
maternal dose and any infant medications. An additional nineteen NNNS assessments 
(20%) were included that had been conducted by the previous NNNS assessor employed 
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by the larger study. This earlier assessor had been trained by the same instructor as the two 
primary assessors.  
 
Quality of assessment procedures and inter-rater reliability of NNNS assessments were 
checked in June 2004 by a certified NNNS trainer. In order to enhance reliability and 
identify any potential biases that may have been occurring the trainer was blind to both 
maternal and infant exposure status. Reliability was assessed by comparing independent 
scoring of both videotaped and live assessments. Reliability conformed to criteria 
suggested in Lester et al. (2004). This indicates “no more than a two-point difference was 
found on items with >9 scale points, and for items with <5 scale points, agreement had to 
be exact with no more than five disagreements” (Lester et al., 2004, pp677).  
 
2.4.3.2 Cry Measures 
 
Consecutive vocalisation recordings from a large sub-sample of infants were undertaken 
during the NNNS assessment. In line with previous acoustic cry studies and due to the fact 
that many infants did not cry at all or only “fussed” during the assessment, recordings were 
subjected to a cry criterion in order to be included in later cry analyses. Grau, Robb & 
Cacace (1995) defined a crying episode as the uninterrupted crying activity that begins 
following administration of a cry-eliciting stimulus and continues to the eventual cessation 
of crying. To meet criteria for the current study, a crying episode had to be perceived as a 
high intensity period of distressed vocalisation sustained for a minimum of 15 seconds. 
Based on this definition a smaller sub-sample of ten infants from each group whose crying 
episode met these criteria was used for cry analyses.  
 
On the basis of each infant‟s episode of crying, a series of cry utterances were identified. 
Lester et al., (2002) defined a cry utterance as an individual segment of crying that occurs 
during the expiratory phase of respiration. A cry utterance typically lasts for a period of 
500 msec or longer. The present study extended this definition to only include cry 
utterances that only occurred upon exhalation, contained clear harmonic structure, and 
persisted for at least on second or longer. Based on information provided about typical 
infant cries and a review of the definitions used in previous cry studies (Hopkins, 2000) 
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this definition was assumed to provide the least ambiguous approach to identifying and 
acoustically measuring moments of crying. A total of five cry utterances were considered 
in the acoustic analysis of each infant. 
 
Prior to acoustic analysis, each crying episode was converted to a “wav” file using a 
commercially available software package (Acoustica 3.2). Each wav file was then imported 
to a signal processing system (PRAAT 4.3.12). Cry utterances were then measured using a 
combination of amplitude-by-time displays and narrow band spectrographic displays. A 
narrow band spectrographic analysis involves a detailed analysis of the entire acoustic 
spectrum of the cry signal in intervals of 45 Hz. The outcome of this analysis results in a 
cry spectrogram which provides a representation of the F0 of the cry signal and the 
associated harmonic components of the cry. Appendix 6 provides a visual illustration of 
the computer generated wav files of the infant utterances that were chosen for analysis after 
meeting the applied criteria. Pictorially this may be helpful in aiding the reader or future 
researchers wishing to replicate the current research in distinguishing cries that meet the 
criteria described. 
 
On the basis of the spectrographic displays, two acoustic measurements were made: 
1. Cry duration: Defined as the total time elapsed between the onset and offset of each cry 
utterance. Cry duration was measured (in msec) by superimposing a pair of vertical 
cursors at the onset and offset of acoustic energy summation of each cry utterance. 
2. F0: Defined as the lowest frequency component (in Hz) of the cry utterance. 
Measurements of F0 were made manually over increments of 0.1 second across the 
duration of each cry utterance.  
 
On the basis of the cry F0 measures a number of statistical calculations were performed: 
3.  Mean F0: An average of the incremental 0.1 second measures for each cry utterance. 
4. F0 SD: The standard deviation of the F0 measures for each cry utterance. 
5. The coefficient of variation: The standard deviation divided by the mean of each cry. 
This represents a general measure of variability between the two data sets.  
6. Jitter Factor: A measure of F0 perturbation (variability). As defined by Baken (1987) 
the jitter factor is “the mean difference between the frequencies of adjacent cycles 
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divided by the mean frequency, multiplied by 100” (p. 175). The equation to calculate 
jitter factor taken from Baken (1987, p175) is provided below: 
 
7. Percentage of jitter directionality change: The number of times a frequency shift 
changes direction i.e. when the algebraic sign changes direction.  
8. Melody contour: An approximation of the general pattern of F0 of each cry (i.e. rising, 
falling or flat). This was assessed by fitting a first-order polynomial (i.e. linear 
regression) to the F0 measurements.        
 
2.4.4 Additional Measures 
 
Information on confounding variables and maternal characteristics were taken from self 
reported answers to questions in the maternal interview and supplemented with 
information available on hospital records. The maternal interviews conducted were 
developed as part of the larger study by the previous research group co-ordinator and the 
primary investigator prior to the author‟s (ZQ) involvement in the research group. The 
interview questionnaire contained a combination of custom written questions with a 
number of structured questionnaire measures. Interviews included a large cross section of 
information with the aim of providing a comprehensive understanding of the 
environmental context and influences faced by each group. Information collected included 
maternal demographics, maternal well-being, important perinatal details (e.g. previous 
pregnancies, type of antenatal care) and a brief personality questionnaire. (Given the scope 
of the current thesis, only specifically selected information from the maternal interviews 
has been presented and used. More in-depth reporting of the information collected at 
maternal interview will be available in future reports and follow-up studies currently under 
way by the research group.) Attached as Appendix 4 is a copy of the complete Maternal 
Interview.    
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2.4.4.1 Maternal Background Characteristics 
 
This information included details such as maternal age, ethnicity, education level, living 
arrangements, partner relationships and income. The majority of maternal characteristics 
(ethnicity, education level, living arrangements and partner relationship) were collected 
using a scaled check-box approach where the most applicable answer was circled. For 
example education level was graded on a seven point scale where; “1 = Left school 
between 13-16 years, no qualifications”, “2 = School Certificate ( >2 subjects)”, “3 = 
Further secondary education, eg UE, HSC or Bursary”, “4 = Secretarial or trade 
qualifications”, “5 = Professional qualifications without a degree”, “6 = University degree” 
and “7 = Other qualifications, describe _____”. Income information was gathered via a 
number of questions, for example “Are you working (in paid employment) at the 
moment?”, “How much do you receive each week after tax?”, “How much do you receive 
in benefit payments per week?” For a more detailed understanding of the questions asked 
to establish maternal background characteristics see Sections A and C of the Maternal 
Interview attached as Appendix 4. 
 
2.4.4.2 Maternal Nutritional Information 
 
Maternal nutritional intake was established using a “servings per week” approach. Each 
woman was asked to calculate how many servings of fruit, vegetables, meat, bread, 
carbohydrates, milk and eggs she had eaten per week during pregnancy. For each of the 
food groupings, definitions were provided and example serving sizes were given, for 
example, “Fruit including fresh, frozen, canned, and stewed. 1 serving = 1 apple or 2 small 
apricots”. A complete list of definitions and serving sizes are provided in Section D of the 
Maternal Interview attached as Appendix 4. 
 
2.4.4.3 Maternal Well-being 
 
Data on maternal well-being included questions relating to both maternal physical and 
mental health. Self report information provided by each woman was then supplemented 
and checked against available hospital records. An extensive list of maternal health 
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questions were asked including any history of epilepsy, hepatitis, diabetes, high blood 
pressure, thyroid trouble, anaemia and current or past psychiatric illness. The majority of 
these were answered using a dichotomous yes/no selection. Where applicable, such as with 
mental health diagnoses, additional details such as treatment or current medication were 
inquired about. Again, these are included in the Maternal Interview attached as Appendix 
4. 
 
2.5 Data Analysis 
 
The majority of statistical data analysis was conducted using SPSS 14.00 for Windows. 
Clinical data and NNNS assessment results were entered directly into SPSS while Maternal 
Interviews were entered into Access then converted to SPSS for analysis and Cry 
Measurements were entered onto Excel and then converted to SPSS for analysis. (Data 
analysis to ascertain the summary scores of the NNNS assessment was executed using 
syntax files for SPSS specifically designed for use with the NNNS assessment by the 
Maternal Lifestyles Study provided by the author of the NNNS.)   
 
Power for the current study was considered sufficient, based on the information that a large 
effect size (ES = 0.8) requires a sample size of 26 (n = 26) in order to obtain 80 percent 
statistical power. Bivariate analytic techniques were used to examine between group 
differences on each of the infant outcomes specified. For continuously distributed 
variables, two tailed independent samples t-tests were used, whilst for dichotomous 
variables, chi-square tests were used. Analyses of dose measures were conducted using 
univariate one-way analysis of variance (ANOVAS). . Where applicable the Levenes test 
was used to determine homogeneity of variance between the two groups. All tests were 
initially conducted using the ninety-five percent confidence level (i.e. a significance level 
of p < .05). These statistical tests were chosen for their functionality and simplicity. 
Additional information on further statistical analyses, including any more refined or 
alternative procedures, is specified in the results section. 
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Results 
 
 
3.1 Layout and Organisation of the Results Section 
  
The results section of this thesis is divided into three sections, as guided by the aims of the 
research described at the end of the introduction. The first section compares the clinical 
and neurobehavioural characteristics (NNNS scores followed by analyses of infant cry) of 
the methadone exposed infants with the non-methadone exposed control comparisons. The 
second section examines the association between maternal methadone dose during 
pregnancy and infant outcomes. This begins with a reiteration of the maternal dose 
groupings and is followed by the presentation of between-group findings, across “no dose” 
(non-methadone exposed control comparisons) “low dose” and “high dose” groups, for 
clinical and neurobehavioral (NNNS score) measures. The final section of the results, 
examines the roles of confounding variables and their influence on the data examined in 
the earlier sections.  
 
Note: One woman on the Methadone Maintenance Group had twins therefore infant 
sample size for the Methadone Exposed Group is 51 while maternal sample size is 50.  
 
3.2 Section 1: Between Group Comparisons of Clinical and Neurobehavioural 
Characteristics: Methadone Exposed Infants and Non-Exposed Comparison Infants 
 
3.2.1 Clinical Characteristics of Methadone Exposed and Non-Exposed Comparison 
Infants 
 
Table 4 compares the clinical characteristics of the infants exposed to methadone during 
pregnancy and comparison infants not exposed to methadone during pregnancy. Between-
group comparisons were tested for significance using the chi squared test of independence 
for dichotomous variables (presented in percentages) and independent samples t-tests for 
continually distributed variables (presented with means and standard deviations). 
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The results presented in Table 4 reveal the presence of significant differences between the 
two groups on measures of infant birth weight (p < .0001) and head circumference (p < 
.001) with infants exposed to methadone during pregnancy found to be significantly lighter 
with smaller head circumferences. There was also a tendency for those infants exposed to 
methadone during pregnancy to be slightly shorter at birth (p = .093). 
 
The two groups of infants also differed significantly across Finnegan‟s scores (p < .0001), 
treatment for neonatal abstinence syndrome (p < .0001) and days in hospital (p < .0001) 
with a large number of the methadone exposed infants requiring treatment for neonatal 
abstinence syndrome and more likely to spend longer in hospital. Notably, the mean stay of 
the methadone exposed infants in hospital was 18 days (SD = 13.40) with a range of four 
to 77 days, while in contrast, the non-methadone exposed comparison infants had a mean 
stay of three days (SD = 1.82) with a range of no days to seven days. 
 
No significant differences between the two groups were found on measures of infant 
gender, gestational age at birth, frequency of preterm (<37 weeks) birth or infant APGAR 
scores at both one and ten minutes. 
 
Table 4  
A Between Group Analysis of the Means (M) and Percentage (%) Values of Infant Clinical 
Characteristics for Infants Exposed to Methadone During Pregnancy and Non-exposed 
Comparison Infants. Standard Deviations provided in Parentheses 
 
Clinical Measure 
ME 
(n=51) 
Control 
(n=42) 
t/2 df p 
% Male 51 (n=26) 48 (n=20) .10 1 .747 
M Gestn (wks) 38.82 (1.79) 39.22 (2.12) -.99 91 .326 
% Preterm (<37 wks) 8 (n=4) 2 (n=1) 1.35 1 .245 
M  Birth Weight (gms) 2,963.04 
(506.75) 
3,478.21 
(562.49) 
-4.64 91 <.0001 
M Birth Length (cm)
§
 49.98 (3.45) 51.67 (6.00) -1.70 90 .093 
M Head Circ. (cm)
§
 33.60 (2.09) 34.81 (1.26) -3.42 90 .001 
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M Days Hospital 18.20 (13.40) 2.76 (1.82) 8.06 90 <.0001 
M 1min APGARª 8.22  (1.56) 8.30 (1.42) -.13 90 .894 
M 10min APGARª 9.90  (0.36) 9.81 (0.67) .82 90 .414 
M Highest Finnegan
¥
 13.40 (3.46) 0 (0.00) 27.35 89 <.0001 
% NAS treatment 86 (n=44) 0 68.77 1 <.0001 
ª One infant was a home birth no APGAR scores collected.  
§
 One infant missing data on length and head circumference. 
¥ Two infants missing data on Finnegan‟s Score 
 
3.2.2 Neurobehavioural Characteristics of Methadone Exposed and Non-Exposed 
Comparison Infants  
 
3.2.2.1 Analyses of NNNS Outcomes 
 
The following section presents the results of infant neurobehavioral integrity assessed 
using the NICU Network Neurobehavioural Scale (NNNS). Prior to analysis of summary 
scores, independent sample t-tests were run in order to ascertain any differences between 
the testing ages of the two groups of infants. Analysis was conducted in regards to both 
gestational age and corrected age (i.e. actual age in whole days since birth). At the time of 
neurobehavioural assessment the mean gestational age of the methadone exposed infants 
was 52 days old (SD = 13.00), while the equivalent mean was 54 days (SD = 10.64) for the 
controls infants. Means for actual age at time of assessment was 20 days (with a range of 2 
to 78) for the methadone exposed infants and 16 days (with a range of 4 to 38) for the 
control infants. Both tests showed that there were no significant differences between the 
two groups at time of testing (gestational age: t(87) = -.520, p = .604; actual age: t(87) = 
1.391, p = .168).  
 
Table 5 shows sample numbers, means and standard deviations of the summary scores of 
the NNNS for methadone exposed and non-exposed infants. Summary scores for the 
NNNS assessment were computed via a SPSS syntax file which accompanied the 
assessment measure as provided by the author (Lester & Tronick, 2004). This syntax 
calculates the infant‟s performance across relevant individual items in order to obtain 
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summary scores as explained in the methods section. Between group differences were 
assessed using the independent samples t-test for each summary score. 
 
Sample numbers for each of the summary scores differ due to infant state and the related 
inability to perform aspects of the NNNS assessment when the infant is in an inappropriate 
state (as explained in the Methods section). If an infant was still unable to be assessed after 
four separate attempts, endeavours to complete the NNNS assessment were abandoned. 
Based on these criteria, three of the methadone exposed infants were unable to be assessed, 
two of the methadone exposed infants took four attempts, six took three attempts, eight 
took two attempts and 32 took one attempt. In contrast, one non-exposed control infant 
took three assessment attempts to assess, seven took two attempts and 34 took one attempt. 
When tested statistically, these differences between the two groups, in regards to number 
of attempts required to complete the NNNS assessment, were insignificant (2(4) = 7.902, 
p = .095). It is important to note that the results presented below do not include any data 
obtained from the three methadone exposed infants that were unable to be assessed.  
 
Examination of the neurobehavioural profiles showed that significant differences occurred 
across the large majority of the NNNS summary scores. Namely there were significant 
differences across NNNS Habituation, NNNS Attention, NNNS Handling, NNNS Quality 
of Movement, NNNS Regulation, NNNS Non-optimal Reflexes, NNNS Stress/Abstinence, 
NNNS Arousal, NNNS Excitability and NNNS Hypertonicity. (Summary scores that were 
not statistically significant were NNNS Lethargy and NNNS Hypotonicity.) For each of 
the summary scores, the higher the score, the more the infant reflects that characteristic.  
 
The summary scores on which the two groups of infants differed the most were NNNS 
Quality of Movement, NNNS Regulation, NNNS Stress/Abstinence and NNNS 
Excitability. NNNS Quality of Movement is a measure of smoothness of movement and 
motor control. Mean scores on the NNNS Quality of Movement summary item were 
significantly higher for the non-methadone exposed control group in comparison to the 
methadone exposed group (p < .0001) indicating that the non-methadone exposed control 
infants displayed significantly smoother movements and better motor control. Likewise 
non-methadone exposed control infants scored higher than their methadone exposed 
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counterparts on the summary score of NNNS Regulation (p < .0001). This summary score 
is among the most global and reflects how well the infant was able to cope with the 
assessment and settle his or herself. The higher scores obtained by the non-methadone 
exposed control infants reflects that they were better able to do this. Not surprisingly, the 
methadone exposed group displayed a significantly higher group mean on the NNNS 
Stress/Abstinence summary score (p < .0001) indicating that the methadone exposed 
infants displayed more signs commonly representative of neonatal abstinence and stress, 
for instance tremors, startles and rapid changes of skin colour. The methadone exposed 
group of infants also displayed a significantly higher mean NNNS Excitability summary 
score (p < .0001). This summary score is a measure of infant reactivity that takes into 
account physiological aspects of reactivity; therefore, this heightened mean indicates that 
the methadone exposed group were more sensitive during the assessment than their non 
methadone exposed control counterparts.  
 
The six other significant summary scores were NNNS Habituation, NNNS Non-optimal 
Reflexes, NNNS Arousal, NNNS Hypertonicity, NNNS Attention and NNNS Handling. 
Sample sizes across the NNNS Habituation scores were low in both groups. This smaller 
number is likely to reflect the fact that the infant is required to be in a sleeping state at the 
beginning of the NNNS assessment in order for this part of the NNNS assessment to be 
administered. However, across the current numbers the mean NNNS Habituation score for 
the non-methadone exposed control group was significantly higher than that of the 
methadone exposed group (p =.001). This indicates the methadone exposed infants were 
slower and less able to progressively tune out intrusive noises compared to the control 
infants. In “real” terms, this indicates that the methadone exposed infants took 
approximately seven or eight trials to block out the noise of a rattle or bell while it took the 
non-methadone exposed infants three or four trials. Infants in the methadone exposed 
group were also found to have a higher mean on the summary score of NNNS Non-optimal 
reflexes, indicating a significantly higher number of sub-optimal reflexes (p = .001). The 
methadone exposed group had a significantly higher mean Arousal summary score (p = 
.001) indicating that this group of infants was quicker to fuss or cry during the 
administration of the NNNS assessment than their non-methadone exposed control 
counterparts. Methadone exposed infants also obtained a significantly higher mean across 
 57 
the NNNS Hypertonicity summary score (p = .001) signifying that a higher proportion of 
the methadone exposed infants displayed notably heightened muscle tone in legs, arms and 
torso. NNNS Attention reflects the infant‟s ability to attend to auditory and visual 
stimulation. Those infants in the methadone exposed group had lower mean Attention 
scores than the non-methadone exposed control counterparts indicating a shorter or weaker 
ability to attend (p =.004). Finally, NNNS Handling is a measure of the amount of 
examiner support the infant needed during assessment to maintain an appropriately 
responsive state. Findings showed that methadone exposed infants required more support 
in comparison to the non-exposed group (p =.031) signifying that more assistance such as 
talking to the infant and picking the infant up was required by the assessor to keep the 
infants in the methadone exposed group in an appropriate state. Finally, there were no 
significant between group differences on summary score measures of NNNS Hypotonicity 
(notably decreased muscle tone) or NNNS Lethargy (sluggish or delayed responsivity).  
 
Collectively these summary scores suggest that the methadone exposed infants were more 
reactive, showed less motor maturity, were less able to maintain themselves in an 
appropriate responsive state and displayed more signs of stress than their non-methadone 
exposed control comparisons.  
 
As mentioned previously, the results presented do not include any data obtained from the 
three methadone exposed infants that were unable to be assessed. These infants were not 
assessed because they were overly reactive, generally unsettled and never in an appropriate 
state to administer the NNNS assessment. No infants in the non-exposed comparison group 
were unable to be assessed. Thus it is likely that the current analysis may to some extent 
underestimate any differences between the two groups. 
 
Table 5  
A Between Group Analysis of Infant Neurobehavioural Outcomes for Infants Exposed to 
Methadone During Pregnancy and Non-exposed Comparison Infants at Approximately 42 
weeks Gestation                          
 ME Control    
 (n = 48) (n = 42)    
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NNNS Scale n Mean SD n Mean SD t df p 
Habituation 27 5.98 2.10 17 7.68 .90 -3.70 42 .001 
Attention 34 5.93 1.63 37 6.95 1.11 -3.02 69 .004 
Handling 40 0.31 0.30 41 0.17 0.25 2.19 75.43 .031 
Quality of 
Movement 
44 3.95 1.03 42 
 
4.82 0.80 -4.39 84 <.0001 
Regulation 45 5.31 0.93 42 6.26 0.80 -5.10 85 <.0001 
Non opt. 
Reflexes 
48 4.31 2.54 42 2.86 1.52 3.35 88 .001 
Stress/Abstin 48 0.18 0.09 42 0.10 0.06 5.60 78.46 <.0001 
Arousal 45 4.39 0.79 42 3.84 0.61 3.62 82.06 .001 
Excitability 48 4.21 2.71 42 2.14 1.98 4.16 85.49 <.0001 
Hypertonicity 46 0.57 0.90 42 0.10 0.37 3.38 62.29 .001 
Hypotonicity 46 0.13 0.34 42 0.12 0.33 .16 86 .874 
Lethargy 48 3.16 2.49 42 2.98 1.33 .46 73.71 .647 
 
 
3.2.2.2 Analysis of Cry Characteristics 
 
This section presents neurobehavioural findings relating to analysis of infant cry. As infant 
cry measures were taken during the assessment of the NNNS, analyses in regards to age at 
time of testing were unnecessary. As noted above, there were no significant (p < .05) 
differences between the two groups in regards to age at testing. 
 
Forty-five cries meeting criteria were collected from the sub-sample of ten methadone 
exposed infants while 44 cries were collected from the sub-sample of ten comparison 
infants.  
 
To evaluate differences between the cry characteristics of the two groups, a number of 
two-tailed independent samples t-tests were performed. The means and standard deviations 
of the cry characteristics, and the results from the t-tests run are provided in Table 6. 
Results of the t-tests revealed that there were significant between group differences across 
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all measures of frequency perturbation. Both jitter factor (p = .012) and jitter directionality 
(p = .015) were significantly different between the two groups. In both cases the 
methadone exposed infants had higher jitter values than the non-exposed control infants. In 
general the results of the jitter analyses were indicative of the infants in the methadone 
groups demonstrating more cycle-to-cycle variability in the vocal fold vibration of their 
cries. The coefficient of variation was also significant (p = .008), indicating that even at a 
more rudimentary level the methadone exposed infants had a higher level of overall 
variation than their non-methadone exposed comparisons. In order to illustrate this, 
examples of cry utterances containing a particularly stable F0 and a particularly erratic F0 
are presented in Figure 3 and Figure 4 below.  
 
T-tests run on the duration of infant cry utterance, mean F0, F0 standard deviation, and the 
melody contour of the infants‟ cries returned no significant results. This indicates that there 
were little or no differences across the measures of utterance duration of those infants 
exposed to methadone during pregnancy in comparison to non-methadone exposed control 
infants. There was also little or no difference between the two groups in regards to F0 or the 
SD of the F0. Finally, there was little or no difference between the melody contours (i.e. 
slope of the cry) between those infants exposed to methadone during pregnancy in 
comparison to non-methadone exposed control infants. 
 
Table 6  
A Between Group Analysis of the Mean Values of Infant Cry Characteristics for Infants 
Exposed to Methadone During Pregnancy and Non-exposed Comparison Infants with  
Standard Deviations Provided in Parentheses 
 ME Control t df p 
Cry Characteristic (n = 45) (n = 44)    
Utterance Dur (secs) 1.39 (0.44) 1.47 (0.47) -.945 87 .347 
F0 (Hz) 508.00 (164.51) 494.71(244.37) 0.30 87 .764 
SD of  F0 (Hz)  100.37 (78.44) 72.81 (84.21) 1.60 87 .114 
Jitter Factor (Hz) 112.30 (82.77) 75.62 (45.62) 2.60 68.79 .012 
% Directional Jitter  32 (14) 24 (14) 2.48 87 .015 
Coefficient of 0.20 (0.12) 0.14 (0.08) 2.72 77.20 .008 
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Variation (Hz) 
Melody Contour 3.06 (15.86) 0.98 (9.53) 0.75 72.41 .453 
 
 
 
 
 
Figure 3 
Example of an Infant Cry with Stable Fundamental Frequency (displaying low frequency 
perturbation). The top panel provides an amplitude-by-time display of two cry utterances. 
The bottom panel is a spectrographic representation of the same two cry utterances. 
Frequency (Hz) is depicted on the ordinate and time (sec) is depicted along the abscissa. 
The lowest horizontal line represents the F0 with the associated harmonic components 
depicted above the F0.  
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Figure 4 
Example of an Infant Cry with Erratic Fundamental Frequency (displaying high frequency 
perturbation). The top panel provides an amplitude-by-time display of two cry utterances. 
The bottom panel is a spectrographic representation of the same two cry utterances. The 
lowest horizontal line represents the F0 with the associated harmonic components depicted 
above the F0.  
 
3.3 Section 2: Examination of the Relationship Between Maternal Methadone Dose 
During Pregnancy and Infant Outcomes  
 
3.3.1 Maternal Methadone Dose Distribution and Groupings 
 
The findings discussed above suggest that there are significant differences across both the 
clinical and neurobehavioural profiles of methadone exposed infants in comparison to non-
methadone exposed control infants. A further important issue in the literature related to 
methadone exposure in utero is that of maternal methadone dose. In order to examine this 
issue, the analysis was extended to examine the extent to which increased levels of 
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methadone exposure during pregnancy were associated with increased infant risk. As 
previously described in the Methodology Section (2.3.1.1) study infants were divided into 
three groups. 
 
Grouping used a median split based on mean maternal methadone dose during trimester 
three. Infants exposed to maternal methadone doses of 60 mg/day and below were 
considered “Low Dose” (n = 26) while those exposed to maternal doses of greater than 60 
mg/day were considered “High Dose” (n = 25). The group of control infants was referred 
to as the “No Dose” (n = 42) group as these infants were not exposed to methadone in 
utero. 
 
3.3.2 Infant Clinical Characteristic Analysed by Maternal Methadone Dose During 
Pregnancy 
 
Table 7 examines the relationship between infant clinical characteristics and maternal 
methadone dose. Between group differences were tested using the chi squared test of 
independence for dichotomous measures or one way analysis of variance for continuously 
distributed measures (ANOVA) with tests for linear trends. F statistics presented represent 
those for tests related to linearity. 
 
As shown in Table 7 clear linear associations were found between the groups across the 
clinical measures of birth weight (p < .0001), birth length (p = .022), head circumference 
(p < .0001) and days in hospital (p < .0001). Increasing maternal methadone dose during 
pregnancy was associated with a higher risk of the infant being born lighter, shorter, 
having a smaller head circumference and having a longer stay in hospital. There were no 
significant (p < .05) non-linear trends found in the data. Tests for linear trends were also 
significant across Finnegan‟s Scores (p < .0001) and treatment of neonatal abstinence 
syndrome (p < .0001). However, it should be noted that these measures were also 
associated with significant non-linear trends (p < .0001). This violation is likely to be 
because no control infants were given Finnegan‟s scores or treated for neonatal abstinence 
syndrome. 
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Results that were not significant, included gestational age, rates of prematurity and infant 
APGAR scores at both one and ten minutes.  
 
Table 7  
Association between Maternal Methadone Dose During Pregnancy and the Means (M) and 
Percentage (%) Values of Infant Clinical Characteristics. Standard Deviations Provided in 
Parentheses 
 
 
Clinical Measure 
No Dose 
 
(n=42) 
Low Dose 
≤ 60mg/day 
(n=26) 
High Dose 
> 60mg/day 
(n=25) 
F/
2
 df p 
M Gestation (wks) 39.22 (2.12) 39.17 (1.29) 38.47 (2.16) 2.13 1 .148 
% Preterm  
(<37 wks) 
2 (n=1) 4  (n=1) 12  (n=5) 2.58 1 .108 
M Birth Weight  
(g)  
3,478.21 
(562.49) 
3,115.00 
(401.33) 
2,805.00 
(562.30) 
26.81 1 <.0001 
M Birth Length
§
 
(cm)         
51.67 (5.99) 51.12 (3.01) 48.80 (3.54) 5.40 1 .022 
M Head Circ.
§
  
(cm) 
34.81 (1.24) 34.05 (1.17) 33.14 (2.70) 14.24 1 <.0001 
M 1min APGARª 8.26 (1.42) 8.16 (1.68) 8.28 (1.46) 0.00 1 .996 
M 10min APGARª 9.81 (0.67) 10 (0.0) 9.80 (0.50) 0.20 1 .887 
M Days Hospital 2.76 (1.82) 15.85 (14.22) 20.75 (12.22) 56.07 1 <.0001 
M > Finnegan
¥
 0 (0.00) 12.77 (3.53) 14.08 (3.34) 539.06 1 <.0001 
% NAS Treatment 0 77(n=20) 96 (n=24) 63.77 1 <.0001 
ª One infant was a home birth no APGAR scores collected.  
§
 One infant missing data on birth length and head circumference. 
¥ Two infants missing data on Finnegan‟s Score 
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3.3.3 Infant Neurobehavioral Outcomes Analysed by Maternal Methadone Dose 
During Pregnancy  
 
3.3.3.1 Analyses of NNNS Outcomes  
 
Table 8 describes the relationship between maternal methadone dose and infant 
neurobehavioural outcomes assessed using the NNNS. Analysis was conducted using the 
chi squared test of independence for dichotomous measures or one way analysis of 
variance for continuously distributed measures (ANOVA) with tests for linear trends. F 
statistics presented represent those related to linearity. 
 
As before, preliminary analyses were conducted using a one-way ANOVA to check for 
differences across age at time of testing and number of attempts made. There were no 
significant (p < .05) linear trends across any of these factors. However, there was a 
significant difference between the groups across the number of attempts at assessment 
made (F(2) = 11.290, p <.000). When post hoc multiple comparisons were examined, these 
between-group differences lay between the low dose group and both the high dose (p 
<.000) and the no dose group (p <.000). This difference reflects a mean number of 2.19 
(SD = 2.19) assessment attempts in the low dose group in comparison to a mean of 1.28 
(SD = .678) for the high dose group and 1.21 (SD = .470) for the no dose group. 
 
The results of Table 8 reveal strong associations between dose related exposure in utero 
and infants neurobehavioural performance on measures of NNNS Habituation (p = .005), 
NNNS Attention (p = .007), NNNS Quality of Movement (p < .0001), NNNS Regulation 
(p < .0001), NNNS Non-Optimal Reflexes (p < .0001), NNNS Stress/Abstinence (p < 
.0001), NNNS Arousal (p < .0001), NNNS Excitability (p < .0001) and NNNS 
Hypertonicity (p < .0001). The summary score of NNNS Handling also came close to 
significance (p = .064). These results signify that the higher the maternal methadone dose 
during pregnancy the harder the infant finds it to regulate his or herself, manifested in an 
inability to block out intrusive stimuli, and maintain focused attention to presented stimuli. 
Quantifiably, this means that high dose infants took almost twice as long as non-exposed 
comparisons to habituate to intrusive stimuli (nine presentations as opposed to five or six 
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presentation) and were less likely to be able to follow a ball for more than a 30 degree arc. 
An increase in maternal dose also relates to a more easily upset infant, going through more 
withdrawal symptoms with a more rigid yet less maturely developed musculature.  
 
For the majority of neurobehavioural summary scores no significant (p < .05) deviation 
from linearity was returned. However, for both NNNS Stress/Abstinence (F(1) = 5.11, p = 
.026)  and NNNS Regulation (F(1) = 5.65, p = .020) significant deviation from linearity 
was reported. This suggests these relationships do not follow a purely linear trend.  
 
Neurobehavioural areas that were clearly not significantly different between the groups 
and returned no linear trends were again NNNS Hypotonicity and NNNS Lethargy.  
 
Table 8 
Association between Maternal Methadone Dose During Pregnancy and Mean Values (M) 
of Infant Summary Scores on the NNNS. Standard Deviations provided in Parentheses 
 
 
NNNS Information 
No Dose 
 
(n=42) 
Low Dose 
≤ 60mg/day 
(n=26) 
High Dose 
> 60mg/day 
(n=25) 
F df p 
M Gestational Age 
at Testing 
15.95 
(8.26) 
19.68 
(13.45) 
19.60 (17.03) 1.20 1 .277 
M Actual Age at 
Testing 
53.60 
(10.64) 
54.95 
(13.03) 
49.92 (12.76) 1.54 1 .218 
M # of Assesst 
Attempts 
1.21 (0.47) 2.19 (1.39) 1.28 (0.68) .90 1 .346 
M Habituation 7.68 (0.90) 6.12 (2.06) 5.89 (2.20) 8.59 1 .005 
M Attention 6.95 (1.11) 5.96 (1.68) 5.90 (1.63) 7.88 1 .007 
M Handling 0.17 (0.25) 0.32 (0.31) 0.30 (0.31) 3.53 1 .064 
M Qual. Movt 4.82 (0.80) 4.18 (1.17) 3.72 (0.87) 21.93 1 <.0001 
M Regulation 6.26 (0.80) 5.27 (0.93) 5.34 (0.94) 20.16 1 <.0001 
M Non-opt. 
Reflexes 
2.86 (1.52) 3.43 (1.83) 5.12 (2.85) 18.27 1 <.0001 
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M Stress/Abstin 0.10 (0.06) 0.18 (0.09) 0.19 (0.08) 24.42 1 <.0001 
M Arousal 3.84 (0.61) 4.26 (0.82) 4.50 (0.76) 14.04 1 <.0001 
M Excitability 2.14 (1.98) 3.48 (2.86) 4.88 (2.42) 21.52 1 <.0001 
M Hypertonicity 0.10 (0.37) 0.36 (0.66) 0.75 (0.99) 14.86 1 <.0001 
M Hypotonicity 0.12 (0.33) 0.09 (0.29) 0.17 (0.38) 0.22 1 .683 
M Lethargy 2.98 (1.33) 3.30 (2.16) 3.04 (2.81) 0.41 1 .840 
NB. Sample sizes range from 11 to 42. Sample size of 11 is for NNNS Habituation Low Dose Group. 
Given the low sample size of the infant cry measure, cry analyses were not undertaken 
across maternal dose groups.   
 
3.4 Section 3: Consideration of Maternal Lifestyle Factors Associated with Maternal 
Methadone Maintenance Treatment During Pregnancy  
 
The preceding analyses have established that significant results do exist between the 
methadone exposed group and their non-methadone exposed control comparisons and that 
clear and pervasive dose responses also exist. However, before causal effects can be 
established it is important to consider whether these results are a direct reflection of 
methadone exposure during pregnancy or whether they have occurred due to confounding 
factors (unconsidered external factors) correlated with maternal methadone use. Therefore, 
confounding variables need to be factored into the analyses. In layman‟s terms, any 
influence from other factors that may be creating the differences between the two groups 
needs to be taken into account before any definite conclusions can be drawn.  
 
Factors that were considered to be confounding variables included maternal drug use 
during pregnancy (other than methadone use), maternal nutritional intake during pregnancy 
and maternal health factors, including both physical and mental well being. These are all 
factors which have been raised in previous critiques as important yet often inadequately 
considered (Householder et al, 1982; Jacobson & Jacobson, 2005; Kaltenbach, 1994). Each 
of these factors is discussed below in further detail. 
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3.4.1 Maternal Drug Use During Pregnancy  
 
It is a well acknowledge fact in the literature that a large minority of women on methadone 
maintenance programmes are polydrug users, and continue to use other drugs while 
undergoing methadone treatment (Lester et al., 2001 cited in Coles & Black, 2006). Initially 
a chi square analysis was undertaken in order to ascertain between group differences in drug 
use. This revealed that women in the methadone maintenance group were significantly more 
likely to have smoked tobacco (p <.0001), used marijuana (p <.0001), benzodiazepines (p 
<.0001) stimulants (p = .006), opiates (additional to methadone) (p <.0001) and Ritalin (p = 
.031) during their pregnancy. However, similar rates of alcohol use were reported across the 
two groups. Having found substantive differences across the two groups, drug use was 
further analysed across maternal methadone dose rates. Table 9 provides a list of drugs used 
during pregnancy and the percentages of each group that used each type of drug. Again, a chi 
square analysis was undertaken in order to ascertain between group differences.  
 
An indication of poly-drug drug use was calculated by counting up the number of drugs a 
woman acknowledged using during pregnancy. (This measure is represented in Table 9 as 
Poly-drug Measure). Between group differences across this measure were calculated using 
one way analysis of variance. Based on the means displayed, poly-drug use did not appear 
to follow a linear trend. While the mean number of drugs used by the comparison women 
during pregnancy approximated one (in whole numbers), the mean of the high dose group 
approximated to two (in whole numbers) while the mean of the low dose group 
approximated to three.  
 
Table 9  
Maternal Drug Use During Pregnancy for Women Enrolled in Methadone Maintenance 
Treatment During Pregnancy and Comparison Women 
 
 
Drug Type 
No Dose 
 
(n=42) 
Low Dose 
≤ 60mg/day 
(n=26) 
High Dose 
> 60mg/day 
(n=25) 
F/2 df p 
% Using Tobacco  31 100 92 44.33 2 <.0001 
% Using Marijuana  5 46 40 17.97 2 <.0001 
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% Using Alcohol  29 31 16 1.76 2 .415 
%  Using 
Benzodiazepines  
0 23 40 18.48 2 <.0001 
% Using  Stimulants  2 23 20 7.65 2 0.22 
% Using Opiates 
(excluding Methadone) 
0 42 20 30.37 2 <.0001 
% Using Ritalin 1 7 2 7.98 2 .019 
M (SD) Poly drug 
Measure 
0.69 (1.02) 2.85 (1.35) 2.36 (1.35) 29.87 2 <.0001 
N.B. Drug use was considered positive if it was acknowledged at any stage during pregnancy 
 
3.4.2 Maternal Nutrition and Diet During Pregnancy 
 
Another aspect of maternal lifestyle that is likely to affect foetal development in utero and 
therefore represents a confounding variable is maternal nutritional intake (diet) during 
pregnancy. Initially, independent samples t-tests were done to ascertain whether there were 
any differences between women enrolled in methadone maintenance treatment and the 
comparison women. This returned several significant results with women in the methadone 
maintenance group eating significantly less fruit (t(91) = -3.64, p <.000), vegetables (t(91) 
= -4.36, p <.000), carbohydrates (pasta, rice and cereal) (t(72.07) = -1.33, p <.000) and 
drank less milk (t(91) = -2.41, p = .018) than the control women. Most notably, they ate 
almost half the number of vegetables and half the amount of bread when compared to the 
comparison women. Given these differences a between group one way analysis of variance 
was undertaken to examine if these differences lay primarily with either the low dose 
group or high dose group. 
 
Table 10 presents the average number of weekly servings of food types eaten per week 
throughout pregnancy divided into maternal dose groupings. Post-hoc multiple 
comparisons on the one way ANOVA revealed that all significant (p < .05) differences lay 
between the controls and the methadone exposed group. With no differences evident 
between the low and high dose methadone groups. 
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Table 10 
Analysis of Maternal Nutritional Servings Throughout Pregnancy Based on Maternal Self-
Report Comparisons Across Maternal Methadone Dose During Pregnancy. Standard 
Deviations provided in Parentheses 
 
Food Type 
(Serves per wk) 
No Dose 
 
(n=42) 
Low Dose 
≤ 60mg/day 
(n=26) 
High Dose 
> 60mg/day 
(n=25) 
F df p 
Fruit 15.57 (8.58) 11.50 (9.40) 7.48 (3.83) 8.35 2 <.0001 
Vegetables 15.43 (7.42) 9.46 (8.97) 7.84 (5.57) 9.75 2 <.0001 
Meat 7.74 (4.95) 7.00 (3.10) 5.60 (2.22) 2.37 2 .100 
Bread 22.71 (15.04) 13.19 (6.76) 11.44 (7.24) 9.72 2 <.000 
Carbohydrates 9.31 (6.33) 7.31 (3.38) 8.24 (5.47) 1.12 2 .330 
Milk 13.67(12.91) 9.54 (8.45) 7.56 (5.49) 3.12 2 .049 
Eggs 2.76(3.15) 2.65 (2.98) 3.88 (2.95) 1.28 2 .284 
Total Servings 87.19 (27.98) 60.65 (25.96) 51.88 (15.32) 18.87 2 <.0001 
 
3.4.3 Maternal Health – Physical and Mental Health 
 
Maternal health was also considered in regards to infant development in utero. Health was 
considered in regards to both physical and mental well being. Physical health measures 
included, but were not limited, to items such as heart disease, asthma, diabetes and 
hepatitis. (A full listing of these is supplied in Appendix 4.) Maternal physical well being 
was calculated by taking a tally of how many of these factors featured in the history of 
each pregnant woman. Maternal mental health was taken as past or current history of 
diagnosed mental illness. Table 11 illustrates the differences between the two groups in 
regards to maternal health. Differences in physical health were established via a one way 
analysis of variance, while differences in mental health were analysed using a chi square 
test. Significant differences occurred across both measures of maternal health. Post hoc 
comparisons on the one way analysis of variance again revealed that these differences 
existed solely between those women enrolled in the methadone maintenance programme 
and the control women (and not between the low and high dose methadone groups). 
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 Table 11 
Associations Between Measure of Maternal Health and Maternal Methadone Dose During 
Pregnancy. Standard Deviations provided in Parentheses 
 
 
Maternal Health Measure 
No Dose 
 
(n=42) 
Low Dose 
≤ 60mg/day 
(n=26) 
High Dose 
> 60mg/day 
(n=25) 
F df p 
M Physical Health  0.48 (0.79) 1.50 (0.99) 1.88 (1.05) 21.74 2 <.0001 
Mental Health 19 58 48 13.22 4 .010 
NB. Information on the mental health of two control women was not obtained 
 
 
3.4.4 Analyses of Between Group and Dose Related Differences When Considering 
Related Maternal Lifestyle Factors 
 
In order to consider the influence of maternal lifestyle factors on the differences observed 
between the groups, as presented in the earlier analyses, a linear regression model was 
used. Several steps were involved in this process. Initially, a correlation matrix was run. 
The purpose of this matrix was twofold: one, to ensure that variables entered into the 
regression model were indeed correlated with the dependent variable being tested; and two, 
to examine any large overlaps between co-variate variables that would mean having both 
variables entered into the model would make them redundant. Only one large overlap of 
this type was found this overlap was between stimulant use during pregnancy and Ritalin 
use during pregnancy (0.63). Because this was the only large overlap all variables were 
utilised in model building, however, in cases where both these variables (i.e. stimulant and 
Ritalin use during pregnancy) were significant predictors, thought was given as to which 
provided the stronger contribution to the variance observed. 
 
Fitting of the linear regression model followed two steps. First, all acknowledged co-
variate factors were entered into the model and significant (p < .05) factors were identified. 
Second, a forwards and backwards variable elimination was used in order to identify a 
stable set of variables creating the most parsimonious model. 
 
 71 
The results of these analyses are presented in Table 12 through Table 15. Models were first 
run for methadone exposure alone (i.e. between methadone exposed and controls). These 
models are presented in Tables 12 and 13. Then run with consideration in regards to 
exposure related to maternal dose during pregnancy. These models are presented in Tables 
14 and 15.  
 
In brief, these models show that even when controlling for confounding variables, 
methadone exposure during pregnancy remained a significant predictor of a number of 
infant clinical and neurobehavioural characteristics. Namely, for the clinical characteristics 
these were birth weight, head circumference (across dose), days in hospital, Finnegan 
scores and neonatal abstinence treatment and for the neurobehavioural measures: NNNS 
Attention, NNNS Handling, NNNS Regulation, NNNS Non-optimal Reflexes, NNNS 
Stress/Abstinence, NNNS Arousal, NNNS Excitability and NNNS Hypertonicity. It should 
also be noted that in a number of cases (across both clinical and neurobehavioural 
characteristics) although methadone exposure did not reach significance (p < .05) it was 
close to or nearing significance as opposed to being a complete non-contributor to the 
model. For example, in the between group models for head circumference (p = .061) and 
NNNS Habituation (p = .056). 
 
Table 12 
Summary of Regression Analysis Considering the Association Between Methadone 
Exposure During Pregnancy, Covariate Factors and Infant Clinical Characteristics 
Clinical Measure B SE B p 
Birth Weight (g)  
R
2
 = .42, Model F (3,89 ) = 21.83, p < .0001 
   
Gestational age in weeks 131.98 24.51 <.0001 
Marijuana use during pregnancy -298.75 119.77 .014 
Methadone treatment during pregnancy 347.71 105.64 .001 
Birth Length (cm) 
R
2
 = .28, Model F (3,88 ) = 11.57, p < .0001 
   
Tobacco use during pregnancy -4.21 1.28 .001 
Stimulant use during pregnancy -5.92 1.33 <.0001 
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Methadone treatment during pregnancy -2.25 1.24 .073 
Head Circumference (cm) 
R
2
 = .30, Model F (3,88 ) = 12.84, p < .0001 
   
Gestational Age in weeks 0.32 0.09 <.0001 
Benzodiazepine use during pregnancy -1.24 0.49 .014 
Methadone treatment during pregnancy 0.69 0.36 .061 
Days in Hospital 
R
2
 = .43, Model F (2,89 ) = 33.41, p < .0001 
   
Stimulant use during pregnancy 8.69 3.12 .006 
Methadone treatment during pregnancy -13.73 3.35 <.0001 
Finnegan 
R
2
 = .88, Model F (2,88 ) = 319.91, p < .0001 
   
Opiate use during pregnancy -1.60 0.77 .039 
Methadone treatment during pregnancy -13.91 0.59 <.0001 
NAS Treatment 
R
2
 = .74, Model F (1,91 ) = 258.32, p < .0001 
   
Methadone treatment during pregnancy -0.86 0.05 <.0001 
 
 
Table 13 
Summary of Regression Analysis Considering the Association Between Methadone 
Exposure During Pregnancy, Covariate Factors and Infant Neurobehavioural 
Characteristics 
Neurobehavioural Measure B SE B p  
NNNS Habituation 
R
2
 = .33, Model F (2,41 ) = 9.87, p < .0001 
   
Benzodiazepine use during pregnancy -1.88 0.66 .007 
Methadone treatment during pregnancy 1.08 0.55 .056 
NNNS Attention  
R
2
 = .12, Model F (1,69 ) = 9.43, p = .003 
   
Methadone treatment during pregnancy 1.01 0.33 .003 
NNNS Handling    
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R
2
 = .13, Model F (2,78 ) = 5.97, p = .004 
Maternal psychological health 0.07 0.03 .011 
Methadone treatment during pregnancy -0.18 0.06 .005 
NNNS Quality of Movement 
R
2
 = .33, Model F (3,82 ) = 13.55, p < .0001 
   
Tobacco use during pregnancy -0.65 0.26 .014 
Maternal physical health -0.37 0.10 <.0001 
Methadone treatment during pregnancy 0.03 0.28 .926 
NNNS Regulation 
R
2
 = .40, Model F (3,83 ) = 18.78, p < .0001 
   
Gestational age in weeks 0.13 0.04 .003 
Ritalin during pregnancy -1.13 0.28 <.0001 
Methadone treatment during pregnancy 0.73 1.65 <.0001 
NNNS Non-optimal Reflexes 
R
2
 = .11, Model F (1,88 ) = 10.51, p = .002 
   
Methadone treatment during pregnancy -1.46 0.45 .002 
NNNS Stress/Abstinence 
R
2
 = .38, Model F (4,85 ) = 13.24, p < .0001 
   
Gestational age in weeks -0.01 <0.00 .029 
Ritalin use during pregnancy 0.06 0.03 .034 
Maternal physical health  0.02 0.01 .008 
Methadone treatment during pregnancy -0.05 0.02 .007 
NNNS Arousal 
R
2
 = .13, Model F (1,85 ) = 12.87, p = .001 
   
Methadone treatment during pregnancy -0.55 0.15 .001 
NNNS Excitability 
R
2
 = .27, Model F (3,86 ) = 9.87, p < .0001 
   
Gestational age in weeks -0.31 0.12 .014 
Maternal physical health 0.66 0.26 .014 
Methadone treatment during pregnancy -1.16 0.58 .047 
NNNS Hypertonicity 
R
2
 = .17, Model F (2,85 ) = 8.62, p < .0001 
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Ritalin use during pregnancy -0.38 0.14 .017 
Methadone treatment during pregnancy 0.58 0.24 .009 
 
Table 14 
Summary of Regression Analysis Considering the Association Between Methadone 
Exposure in Regards to Maternal Dose During Pregnancy, Covariate Factors and Infant 
Clinical Characteristics 
Clinical Measure B SE B p  
Birth Weight (g)  
R
2
 = .45, Model F (3,89 ) = 23.95, p < .0001 
   
Gestational age in weeks 125.82 24.16 <.0001 
Marijuana use during pregnancy -310.47 113.52 .008 
Methadone treatment during pregnancy -233.87 60.49 <.0001 
Birth Length (cm) 
R
2
 = .26, Model F (3,88 ) = 10.10, p < .0001 
   
Tobacco use during pregnancy -2.68 1.16 .024 
Stimulant use during pregnancy -5.47 1.35 <.0001 
Methadone treatment during pregnancy 0.07 0.69 .915 
Head Circumference (cm) 
R
2
 = .32, Model F (3,88 ) = 13.70, p < .0001 
   
Gestational Age in weeks 0.31 0.09 .001 
Stimulant use during pregnancy -1.26 0.51 .016 
Methadone treatment during pregnancy -0.60 0.20 .004 
Days in Hospital 
R
2
 = .44, Model F (2,89 ) = 34.93, p < .0001 
   
Stimulant use during pregnancy 9.50 3.04 .002 
Methadone treatment during pregnancy 8.36 1.24 <.0001 
Finnegan 
R
2
 = .79, Model F (2,88 ) = 166.56, p < .0001 
   
Tobacco use during pregnancy 3.82 0.91 <.0001 
Methadone treatment during pregnancy 6.23 0.52 <.0001 
NAS Treatment    
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R
2
 = .74, Model F (3,89 ) = 85.59, p < .0001 
Tobacco use during pregnancy 0.18 0.07 .014 
Ritalin use during pregnancy 0.25 0.09 .008 
Methadone treatment during pregnancy 0.43 0.04 <.0001 
 
 
Table 15 
Summary of Regression Analysis Considering the Association Between Methadone 
Exposure in Regards to Maternal Dose During Pregnancy, Covariate Factors and Infant 
Neurobehavioural Characteristics. 
Neurobehavioural Measure B SE B p  
NNNS Habituation 
R
2
 = .30, Model F (2,41 ) = 8.74, p = .001 
   
Benzodiazepine use during pregnancy -1.92 0.70 .009 
Methadone treatment during pregnancy -0.48 0.32 .145 
NNNS Attention  
R
2
 = .16, Model F (2,68 ) = 6.60, p = .002 
   
Ritalin use during pregnancy -1.15 0.52 .030 
Methadone treatment during pregnancy -0.52 0.21 .013 
NNNS Handling 
R
2
 = .11, Model F (2,78 ) = 4.82, p = .011 
   
Maternal psychological health 0.06 0.03 .017 
Methadone treatment during pregnancy 0.09 0.04 .016 
NNNS Quality of Movement 
R
2
 = .34, Model F (3,82 ) = 13.98, p < .0001 
   
Tobacco use during pregnancy -0.55 0.23 .021 
Maternal physical health -0.37 0.10 .001 
Methadone treatment during pregnancy -0.14 0.15 .353 
NNNS Regulation 
R
2
 = .39, Model F (3,83 ) = 17.45, p < .0001 
   
Gestational age in weeks 0.12 0.04 .007 
Ritalin during pregnancy -1.30 0.28 <.0001 
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Methadone treatment during pregnancy -0.39 0.10 <.0001 
NNNS Non-optimal Reflexes 
R
2
 = .17, Model F (1,88 ) = 18.22, p < .0001 
   
Methadone treatment during pregnancy 1.01 0.26 <.0001 
NNNS Stress/Abstinence 
R
2
 = .37, Model F (4,85 ) = 12.32, p < .0001 
   
Gestational age in weeks -0.01 <0.00 .041 
Ritalin use during pregnancy 0.07 0.03 .013 
Maternal physical health  0.02 0.01 .006 
Methadone treatment during pregnancy 0.03 0.01 .027 
NNNS Arousal 
R
2
 = .23, Model F (3,83 ) = 8.31, p < .0001 
   
Gestational age in weeks -0.09 0.04 .020 
Ritalin use during pregnancy 0.51 0.24 .037 
Methadone treatment during pregnancy 0.28 0.09 .002 
NNNS Excitability 
R
2
 = .28, Model F (3,86 ) = 11.19, p < .0001 
   
Gestational age in weeks -0.28 0.12 .024 
Maternal physical health 0.59 0.26 .026 
Methadone treatment during pregnancy 0.84 0.34 .016 
NNNS Hypertonicity 
R
2
 = .22, Model F (2,85 ) = 12.05, p < .0001 
   
Ritalin use during pregnancy 0.63 0.16 .006 
Methadone treatment during pregnancy 0.29 0.09 <.0001 
 
 
In order to help understand what these models represent in terms definable differences in 
infant characteristics adjusted means were calculated using the models constructed. Table 
16 to Table 19 display these adjusted means. These means provide an illustration of what 
would be expected if all infants had been exposed to similar levels of the confounding 
variables. That is, they offer a representation of the differences that would be expected 
from the influence of methadone exposure alone (as if other factors known to influence 
these measures were held constant). 
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Mean birth weight (p = .001), Finnegan scores (p < .0001) and days in hospital (p < .0001) 
remained significantly different between the two groups. Differences between the head 
circumferences of the two groups was no longer significantly different (p = .061) and as 
was mean difference in birth length (p = .073). The majority of NNNS summary measures 
remained significantly different between the two groups (p < .05) with the exceptions 
being Quality of Movement (p = .926) and Habituation (p = .056).     
 
When means were calculated across all three dose measures it becomes easier to see what 
exposure to methadone might mean for these infants. On the whole similar results were 
obtained but with differences becoming more clearly pronounced. Of note is the clinical 
characteristic of head circumference. When the model is considered across dose rather than 
solely between exposure and non-exposure a significant difference between groups re-
appears (p = .004). Among the NNNS summary scores again a similar pattern of results 
occurred as with the between group findings with clear linear trends apparent across the 
majority of the means. Only the NNNS summary scores of Quality of Movement (p = 
.353) and Habituation (p = .145) returned values that suggested there were no differences 
between the groups. 
 
Table 16 
Means of Infant Clinical Characteristics Adjusted for Confounding Variables 
 
Clinical Measure 
ME 
(n = 51) 
Control 
(n = 42) 
p  
M Birth Weight (g)  3,039.22 3,386.94 .001 
M Birth Length (cm)         51.74 49.49 .073 
M Head Circ. (cm) 33.83 34.52 .061 
M Days in Hospital 17.47 3.73 <.0001 
M > Finnegan 13.62 N/A <.0001 
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Table 17 
Means of Infant Neurobehavioural Scores on NNNS Assessment Adjusted for Confounding 
Variables  
 
Neurobehavioural Measure 
ME 
(n = 51) 
Control 
(n = 42) 
p 
M Habituation 6.21 7.29 .056 
M Attention 5.88 6.90 .003 
M Handling 0.32 0.14 .005 
M Quality of Movement 4.36 4.38 .926 
M Regulation 5.42 6.15 <.0001 
M Non-Optimal Reflexes 4.32 2.86 .002 
M Stress/Abstinence 0.17 0.12 .007 
M Arousal 4.39 3.84 .001 
M Excitability 3.79 2.63 .047 
M Hypertonicity 0.52 0.14 .009 
 
Table 18 
Means of Infant Clinical Characteristics Adjusted for Confounding Variables Across 
Maternal Dose Groupings 
 
Clinical Measure 
No Dose 
(n = 42) 
Low Dose 
(n = 26) 
High Dose 
(n = 25) 
p  
M Birth Weight (g)  3,386.82 3,152.95 2919.07 <.0001 
M Birth Length (cm)         50.68 50.75 50.82 .915 
M Head Circ. (cm) 34.64 34.04 33.43 .004 
M Days in Hospital 4.42 12.79 21.15 <.0001 
M > Finnegan N/A 8.52 14.76 <.0001 
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Table 19 
Means of Infant Neurobehavioural Scores on NNNS Assessment Adjusted for Confounding 
Variables Across Maternal Dose Groupings 
 
Neurobehavioural Measure  
No Dose 
(n = 42) 
Low Dose 
(n = 26) 
High Dose 
(n = 25) 
p 
M Habituation 7.10 6.62 6.12 .145 
M Attention 6.82 6.30 5.78 .013 
M Handling 0.17 0.26 0.36 .015 
M Quality of Movement 4.48 4.34 4.20 .353 
M Regulation 6.08 5.69 5.29 <.0001 
M Non-Optimal Reflexes 2.75 3.84 4.93 <.0001 
M Stress/Abstinence 0.12 0.15 0.17 .027 
M Arousal 3.90 4.18 4.46 .002 
M Excitability 2.56 3.40 4.24 .016 
M Hypertonicity 0.11 0.40 0.70 <.0001 
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Discussion 
 
 
 
4.1 Summary of Findings of the Current Research 
 
The current study examined five hypotheses in relation to infant clinical and 
neurobehavioural outcomes at term for infants exposed prenatally to methadone. 
 
Brief Summary of Findings Relating to Hypothesis One 
Methadone exposed infants were significantly lighter, had smaller head circumferences 
and spent longer in hospital than the non-exposed infants. 
 
Brief Summary of Findings Relating to Hypothesis Two 
Methadone exposed infants had significantly different profiles across the neurobehavioural 
measures of NNNS Regulation, NNNS Attention, NNNS Excitability, NNNS Arousal, 
NNNS Handling and NNNS Habituation. Descriptively, this manifested itself as a more 
volatile infant, who was easily aroused but difficult to maintain in a happy attentive alert 
state. Instead, the infant was often quick to cry and difficult to soothe. Frequently, these 
infants showed less motor maturity and displayed numerous signs that they were going 
through withdrawal.  
 
Brief Summary of Findings Relating to Hypothesis Three 
Acoustically these infants also often sounded quite different. Although statistically there 
was no difference in the pitch of the cries of the two groups, the infants exposed to 
methadone showed much greater variability in the cycle-to-cycle microfluctuations of cry. 
This can be heard in the harsh or rough sounding quality of these infants‟ cries.  
 
Brief Summary of Findings Relating to Hypothesis Four 
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When the data were analysed on the basis of maternal dose, infants in the group exposed to 
higher maternal doses during pregnancy fared less well than those exposed to lower 
maternal doses.  
 
Brief Summary of Findings Relating to Hypothesis Five 
Careful consideration of a large number of confounding variables showed that even after 
controlling for these variables prenatal exposure to methadone made a significant 
independent contribution to increasing both clinical and neurobehavioural risk.   
 
4.2 Detailed Consideration of the Current Study Findings Including Relevance and 
Links to Previous Research 
 
4.2.1 Clinical Outcomes Associated with Prenatal Methadone Exposure when 
Measured at Birth 
 
The majority of previous studies that have examined the effect at birth of prenatal exposure 
to methadone have taken measures of infants‟ clinical outcomes. This study made clinical 
findings similar to those reported in previous studies. Where there were differences, 
findings from the current study appeared less unfavourable than those of previous research.  
 
Consistent with much of the earlier research the current study found infants in the 
methadone exposed group had a mean gestational age just under 39 weeks which reflected 
a slightly shorter gestation when compared to the non-exposed comparison infants. As with 
previous studies this was not a statistically significant finding.  
 
The mean birth weight of the methadone exposed infants in the current study was slightly 
higher (approx 2,900 gm) than the means cited in previous literature (approx 2,700 gm). 
Despite this discrepancy there was still a statistically significant difference between the 
infants exposed to methadone and the non-methadone exposed infants in the current study 
who had a mean birth weight (approximately 3,400 gm), consistent with the national 
average.  
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Similar to previous studies, the current study found that infants exposed to methadone in 
utero had smaller head circumferences than their non-exposed comparisons. However, as 
with birth weight, the mean head circumference measurement of the current study (33.6 
cm) was slightly closer to that of the non-methadone exposed infants (34.8 cm) than the 
mean of head circumferences reported in previous studies (32.17 cm) (Chasnoff et al., 
1984; Choo et al., 2004; Hagopian et al., 1996; Lester et al., 2002).  
 
The current study examined infant birth length, a clinical measurement not considered in 
the majority of previous studies. Although differences in birth length between the two 
groups did not reach significance there may have been a trend towards smaller infants in 
the methadone exposed group.  
 
When considered in context of all confounding variables, the combination of birth 
measurements in the current study suggest that methadone exposed infants are at increased 
risk of being born symmetrically smaller than their non-methadone exposed counterparts. 
Previous research on non-drug exposed infants has found that symmetrically smaller 
infants are at an increased risk of developing social, behavioural, and learning difficulties 
(Davis, 2003; Hack & Fanaroff, 2000; Taylor et al., 2000). It is the finding of smaller head 
circumference (that differentiates asymmetrically from symmetrically smaller infants) that 
is especially worrying. This is because head circumference has been directly correlated 
with IQ (Rushton & Ankney, 1996). Furthermore, there has been recent evidence to 
suggest that restricted brain growth in utero may have long term effects that are not 
ameliorated by postnatal growth catch-up (Frisk, Amsel, & Whyte, cited in Wouldes & 
Woodward, submitted) 
 
After confounding variables were controlled for, the difference in birth weights became 
smaller but remained statistically significant, while the differences in head circumference 
measurements were no longer significant but the possibility of a trend remained. After 
confounding variables were controlled for, birth length was longer for those in the 
methadone exposed group than for those in the non-methadone exposed group. These 
findings suggest that confounding variables considerably attenuate the effects typically 
associated with prenatal methadone exposure in regards to the birth measurements of the 
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newborn. For birth length, the factors of maternal tobacco and stimulant use during 
pregnancy appeared to play a stronger role. For head circumference, gestational age and 
maternal benzodiazepine use during pregnancy were important. These findings are in 
contrast to those of Wouldes and Woodward (submitted), who continued to find strong 
support for the effects of prenatal methadone exposure across all birth measurements after 
controlling for maternal factors. It is difficult to explain the finding of longer birth length, 
in the methadone exposed infant either clinically or statistically.  
 
The mean for total days spent in hospital was not dissimilar from what has been previously 
reported. Although compared cautiously, due to the possibility of regulatory differences, 
the current finding of approximately 18 days is close to both older (mean of 15 days found 
by Blinick et al, 1973) and later studies (mean of 14 days found by McCarthy et al., 2005), 
and definitely within the range of what has been previously reported. Unlike the birth 
dimensions, adjusted estimates of duration of infant hospital stay were similar to those of 
Wouldes and Woodward (submitted) after controlling for confounding variables.  
 
The current study also reported findings within, but at the upper end of the previously cited 
ranges for NAS (which are between 48 and 95%). Unsurprisingly, infants exposed to 
methadone in utero displayed greater signs of stress and withdrawal in comparison to their 
control counterparts. This fits with the comments made by Rosen and Johnson (1993) that 
it is typical to continue to find traces of opiates in infant urine during the first three weeks 
of life. This indicates that these infants are likely to still be going through withdrawal. In 
accordance with this, almost ninety percent of infants in the current methadone exposed 
group required treatment for abstinence symptomatology. It is likely that this accounts for 
a substantial part of the reason that the average hospital stay for methadone exposed infants 
was approximately six times longer than that of those in the control group. 
 
Similarly, as is the case with most of the previous research, there were no differences in 
APGAR scores associated with prenatal methadone exposure. This consistent finding 
would indicate that APGAR scores are not a reliable means of differentiating infants 
exposed to methadone in utero. It also implies that for the most part, these infants are not 
in immediate need of medical attention as a result of prenatal methadone exposure. 
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4.2.2 Neurobehavioural Outcomes Associated with Prenatal Methadone Exposure 
When Measured at Birth 
 
4.2.2.1 Infant NNNS Assessment Outcomes  
 
Information gleaned from the NNNS assessment conducted around two weeks of age 
revealed similar behavioural profiles to earlier research (Bada et al., 2002; Chasnoff et al., 
1984; Lester et al., 2002). The majority of NNNS summary themes showed a significant 
difference between the two groups. Infants prenatally exposed to methadone were 
significantly less well regulated, less attentive, more aroused, and more excitable than their 
non-exposed counterparts. In addition they were more hypertonic, showed less motor 
maturity, required more assessor assistance to calm and displayed more stress and 
abstinence symptomatology. 
 
The current study is unique, to the author‟s knowledge, in the extent to which it examined 
the influence of confounding variables on neurobehavioural outcomes typically associated 
with prenatal methadone exposure. Even after control for confounding variables there were 
numerous significant differences between the NNNS profiles of the two groups. Most 
notable of these was the difference in infants‟ NNNS Regulation summary scores. 
Regulation is the most global of the NNNS summary scores and in essence reflects a 
combination of a number of the other summary scores. More definitively, it provides an 
indication of the infant‟s physiological and attentional activation, the infant‟s ability to 
control its own state of arousal in response to the external environment, and the external 
support required by the infant. The current results suggest that even after factoring out a 
large number of other variables that might influence the newborn‟s regulation capability, 
exposure to maternally ingested methadone while in utero plays a significant role in the 
newborn‟s ability to develop this skill. Learning to self regulate is an essential building 
block upon which a large number of later skills rely. Therefore, problems or delay in the 
area of self regulatory abilities may impact on routine development (Schuetze & Eiden, 
2006).  
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The NNNS summary scores of Attention, Arousal, and Handling, and, to a lesser extent, 
Excitability were also highly significantly different between the two groups, even after 
controlling for confounding variables. These reflect an infant less able to attend, quicker to 
cry and requiring more external support. The NNNS Attention and Arousal findings can be 
regarded as consistent with the orientation items of the NBAS.  The findings of the current 
study are therefore in concurrence with those of Chasnoff et al. (1986), who found 
significant differences in orientation, between 51 infants exposed to methadone in utero 
and 27 non-methadone exposed comparison infants. At two weeks old it is difficult to say 
whether this profile reflects a temperament trait or whether it is a transient observation. 
Research on a large sample of 394 infants by Sheinkopf et al. (2006) found some evidence 
of temperament stability over the first four months of life in cocaine exposed infants 
assessed using the NNNS measure. These researchers cautioned that there is likely to be 
“only a modest level of stability in early infant behaviour” (p. 34). Whichever may be the 
case, the combination of these characteristics presents the reality of a newborn that is more 
easily upset (NNNS Arousal), less able to soothe itself (NNNS Regulation), has difficulty 
attending (NNNS Attention) and requires greater carer input to soothe (NNNS Handling).  
 
Added to this, the methadone exposed infant is more likely to have increased muscle tone 
(NNNS Hypertonicity) and display NNNS Non-optimal reflexes. The later are both 
physiological as well as behavioural markers. Not only can they be used to help identify a 
vulnerable infant but also they imply further physiological difficulties that the infant must 
overcome in his or her fragile state. Another of the physiological summary themes, NNNS 
Quality of Movement, no longer remained a significant differentiating characteristic 
between the two groups when the role of confounding variables was considered, notably 
maternal tobacco use and maternal physical health. This suggests that other factors may be 
more responsible for any difference observed in these infants in regards to motor control 
such as smoothness of movements. 
 
4.2.2.2 Infant Cry Analysis Outcomes 
 
The mean F0 (fundamental frequency) of both the methadone exposed infants and the non-
methadone exposed comparison infants in the current study was approximately 500 Hertz. 
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This measurement falls within the range (425-600 Hz) expected of a healthy newborn child 
(Ostwald and Peltzman, 1974) and is similar to the F0 reported on relatively large sample 
sizes (n = 172) in more recent literature (Michelsson et al., 2002). According to a review of 
the literature, in which differentiation of different cry types are discussed, a F0 of around 
500 Hz is likely to represent good CNS arousal (Soltis, 2004) 
 
The finding of a similar F0 for both groups was contrary to what was hypothesized. Based 
on findings of previous research analysing cry characteristics of infants with CNS insults it 
was anticipated that the F0 of the methadone exposed group would be higher than that of 
the non-methadone exposed group. Two possibilities are offered in regards to the current 
finding. First, in concurrence with the study conducted by Huntington et al., (1990), who 
also failed to find a difference in F0, the lack of finding may be a result of small sample 
size. Second, the finding may be a logical extension of the physiological similarities 
between the two groups. That is, there was no significant difference between the two 
groups in regards to infant length. Logically, this birth measurement provides the best 
predictor of average larynx size. Specifically this is likely to indicate that the two groups 
had similar sized vocal folds and therefore produced the same F0. These two possibilities 
are not mutually exclusive. That is to say, if a larger sample size was to provide evidence 
of a difference in body length it may also reveal a difference in F0.  
 
The mean length of cry utterance in the current study was approximately 1.4 seconds and 
did not differ significantly between the two groups. This is similar to the mean reported in 
Michelsson et al., (2002) but slightly longer than a number of other means reported which 
are closer to one second (Soltis, 2004). Again, the lack of difference between the two 
groups could be a reflection of small sample size. However, given the definition used in 
the current study to qualify a cry utterance (i.e. over one second duration), it is also 
possible that the lack of difference in utterance duration between the two groups is an 
artefact of the definition used. A number of infants‟ cries from both groups were excluded 
for analysis because they did not reach the one second cut off criteria (evidence of this can 
be seen in the cry wave forms attached in Appendix 6). It may be warranted to investigate 
further the number of cry utterances in both groups omitted for definitional reasons.  
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Although the two groups did not differ in regard to mean F0 or utterance duration, the finer-
grained analysis of F0 jitter calculations identified clear group differences. This finding 
was consistent with the hypothesis that the methadone exposed infants‟ F0 would display 
higher rates of jitter than their control counterparts. Given that there were no significant 
differences between the two groups in regards to age at testing, mean F0 of the two groups 
or the types of cries elicited, this is likely to be a valid difference. This suggests that the 
CNS abnormalities affecting laryngeal behaviour are only apparent in the short term, and 
that these short term abnormalities are not revealed when measuring average F0. This is 
probably to be because jitter is a reflection of the microfluctuations of the system. These 
represent instability of neural control as opposed to elementary differences being observed 
via cry characteristics such as F0. In many respects this can be understood as a parallel to 
NNNS Regulation in that jitter can be understood as poor regulation of the infant‟s vocal 
system. This hypothesis fits with the suggestion posited by Grauel, Hock and Rothganger 
(1990) that jitter is a more sensitive measure than either F0 or utterance duration. However, 
as has been mentioned in previous jitter literature, though the sensitivity of jitter 
measurement may be higher than other cry characteristics, it has low specificity. The 
differences observed across the jitter measures in the current study may reflect CNS 
abnormalities related to factors other than prenatal methadone exposure. 
 
4.2.3 Infant Outcomes in Relation to Maternal Methadone Dose During Pregnancy 
When Measured at Birth. 
 
The current study adds weight to those studies that report that maternal methadone dose 
does matter. Examination of between group differences found consistent evidence of a 
negative linear relationship between maternal dose and infant outcomes. That is, the higher 
the maternal dose, the less favourable the infant outcome. This was true across all 
significant between group clinical measures and in all but NNNS Handling of the 
neurobehavioural measures. After controlling for the confounding variables of maternal 
drug use, maternal health and maternal nutrition, strong dose trends were still apparent. 
Birth length, NNNS Habituation and NNNS Quality of movement were the only 
measurements that did not reflect dose trends. 
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Some measures of outcome showed stronger relationships to maternal methadone dose 
than other measures. For example, within the neurobehavioural outcomes, the areas of 
NNNS Regulation, NNNS Non-optimal reflexes, NNNS Arousal and NNNS Hypertonicity 
appear to be more closely linked to maternal dose than the areas of NNNS Attention, 
NNNS Handling and counter-intuitively, NNNS Stress/Abstinence. Two possibilities are 
postulated to account for this. First, it is logical to consider that there are certain areas of 
the developing infant CNS that are more susceptible to methadone exposure than other 
areas. It may be the case that these are areas of the brain affected by the neurobehavioural 
outcomes that show the strongest dose response relationship. Alternatively, it may be that 
the associations between maternal methadone dose and certain neurobehavioural outcomes 
are moderated by the role of confounding variables. This suggestion has been raised, either 
explicitly or more tentatively, by several previous authors in consideration of clinical 
outcomes (Berghella et al., 2003; Choo et al., 2004; Lester et al., 2002). A variety of 
confounding variables that may play a moderating role have been suggested including 
maternal tobacco use, maternal benzodiazepine use and maternal alcohol consumption 
during pregnancy  
 
The outcome of infant head circumference is worth noting in more detail with reference to 
maternal methadone dose. Initial between group analyses, of methadone exposed and non-
methadone exposed infants, including dose related comparisons, demonstrated that those 
infants exposed to higher maternal doses had significantly smaller head circumferences. 
However, later analysis of methadone exposed and non-methadone exposed infants that 
included consideration of confounding variables attenuated these earlier findings to the 
point of negating significance. When examined across dose whilst giving consideration to 
confounding variables, significant returned.  
 
In summary, these findings suggest that infant head circumference is affected by prenatal 
methadone exposure and that higher levels of methadone exposure negatively influence 
head circumference. On the other hand, the findings also suggest that infant head 
circumference is a measure perhaps more closely linked to the confounding variables 
associated with maternal methadone dose than methadone itself. The current finding is in 
contrast to those of Hagopian et al., (1996) who found higher maternal methadone dose to 
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be associated with increased head circumference. They acknowledged that this finding may 
have been mediated by weight change during pregnancy. All maternal doses in the 
Hagopian et al., (1996) study were under 60 mg/day. This may relate to the finding above 
i.e. that infant head circumference is closely linked to confounding variables. In the case of 
the current discrepancy, it may be that dose effects on infant head circumference are 
mediated to an extent by maternal weight gain during pregnancy but become evident at 
higher doses. 
 
4.3 The at Risk Infant in Relation to Environmental Factors 
 
The findings of the current study also raise concerns about the non-optimal family 
environments into which many of these children are born. As discussed in the 
methodology, the mothers of these children are more likely to be less well educated, come 
from a lower socio-economic bracket, be involved in less committed relationships and be 
coping with higher rates of psychosocial difficulties, including mental health and physical 
health issues. This combination of factors will generally be associated with reduced access 
to support and other resources. Bearing in mind that women on the methadone programme 
are (for the most part) doing their best for their children and trying as hard as any mother 
would to provide the best environment possible for her child, the reality is that they 
continue to cope with the consequences of drug addiction, and a large minority are likely to 
be using illicit drugs. Even without the addition of an unsettled newborn this combination 
of factors implies higher rates of maternal stress. Previous research has found that higher 
rates of maternal stress are related to poorer behavioural outcomes during childhood 
(Goldberg et al., 1997, cited in Sheinkopf et al., 2006). These infants are born into a 
context that already poses high risk to them.  
 
The combination of an at risk infant in a high risk environment creates the potential for 
problems in mother infant attachment. Recent research on both drug exposed and non-
exposed infants has found that regardless of exposure status parental stress influences 
parents‟ perceptions of their infant‟s temperament with higher levels of parental stress 
suggesting inflated parental perceptions of difficult infant temperament (Sheinkopf et al., 
2006). Research on parental perception of infant cry has found that infant cries with rates 
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of higher dysphonation and fundamental frequency variation are perceived as more 
distressing, arousing and grating (Protopapas & Emis, 1997, cited in LaGasse et al., 2005). 
It has been postulated from an evolutionary perspective that acoustically difficult sounding 
cries may be more likely to trigger abuse or abuse fantasies in parents (Soltis, 2004). It is 
logical to consider the possibility that the attachment bond between a mother and her at 
risk child may be negatively affected by distorted parental perceptions. The importance of 
the early months of life informing the primary attachment bond (Bowlby, 1979) and the 
influence of this attachment bond on later attachments, personality development and 
vulnerability to adverse experiences (Bowlby, 1982) make this is an important 
consideration. 
 
4.4 Implications of the Current Findings 
 
The current study contributes to knowledge on substance abuse, paediatric psychology, 
neurobehavioural teratology, and neonatal paediatric research. The results obtained are 
particularly relevant to the Canterbury region of New Zealand, but they may be 
generalisable to pregnant women enrolled in methadone maintenance programmes 
elsewhere. The study provides information that can be used by health professionals 
working with newborns exposed to methadone in utero and may be useful for mothers of 
these infants. For example, it is important to reiterate that APGAR scores in no way 
indicated the vulnerabilities of these infants or indeed even differentiated them from their 
non-exposed counterparts. Another example concerns the findings of this study that 
maternal methadone doses over 60 mg/day during pregnancy may have a greater adverse 
effect on the developing foetus than doses lower than 60 mg/day. Although there is still 
controversy around such findings, pregnant women on methadone should at least be made 
aware of this possibility and how it may manifest itself in the newborn. Health 
professionals working with the newborn should bear this potential in mind when infants 
exposed to higher dose levels are born. On the other hand, this is not an argument for 
enforcing lower levels of methadone on women during pregnancy as that might increase 
the likelihood of withdrawal-related conditions in utero or heighten the likelihood of 
additional illicit drug use in order to self manage withdrawal. Both these eventualities are 
known to have detrimental effects on the developing foetus (Finnegan, 1991). 
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Previous sections of this discussion have highlighted potential risk factors pertaining to the 
child exposed in utero to methadone, environmental factors, and interactional effects. 
Some of these risk factors, in particular those pertaining to the child, are often subtle. 
Although this study has found evidence of differences, significant both clinically and 
statistically, between methadone exposed and non-methadone exposed infants, the small 
size of the differences and the comparatively large influence of confounding variables 
mean that the neurobehavioural measures used are not sensitive enough on their own to be 
considered clear predictors of these exposed infants‟ developmental outcomes. However, 
these particular neurobehavioural measures appear to have strong enough specificity to 
highlight that these are at risk infants who display a particular neurobehavioural profile in 
comparison to non-methadone exposed infants. Together the measures used go some way 
to provide a key to understanding the subtle behavioural differences that are likely to be 
exhibited by infants prenatally exposed to methadone, and they provide clues to the 
potential vulnerabilities consequent upon these differences.  
 
A further consideration is that the vulnerabilities of the newborn may not reflect the entire 
picture. Information from this study adds to the evidence from previous research that 
prenatal exposure to methadone affects the CNS of the growing infant. Difficulties may not 
materialize until later years, such as early school years or later teenage development. For 
example, it is known that one of the areas of the brain most sensitive to insult is the 
prefrontal cortex, an area responsible for higher level executive functioning. This area of 
the brain is one of the last to develop, yet it is one responsible for a number of important 
adult skills such as judgment and planning. Adults with drug addiction have been found to 
have cognitive deficits in areas that relate to higher level executive functioning (Breiter & 
Rosen, 1999, cited in Lester et al., 2002). Given the sensitivity of this area to insult, some 
neurobiological and neurobehavioural aspects of methadone exposure in utero may have a 
long latency period.  
 
From the author‟s discussions with pregnant women on the methadone programme 
revealed that many of them already feel very guilty about the effect their drug use may 
have had on their child in utero. This has implications for professionals working with these 
 92 
families. Removal of locus of control and social ostracism have both been reported to 
increase stress (Powis, Gossop, Bury, Payne, & Griffiths, 2000; Skinner, 1996) Therefore, 
recommendations to reduce the level of maternal stress and better the environment in 
which the child will be raised include empowerment and support of these women.  
 
With increasing knowledge there is more hope that appropriate proactive steps can be 
taken to limit or prevent potential deficits and difficulties.  
 
4.5 Strengths of the Current Study 
 
The strengths of the current study lie in its strong methodological approach and 
comprehensive consideration of confounding variables. First, the recruitment rate of 82% 
for women in the methadone maintenance group can be considered high for this 
population. Other authors have commented on the difficulty of recruitment in this area 
(Kumpfer, 1998). Frequently these families lead relatively chaotic, stressful lives and may 
either be difficult to track down or hesitant to consent to being involved with research. This 
high rate is a reflection of the recruitment effort and rapport built by the research nurse 
with the women on the methadone maintenance programme. In turn, the level of this 
rapport is likely to reflect a combination of the consistency of one primary recruiter, the 
personality of that recruiter and the confidentiality assurance offered by the research group.  
 
Second, the current study utilised a prospective, between groups approach. This differs 
from many earlier studies that have been retrospective (Berhella et al., 2003; Hagopian et 
al., 1996; McCarthy et al., 2005) or lacking in control groups (Choo et al., 2004; Kuschel 
et al., 2004; McCarthy et al., 2005). The use of a prospective approach also means a lesser 
likelihood of type I errors (a problem associated with retrospective designs).  
 
Third, because the study was conducted in a relatively small city, all women on the 
methadone maintenance programme had their treatment managed by the same group of 
people (the CADS Methadone In Pregnancy Clinic) and were required to give birth at the 
same hospital. This meant all records were comparable and consistent. Dose charts were 
easier to access, and any questions could be simply directed to the person or people 
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responsible. The chances of having a woman on the methadone maintenance programme 
give birth without the study group being contacted were greatly reduced.  
 
Fourth, the study had numerous procedural and measurement strengths. Data were 
collected by a few trained researchers who underwent inter-rater reliability checks 
regularly. The measures chosen for use were up-to-date and comprehensive. The neonatal 
neurobehavioural assessment measure chosen was modern and specifically designed for 
use with this population. The cry characteristics chosen were well rationalised, and the 
maternal interview gave an appropriately broad overview of confounding variables. 
Analyses were thorough and intensive. A large number of confounding variables that have 
previously been either overlooked or mentioned but not considered were factored into the 
current analyses.  
 
Finally, it may be said that the results presented in the current study are likely to 
underestimate rather than overestimate any neurobehavioural effects of methadone 
exposure in utero on the newborn. This assertion is based on two factors. First, as already 
mentioned, a number of the more vulnerable infants were not included in the current 
analyses, specifically, one methadone infant born prior to 33 weeks gestation and three 
methadone infants who were unable to be assessed using the NNNS examination. 
Similarly, a qualitative observation of the cry analysis showed that a total of 21 control 
infants‟ recordings were required whilst only 12 methadone exposed infants‟ recordings 
were required in order to obtain a sub-sample of ten infants‟ cries from each group that met 
criteria. Second, the relatively low sample sizes of the current study combined with the 
subtle differences being examined, would suggest that there is more risk of making a type 
II error (accepting the null hypothesis when there is in fact a difference) than a type I error 
(rejecting the null hypothesis when it is correct). 
 
 
 
4.6 Limitations of the Current Study. 
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There are several limitations to this study. Although considerable effort went into 
voluntary recruitment of the women on the methadone maintenance programme, 
recruitment rates of women in the control group were comparatively low and hindered by a 
number of complications. These complications included flaws in the hospital database 
which caused a large number of the early information mail outs to be sent to women who 
had already delivered their babies rather than those due for delivery. The use of a hospital 
database that is updated only intermittently meant that letters were posted out only to 
women who were due to deliver in the later months (at the end of the database), which 
provided a smaller number of women from whom randomly to select. It was found that a 
number of control women had concerns about consenting to participate in a study 
examining the effects of drugs on newborn infants and/or were concerned about putting 
their newborn infant through a magnetic resonance imaging (MRI) scan. Along with the 
typically busy household problems and stress of giving birth and looking after a newborn 
baby, there are two possible explanations for these concerns that are pertinent to the nature 
of this study. First, these women may not have understood what being a control entailed 
and may have been fearful that their own infant might be exposed to methadone in order to 
participate. Second, given the stigma attached to drug use (especially during pregnancy), 
control women may not have wanted to be involved with a study that was examining the 
effects of maternal drug use. To minimise this problem, future studies might make the role 
of a control mother and infant more explicit in the information mail out or provide 
incentives (e.g. remuneration or gifts) in order to encourage the women to sign up. Other 
suggestions include different recruitment techniques, such as advertising at antenatal 
classes. This has the disadvantage of changing recruitment away from the random 
approach commonly considered best practice in empirical research. Additionally, an 
analysis to gain a better understanding of women who do not agree to consent could be 
undertaken. This might take the form of a follow-up telephone call or the inclusion of a 
postage paid return envelope with a list of reasons included in the information mail out. 
 
Another problem relevant to any kind of human based research is the labour intensity and 
associated difficulty of co-ordinating schedules and keeping errors due to differences in 
time and place of assessments to a minimum. The current study was lucky to have a 
number of trained and paid researchers involved, for some, such as the research 
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coordinator, this was their primary employment. This is likely to have minimised this 
problem. Clarifying in the information mail out the importance of assessment timing and 
attendance might increase participant motivation.  
 
In issues involving social stigma and safety concerns such as maternal drug use during 
pregnancy, it is important to consider the validity of self report measures. New Zealand 
does not require mandatory reporting of maternal drug use, unlike the United States, where 
the majority of research in this area is undertaken utilising a “Certificate of 
Confidentiality”. As discussed in another New Zealand study (Wouldes and Woodward, 
submitted), absence of mandatory reporting may have decreased the chances that the 
women in this study have under-disclosed their drug use. Also, the consistent use of a 
single interviewer in order to develop rapport and a trusting relationship with the women 
enrolled in the methadone maintenance programme will have promoted openness. Given 
that the quantities of both licit and illicit drug use reported in the current study were similar 
to or higher than those reported in other studies (Lester et al., 2002), it is reasonable to 
believe that the findings are representative of actual drug use. Additional suggestions for 
further overcoming this difficulty include the use of meconium testing (which is being 
undertaken as part of the larger study) or the use of other chemical testing measures, for 
example, hair analysis.  
  
One of the major methodological shortcomings of the current study was the difficulty 
maintaining blind testing. Even though precautions were taken to ensure at least one of the 
NNNS assessors was blind to infant status, this was not always achieved. For the majority 
of the recruited participants the author of the study (also an NNNS assessor) was heavily 
involved in control recruitment, including maternal interviews. In addition, the second 
NNNS assessor was working as the neonatal physiotherapist at the hospital through which 
all the women were recruited. This meant that at times she was made aware of maternal 
status via the requirements of her other role. Lack of assessor blinding has been shown in 
previous research to limit severely the validity of results collected (Schulz & Grimes, 
2002). In defence of the current study, three points should be noted. First, the NNNS 
assessment follows a relatively strict quantitative scoring schedule (a copy of the scoring 
guide is available online at http://pediatrics.aappublications.org). Second, neither assessor 
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had knowledge of maternal dose or dose of any infant treatment. Third, randomly selected 
NNNS assessments of all assessors were cross checked for inter-rater reliability with the 
original trainer, who was blind to infant status. These three factors are likely to have 
reduced the amount of bias that the assessors may have unwittingly introduced due to lack 
of blinding. The issue of blindness needs to be further addressed in future studies.  
 
Another limitation that affects many studies of this kind is the relatively small sample size. 
Limitations of sample size are particularly evident in the dose-related summary scores of 
the NNNS assessment, in particular in the NNNS Habituation scores. Approximately half 
of the infants were not assessed on this measure due to the requirement that the infant be 
asleep for this to be administered. Sample sizes for the NNNS Habituation measure were 
17, 11, and 16 for the non-methadone exposed, lower maternal exposure group and higher 
maternal exposure groups respectively. Small sample sizes reduce the ability to detect 
significant between group differences due to a lack of power. This increases the probability 
of a type II error (accepting the null hypothesis when in actuality a difference does exist). 
Given the subtle nature of the differences being examined in the current study and the 
limited sample size, no adjustments were made for multiple comparisons. Lester et al. 
(2002) noted that this can be considered as a means of maximising sensitivity and 
minimising type II error. On the other hand, not adjusting for multiple comparisons 
increases the likelihood of type I error (rejecting the null hypothesis when it is true). A 
suggestion for future research is to use a larger sample size, perhaps in a multi-site study. 
Given the time limit imposed on the current research and the reasonable recruitment rates, 
the sample sizes provided should be considered acceptable. 
 
Despite the strength of the current study in considering a large and varied range of possible 
confounding variables and their influence on the findings, still more variables could have 
been considered. Two of the more important variables that have been shown to influence 
infant outcomes that could have been considered in further detail are maternal socio-
economic status (Luo, Wilkins, & Kramer, 2006) and prior pregnancy history (for 
example, parity). Although both are in some way considered indirectly, for example, 
nutritional intake has been correlated with socio-economic status (Shi, Lien, Kumar, 
Dalen, & Holmboe-Ottesen, 2004) and maternal health may be linked to prior pregnancy 
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history, both could have been considered more directly. Additionally, the analyses of the 
current study would have benefited from the consideration of interactional effects between 
confounding variables. This requires a more complex and intensive statistical analysis than 
was conducted in the current study. The difficulty, however, relates to the sample size 
required to undertake such a thorough analysis. The examination of the interactional 
effects of confounding variables would be an area recommended for future research. 
  
4.7 Suggestions and Directions for Future Research 
 
Some avenues of future research have already been suggested within the previous section, 
which discussed the limitations of the current study. The next section will focus on 
additional avenues for future research. 
 
As with almost any research in the area of human development, one of the most pressing 
areas for future research involves longitudinal follow-up, which is planned for the infants 
in the current study. It is envisaged that the follow-up will utilise comparable and 
developmentally considered and appropriate measures to reassess the progress of these 
children as they age. As discussed, many of these children are born into lower socio-
economic families and are often subject to pre-existing early risk factors. Follow-up needs 
to take into consideration the interplay between contextual factors and the effects of early 
exposure to methadone during pregnancy. Follow-up will also be useful in determining the 
predictive value of both the NNNS and jitter analysis in regards to the developmental 
outcome of these infants. Particular areas of interest for follow-up that have stemmed from 
the current research include the self-regulatory processes of these children and further 
examination of how these develop. An interesting adjunct would be to examine if these 
self-regulatory difficulties relate to later childhood difficulties in areas such as attention 
deficit, attachment, and emotional development. This subsequent research will be 
instrumental in clarifying what early intervention strategies may be required in future for 
the offspring of mothers using methadone. Ultimately, follow-up should be conducted on a 
regular basis through to adulthood or to a point where, after so many years, follow-up can 
no longer discern the influence of methadone exposure in utero on the developing child.  
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Another research avenue that would both benefit this population and provide useful 
knowledge in regards to the sensitivity and specificity of predictive measures would be to 
undertake a serial assessment study. For example, a combination of the NNNS assessment 
and cry analyses used in the current study could applied at birth, two weeks, four weeks, 
and six weeks. This type of research might help differentiate the effects of NAS from the 
influence of infant temperament. It would also provide a more detailed and comprehensive 
picture of how these infants‟ vulnerabilities change over the initial weeks of life when 
withdrawal is at its most severe. It may also provide insight into resilience patterns 
associated with factors such as gender. Last, multiple comparisons over a relatively short 
period of time might offer answers as to the most pervasive difficulties these infants face 
and how best to identify the infants at the highest risk. Correlations between the 
neurobehavioural measures could be utilised to examine predictive validity and 
discriminant analysis could be undertaken to identify the most efficient predictors of infant 
vulnerability.  
 
Methadone maintenance is used worldwide in the treatment of opiate addiction and 
therefore requires research across several countries and cultures. To examine the validity 
and improve the generalisablitiy of this research, it is recommended that future research is 
undertaken in multiple settings across a variety of cultures. To date, the majority of 
research in the area has been conducted in the United States, often with high percentages of 
African American women and their infants living in high density urban areas characterised 
by poverty (Choo et al., 2004; Hagopian et al., 1996; Householder et al., 1982; Lester et 
al., 2002)  
 
Given that the results of the current study reflect physiological differences (for example, 
hypertonicity, non-optimal reflexes, and higher percentages of vocal tract variability) as 
well as neurological (CNS) differences in infants prenatally exposed to methadone, future 
research should consider the use of biologically based measures to help establish 
physiological markers that may provide clues to the vulnerabilities faced by these infants. 
Suggested areas of research include examining cortisol levels and the activity of the 
hypothalamic-pituitary-adrenocortical (HPA) axis in these infants. This would have the 
two-fold advantage of seeking replication of the current findings and allowing more 
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refined quantification of these findings. Future research should attempt to address the 
questions: What do these physiological differences mean? Are these infants more 
biologically susceptible to stressors? Does early prenatal exposure make these infants 
biologically vulnerable to related substance addictions in later life? How can the risks be 
minimised? And, perhaps counter-intuitively, are there any advantages to be found for 
infants exposed prenatally to methadone? 
 
The current research suggests the value of qualitative research in the area. What are the 
values and beliefs of the parents of these infants? It was observed in the current study that 
many of the women in the methadone maintenance group felt very guilty about exposing 
their unborn child to methadone (on the basis of their own addiction). It was considered 
that a large number of potential control recruits were unclear of what “control” meant. 
Qualitative research into areas such as these and the dissemination of the findings may go a 
long way to reducing stereotypes. It could help reduce social stigma attached to treatment 
for addictions, and it may provide information useful for other disciplines involved in the 
area such as nurses and developmental therapists. Similarly, qualitative case studies on a 
number of the dyads in the current study could offer connections to real life examples. 
Doing such research can provide information about and insight into lifestyles of families 
affected by methadone and the stresses they face. Frequently these aspects are easily 
overlooked or dismissed in quantitative research.   
 
Finally, much of the information and many aspects of the methodology from the current 
study could be utilised in future research in other areas of prenatal teratogen exposure, for 
example, the rapidly growing area of methamphetamine exposure. 
 
4.8 Concluding Remarks 
 
The current study examined the effects of prenatal exposure to methadone on clinical and 
neurobehavioural outcomes of infants between 40 and 42 weeks gestation. To a large 
extent study hypotheses were confirmed, with results in general suggesting that methadone 
exposed infants tended to fare less well than their non-methadone exposed counterparts 
across a range of both clinical and neurobehavioural measures. This remained the case 
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even after controlling for a number of confounding variables. Furthermore, there was 
evidence to suggest that higher maternal methadone doses were associated with worse 
outcomes than lower doses. Current trends indicate average methadone maintenance dose 
while pregnant is rising. They also indicate that the number of women enrolled in 
methadone maintenance programmes and therefore the number of infants being born 
prenatally exposed to methadone is also rising. The current findings therefore have 
increasing social and economic implications.   
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Appendix 1: A tabular overview of a number of studies relevant to the area.  
  
Design Source 
of ME 
Group 
Comparison 
Group 
Maternal 
Dose 
Infant Age at 
Assessment 
Measures Clinical Findings Neuro 
behavioural 
Findings 
Acoustic Cry 
Findings 
Dose 
Response 
 
 
[1] Rosen & 
Johnson 
(1988)  
 
Pro- 
spective 
 
25 pregnant 
women from 
prenatal 
clinic  
 
1. 42 
multidrug 
users  
2. 44 
controls  
 
X = 52.mg/day 
(1
st
 trimester) 
49mg/day  
(2
nd
 trimester) 
 
Birth 
F/U = 2wks, 
2months, 4, 
6, 12 
months. 
 
 Clinical Data 
 Brazelton 
(NBAS) 
 Withdrawal 
 
 
M E infants 
worst. 
+ rates prem, -
BW, 
-HC, +SGA,  
+ withdrawal 
  
 
 
lower 
interaction 
scores on 
NBAS 
 
N/A 
 
N/A 
[2] Berghella, 
Lim, Hill, 
Cherpes, 
Chennat, 
&Kaltenbach 
(2003) 
Retro- 
spective 
100 mother 
/neonate 
pairs 
identified 
from hosp 
records 
None 
 
Post hoc 
multidrug 
versus only 
methadone 
Divided into 
low (<80 
mg/day, x=82) 
and high 
(>80mg/day, 
x=95) dose 
groups 
Every 8 hrs 
for first 72 
hrs of life 
 Neonatal 
Abstinence 
Score (NAS) 
No 
comparison 
avail. 
 
XBW = 
2,716grms 
 
(67% required 
treatment for 
NAS) 
N/A No sig dose 
relationship 
to BW, NAS 
or duration 
of treatment.  
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[3] McCarthy, 
Leamon, Parr 
& Anania 
(2005)  
Retro- 
spective 
81 mother 
/neonate 
pairs 
enrolled in 
MM 
treatment 
clinic. 
None Divided into 
low 
(<100mg/day, 
x=62) and 
high 
(>100mg/day, 
x=132) dose 
groups 
Birth 
Hospital 
stay 
 Limited 
Clinical Data 
 NAS 
(Finnegan? 
Doesn‟t say) 
 Treatment 
factors 
 
No 
comparison 
avail. 
 
X gestation at 
delivery = 37 
wks. 
 XBW = 
2,792grms 
No major 
abnormalities  
(46% required 
treatment for 
NAS) 
N/A No sig dose 
relationship 
in regards to 
clinical 
findings,  
treatment for 
neonatal 
abstinence 
or days in 
hosp. 
[4] Chasnoff, 
Schnoll, Burns 
& Burns 
(1984)  
Pro- 
spective 
39 mother 
/neonate 
pairs 
enrolled in 
Addiction 
Project 
placed on 
MM 
 
1. 1. 19 
mother/ 
2. neonate 
pairs 
addicted to 
multiple 
drugs 
 
2. 27 
mother/ 
neonate 
pairs no 
drug history 
 
X = 
14.6mg/day 
Trimester 
three  
(Range =  
5-40mg/day) 
Birth 
F/U = 3, 6, 
12 and 
24months 
  Clinical Data 
  Brazelton 
   (NBAS) 
  Bayleys for F/U 
 
M E infants 
worst. Sig 
-BW, -BL,      
-HC 
Sig diff state 
control, visual 
and auditory 
orientation and 
motor maturity 
N/A N/A 
[5] Sharpe & 
Kuschel 
(2003) 
Retro- 
spective 
24 MM 
from 
hospital 
database 
19 Mother‟s 
on 
Methadone 
for pain 
management 
X = 60mg/day 
MM group 
 
X = 40mg.day  
pain 
management 
group 
 
Birth 
Hospital 
Stay  
 Clinical Data 
 Finnegan 
 Treatment 
factors 
 Adverse 
Complication 
In comparison 
with Pain 
Management 
Infants:  
- rates prem 
- BW, -HC, 
+ treatment 
None taken N/A Possible 
dose 
response but 
unclear and 
unspecified. 
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[6] Lester, 
LeGasse, 
Siefer, 
Tronick, Baur, 
Shankaran, 
Bada, Wright, 
Smeriglio, Liu, 
Finnegan & 
Maza (2003) 
Pro-
spective
. 
4 Urban 
University 
Based 
Research 
Sites 
67 self-
reported 
opiate 
exposed 
women 
1. 360 self 
reported 
cocaine 
exposed 
women. 
2. 554 
comparison 
infants 
matched on 
race, sex and 
gestational 
age. (no 
cocaine or 
opiates) 
Self reported 
opiate 
exposure, 
confirmed by 
meconium 
assay 
One month  Limited 
Clinical data 
 Auditory 
Brain 
Response 
Procedure 
No sig diffs at 
one month 
Not discussed N/A “Longer 
latency to 
peak V and 
a longer III-
V interpeak 
latency” 
(p279) 
[7] Lester, 
LeGasse, 
Siefer, 
Tronick, Baur, 
Shankaran, 
Bada, Wright, 
Smeriglio, Liu, 
Finnegan & 
Maza (2002) 
Pro-
spective
. 
4 Urban 
University 
Based 
Research 
Sites 
91 self-
reported 
opiate 
exposed 
women 
1. 460 self 
reported 
cocaine 
exposed 
women. 
2. 1,120 
comparison 
infants 
matched on 
race, sex and 
gestational 
age. (no 
opiates) 
Self reported 
opiate 
exposure, 
confirmed by 
meconium 
assay 
One month 
(42-44wks 
gest age) 
 Clinical data 
 NNNS 
 Cry Analysis 
 
No sig diffs in 
gestational age 
No adjustment 
for covariants. 
Higher 
orientation 
scores and 
more stress 
abstinence 
signs. After 
adjustment for 
covariates no 
significant 
effects  
Fewer 
short 
utterances 
and more 
hyper-
phonation 
(high 
pitch). 
N/A 
[8] Blinick, 
Jezez & 
Walach (1973) 
Pro-
spective 
105 
consecutive 
pregnancies 
of women 
enrolled in 
MM 
treatment. 
None 80-100mg/day Birth 
Hospital 
stay 
F/U = Up to 
4 yrs 
 Limited 
Clinical Data 
 Withdrawal 
 Treatment 
factors 
-BW,  10% 
depressed 
APGAR 
scores, 
58% 
withdrawal 
signs 
(26% required 
treatment) 
N/A N/A 
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[9] Choo, 
Huetis, 
Schroeder, 
Shin & Jones 
(2004) 
Pro-
spective 
38 women 
recruited 
from a MM 
centre 
(divided into 
light and 
heavy 
smokers) 
None 
 
X = 77mg/day Birth 
 
 Clinical Data 
 Finnegan 
(NAS) every 4-
12hrs for first 
4days of life 
No diff in BW 
or HC across 
the two groups 
Withdrawal 
symptoms in 
the high 
smoking group 
were more 
severe, peaked 
later and lasted 
longer. 
N/A N/A 
[10] 
Fajemirokun-
Odudeyi,  
Sinha,  Tutty,  
Pairaudeau,  
Armstrong, 
Phillips, & 
Lindow (2005) 
Retro-
spective 
108 women 
(110 babies) 
52 women 
taking 
methadone 
alone 
47 women 
taking 
heroin (+/- 
methadone)  
None 
 
47 women 
taking 
heroin (+/- 
methadone) 
 
 
X = 32mg/day 
(at delivery) 
for MM only 
 
X = 33mg/day 
(at delivery) 
for heroin +/- 
methadone)    
Birth 
Hospital 
stay 
 Clinical data 
 Treatment 
factors 
 NAS 
(Finnegan? 
Doesn‟t say) 
No sig diffs in 
clinical data 
between two 
groups. 
Methadone 
only infants 
shorter 
neonatal stays, 
lower 
maximum 
NAS scores, 
lower dosages 
for treatment 
of NAS. 
N/A NA (similar 
methadone 
doses across 
the two 
groups) 
[11] Kuschel, 
Austerberry, 
Cornwell, 
Couch & 
Rowley (2004) 
Pro-
spective 
25 infants 
20 born to 
mothers 
from the 
ADAPT 
service 
(Akl) 5 via 
pain 
management  
None X = 55mg/day 
(range 15-105) 
Birth and 
48hrs 
 Clinical data 
 Finnegan 
(NAS) 
 Treatment 
factors 
 
No 
comparison 
avail. 
 
X gestation at 
delivery = 38 
wks. 
 XBW = 
2,995grms  
(48% required 
treatment) 
N/A Measured 
via 
umbilical 
cord blood. 
No 
significant 
relationship 
between 
maternal 
dose and 
need for 
treatment. 
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[12] Lejeune, 
Simmat-
Durand, 
Gourarier & 
Aubisson 
(2005) In Press 
 
 
 
Pro-
spective 
 
 
 
 100 women 
from 35 
perinatal 
centres of 
public 
hospitals. 
 
 
 
159 women 
on high-dose 
buprenophin
e (HDB) 
 
 
 
X = 57mg/day 
(10-180 
methadone) 
X = 5.4mg/day 
(0.4-24 HDB) 
 
 
 
Birth  
Hospital 
stay 
 
 
 
 Clinical data 
 Lipsitz (NAS) 
 Treatment 
factors 
 
 
 
No sig diffs in 
clinical data 
between two 
groups. 
MM 
XGestational 
age = 38.4 
XBW = 
2,790grms 
 
 
 
 
Mean age at 
maximum 
Lipsitz score 
higher for 
infants 
exposed to 
MM. (trend)  
 
 
 
N/A 
 
 
 
N/A 
[13]  
Hagopian, 
Wolfe, Sokol, 
Ager, 
Warddell, 
&Cepeda 
(1996) 
Retro-
spective 
172 opiate-
addicted 
women 
enrolled in 
MM 
programme 
in an urban 
hospital 
None X = 
0.19mg/kg/day 
(Clinic dose 
prior to 
delivery range 
10-60mg/day)  
Birth 
Hospital 
stay 
 Clinical data 
 Neonatal 
withdrawal 
(doesn‟t 
specify) 
 Treatment 
factors 
 
No 
comparison 
avail. 
 
X gestation at 
delivery = 38 
wks. 
 XBW = 
2,659grms  
(Percentages 
for neonatal 
withdrawal 
No withdrawal 
= 2% 
Mild = 12% 
Mod = 58% 
Severe = 30%) 
N/A Increased 
methadone 
dose 
associated 
with larger 
head 
circumferen
ce and 
growth but 
also more 
severe 
withdrawal. 
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[14] Rosen & 
Johnson 
(1985) 
Pro-
spective 
57 women 
on 
methadone 
maintenance 
(61 infants) 
32 
comparison 
infants 
X = 42 mg/day Birth 
F/U = up to 
36months 
the age 4, 5,  
6 and 7 yrs 
 Clinical data 
 Finnegan 
 Brazelton 
(NBAS) 
 Treatment 
factors 
 
+SGA,  -HC,  (75% mod-
severe 
withdrawal) 
Habituated 
less well, less 
responsive to 
orientation 
items, less 
alert, less 
cuddly, less 
consolable, 
increased tone 
and more 
tremulousness. 
 Dose 
correlated 
positively 
with severity 
of NAS and 
BW. 
 
 
[15]  Jeremy & 
Hans (1985) 
 
 
Pro-
spectve 
 
 
26 mothers 
(29 infants) 
recruited via 
obstetrical 
clinics. 
 
 
35 mothers 
(36 infants) 
recruited via 
obstetrical 
clinics at 
same 
hospital. 
 
 
X = 19.3 
mg/day 
(range 3-40) 
 
 
Birth 
1st week of 
life 
1 month 
 
 
 Clinical data 
 Neonatal 
Behavioural 
Assessment 
Scale with 
Kansas 
Supplements 
(NBAS-K) 
 
 
 
 
-BW (sig 
unspecified) 
 
NB. Infants 
less than 
2,500g and 
less than 
38wks 
gestation 
removed from 
analyses. 
 
 
No 
pharmacologic
al treatment 
for any of the 
group. 
At first test sig 
differences 
mainly related 
to motor 
functioning: 
more 
hypertonic, 
less motor 
maturity, more 
active, more 
tremulousness, 
more irritable.   
 
 
N/A 
 
 
No sig 
effects  
related to 
dosage 
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[16] Bada, 
Bauer, 
Shankaran, 
Lester, Wright, 
Das, Poole, 
Smeriglio, 
Finnegan, 
Maza (2002) 
 
Pro-
spective 
 
University 
Based 
Research 
Sites 
100 self-
reported 
opiate 
exposed 
women 
 
1. 7,442 non 
exposed 
infants 
2. 717 
cocaine 
exposed 
infants  
3. 92 
Cocaine and 
opiate 
exposed 
infants 
 
Self reported 
opiate 
exposure, 
confirmed by 
meconium 
assay 
 
Birth  
First 24-72 
hrs (X = 
36hrs) 
 
 Clinical data 
 CNS/ANS 
signs as 
described in 
Finnegan‟s 
Neonatal 
Abstinence 
Scoring 
System  
 
 
No sig diffs in 
BW and GA 
for the opiate 
exposed group 
in comparison 
to the non 
exposed 
infants.  
But sig -HC 
 
Opiate only 
exposed 
infants showed 
a number of 
CNS/ANS 
signs that were 
significantly 
higher than 
either cocaine 
or non-
exposed 
groups. 
Particularly 
jitteriness/ 
tremors and 
irritability 
 
N/A 
 
N/A 
 
 
 
[17] Sinha, 
Ohadike, 
Carrick, 
Pairaudeau, 
Armstrong & 
Lindow (2001) 
 
 
 
Retro- 
spective 
 
 
 
Hull 
Maternity 
Hospital (as 
reported in 
records via 
referral 
letter from 
GP or 
antenatal 
interview) 
 
 
 
22 women 
taking  
methadone 
only during 
third 
trimester (22 
infants) 
 
 
 
1. 19 women 
taking heroin 
during third 
trimester (19 
infants) 
2. 10 women 
who stopped 
using opiates 
during 
pregnancy (10 
infants) 
 
 
 
Birth  
Hospital 
stay 
 
 
 
 Clinical data 
 Neonatal 
withdrawal 
(via a 
“neonatal 
abstinence 
sheet”) 
 Treatment 
factors 
 
 
 
 
Significances 
not reported. 
XBW = 2868 
(M), 2754 (H) 
& 3008 (nil) 
X gestation at 
delivery =38.2 
(M), 36.5 (H), 
& 39 (nil) 
 
 
 
Methadone 
exposed 
infants sign 
shorter NAS 
duration and 
sig shorter 
stays in NICU 
when 
compared with 
heroin exposed 
infants 
 
 
 
N/A 
 
 
 
Higher 
doses 
associated 
with sig 
longer NAS 
duration and 
sig longer 
stays in 
NICU. 
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Key: 
- = lower  
+ = higher  
BW = birth weight 
Prem = prematurity 
HC = head circumference 
SGA = Small for gestational age 
MM = Methadone Maintenance 
N/A = Not applicable (analysis not undertaken) 
    Appendix 2: Golub and Corwin’s (1985) Physioacoustic Model of Infant Cry (p. 65)   
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                                                    Woman’s Health Division, Department of Paediatrics, Christchurch,  
    Canterbury Child Development Group, University of Canterbury,  
                                                              Psychological Medicine, Christchurch School of Medicine, NZ 
 
 
METHADONE IN PREGNANCY STUDY 
 
INFORMATION SHEET 
 
You are invited to participate with your baby in a study being carried out by Lianne 
Woodward, a Developmental Psychologist from the University of Canterbury, Carole 
Spencer, a Research Nurse from Christchurch Women‟s Hospital, and Jill McKie, a 
Neonatal Paediatrician from Christchurch Women‟s Hospital. 
 
WHAT IS THE STUDY? 
 
The purpose of the study is to learn more about the growth and development of babies 
born to mothers who received methadone during their pregnancy. At present we know 
that most of these babies develop quite normally, while a small group of babies may 
develop problems and not do so well. The kinds of difficulties that these children can 
sometimes experience include health, learning and behaviour problems.  
 
We would like to learn more about what causes some babies to develop problems and to 
find better ways of detecting babies with early difficulties. This information will help 
improve the treatment of mothers and their babies in the future. 
 
The study will involve two groups of babies and their mothers. These groups include: a 
group of babies born to mothers on methadone during their pregnancy and a group of 
babies born to mothers not on methadone during their pregnancy. 
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WHAT DOES THE STUDY INVOLVE? 
 
If you agree to take part, we will ask you some background questions about yourself, 
your pregnancy, and when and where you expect to deliver your baby. Then following 
the delivery of your baby we will visit you and your baby in hospital. This visit will 
consist of three parts. 
 
1.  The first part will involve a brief interview with you about your pregnancy and how 
the delivery went. This will take about 30-40 minutes. 
 
2.  The second part will consist of a detailed assessment of your baby. This assessment 
will consist of a detailed physical examination of your baby and an evaluation of 
your baby‟s ability to change their behaviour in response to different situations such 
as being unwrapped or cuddled. We will look for signs that your baby is healthy such 
as how well s/he can control their behaviour and feelings, communicate their needs 
by crying, and whether s/he shows any symptoms of withdrawal or neurological 
distress. This assessment will take about 1/2 hour.  
 
3.  In the third part of the study your baby will undergo a magnetic resonance image 
scan. The scanner will take pictures of your baby‟s brain using magnetic and 
radiowaves. No medications or x-rays will be used. Before the scan your baby will 
be fed in the usual way. He or she will then be laid down in a comfortable pillow in 
the scanner and monitored over the scan time. The scan will take approximately 1 
hour. During the scan we anticipate that your baby will sleep as normal after being 
fed. 
 
4.  Following our assessment of your baby, we will discuss this with you and you will 
have an opportunity to consider whether you would like your baby‟s results to be 
forwarded to your Paediatrician or GP. 
 
BENEFITS 
 
Participation in this study will in no way affect your hospital care. Following our 
assessment, you will be given a formal report of your baby‟s assessment and scan 
results, along with time to discuss the results. If you want, we can also arrange for these 
results to be sent to your baby‟s GP or paediatrician.  
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INCONVENIENCES OR HAZARDS WHICH MIGHT BE EXPECTED 
 
There are no known risks to magnetic resonance imaging. Such scans are routinely done 
in infants. Most infants will sleep or rest quietly during the study. If your baby wakes or 
becomes distressed for any reason, the study will be stopped. An additional appointment 
time will be offered to you if the scan must be stopped. Sedative medications will not be 
used.  
 
PARTICIPATION 
 
Your participation in this study is entirely voluntary, you do not have to take part if you 
do not wish. If you agree to take part in the study you are free to withdraw at any time 
without giving a reason and this will not affect your or your baby‟s future care. If you 
have any queries or concerns about your rights as a participant in this study you may 
wish to contact the Health and Disability Service Consumer Advocate on telephone 
(03) 377 7501 or 0800 377 766 outside Christchurch. 
 
 
 
 
COMPENSATION 
 
In the unlikely event of a physical injury as a result of your participation in this study, 
you may be covered by ACC under the Injury Prevention, Rehabilitation and 
Compensation Act. ACC cover is not automatic and your case will need to be assessed 
by ACC according to the provisions of the 2001 Injury Prevention Rehabilitation and 
Compensation Act. If your claim is accepted by ACC, you still might not get any 
compensation. This depends on a number of factors such as whether you are an earner 
or non-earner. ACC usually provides only partial reimbursement of costs ad expenses 
and there may be no lump sum compensation payable. There is no cover for mental 
injury unless it is a result of physical injury. If you have ACC cover, generally this will 
affect your right to sue the investigators. If you have any questions about ACC, contact 
your nearest ACC office or the investigator. 
 
CONFIDENTIALITY 
 
All information you give us will be treated in the strictest confidence. Your identity will 
not be revealed in any reports based on the study. No information will ever be released 
about you or your baby to a third party without your written consent. The study will 
have a comprehensive security system, with all information you provide being stored 
anonymously on computer files. Access to these files will be confined to study 
investigators. 
 
 
IF YOU WANT TO KNOW MORE 
 
If you want to know more about the study (either now or at a later date) please feel free 
to contact either: 
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Names Removed for Privacy Purposes 
 
We are committed to treating all our study participants in a fair and ethical manner. This 
study has received ethical approval from the Canterbury Ethics Committee. 
 
Finally, we would like to thank you for considering assisting us with this research. 
 
 
 
 
 
 
 
Lianne Woodward   Carole Spencer   Jill McKie 
   
Principal Investigator   Research Nurse   Co-Investigator
   
 
 
 
  
APPROVED BY THE CANTERBURY ETHICS COMMITTEE 
August, 2002 
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Woman’s Health Division, Department of Paediatrics, Christchurch, 
NZCanterbury Child Development Group, University of Canterbury, NZ 
Psychological Medicine, Christchurch School of Medicine, NZ 
 
  CODE 
NUMBER 
    
 
Initial Interview Contact Details 
 
Mother‟s Surname…………………………………  Given 
Names………………………………… 
Father‟s Surname…………………………………. Given 
Names………………………………… 
Child‟s Name………………………………………  Date of 
Birth………………………………… 
Address……………………………………………………………………………………
……………………………………………………………………………………………
…………………… 
……………………………………………………………………………………………
………… 
Phone……………………………………………………………………………………
…………. 
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Contact 1: 
Name:………………………………………………Relationship to 
child…………………………. 
Address……………………………………………………………………………………
……………………………………………………………………………………………
…………………… 
………………………………………………………Phone……………………………
………. 
 
 
 
Contact 2: 
Name:………………………………………………Relationship to 
child…………………………. 
Address……………………………………………………………………………………
……………………………………………………………………………………………
…………………… 
………………………………………………………Phone……………………………
……………. 
 
Contact 3: 
Name:………………………………………………Relationship to 
child…………………………. 
Address……………………………………………………………………………………
……………………………………………………………………………………………
……………… 
……………………………………………………………Phone 
………………………………. 
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Appendix 4: Complete Maternal Interview 
 
METHADONE IN PREGNANCY STUDY 
 
BACKGROUND INTERVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
CODE NUMBER    
 
 
STATUS CODE     
 
 
INTERVIEWER     
 
 Day Month Year 
DATE       
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SECTION A. RESPONDENT‟S BACKGROUND 
 
A.1 What is your expected date of delivery?  
 
           
 
  D D M M Y Y 
Col 18 
 
Mother 
 
A.2 How old were you on your last birthday?   
  Years    
 
A.3 Which of the following ethnic groups do you belong to or identify with?   
  Yes No  
 NZ Maori 1 2  
 NZ European 1 2  
 Other European (English, Dutch, Scottish, Australian, etc) 1 2  
 Samoan 1 2  
 Tongan 1 2  
 Niuean 1 2  
 Asian 1 2  
 Other Specify: _______________________________________ 1 2 
Col 28 
 
 
A.4 Which of the following best describes your educational qualifications? (circle one) 
 Left school between 13-16 years   1  
 Further secondary education  2  
 Secretarial or trade qualifications  3  
 Professional qualifications without a degree  4  
 University degree  5  
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 Other qualifications, specify: _______________________  6 
Col 29 
Partner Relations 
 
A.5 Are you currently living with a partner?   
  Yes, legally married 1  
  Yes, cohabiting 2  
  Has partner, not cohabiting 3  
  No partner 4  
 
A.6 If yes, is he the father of your new baby?   
  Yes 1  
  No 2  
  No partner 9 
Col 31 
 
IF NO PARTNER ENTER 9s IN A.7 – A.10 AND 
ASK B.1 
 
 
A.7 How old is your partner? Years    
 
 
A.8 Which of the following ethnic groups does your partner 
belong to or identify? 
 
Yes 
 
No 
 
NA 
 
 NZ Māori 1 2 9  
 NZ European 1 2 9  
 Other European (English, Dutch, Australian, etc) 1 2 9  
 Samoan 1 2 9  
 Tongan 1 2 9  
 Niuean 1 2 9  
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 Asian 1 2 9  
 Other, specify: _____________________________________ 1 2 9 
Col 41 
 
 
A.9 Which of the following best describes your partner‟s school/educational 
qualifications? 
  
  Left school between 13-16 years, no qualifications 1  
  School Certificate (>2 subjects) 2  
  Further secondary education, eg UE, HSC or Bursary 3  
  Secretarial or trade qualifications 4  
  Professional qualifications without a degree 5  
  University degree 6  
  Other qualifications, describe: ______________________________ 7  
  Don‟t know 8  
  NA (no partner) 9  
 
 
A.10 How long have you been in this relationship?    
  Months   
Col 44 
SECTION B. PARENTHOOD 
 
B.1 a)  Is this your first pregnancy?    
  Yes 1  
  No 2  
 
 
 b)  If yes, how many times have you been pregnant before?    
  Number  
Col 46 
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IF RESPONDENT HAS HAD OTHER PREGNANCIES, GIVE 
DETAILS BELOW. IF NO PREVIOUS PREGNANCY ENTER 9‟s IN 
RELEVANT ITEMS 
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 PREGNANCY 1:  Age became pregnant Years    
      
  Outcome of pregnancy Child kept by respondent 1  
   Child adopted 2  
   Pregnancy terminated 3  
   Miscarriage 4  
   Still birth 5  
  If other, specify: ____________ Currently pregnant 6  
  __________________________ Other 7  
   NA 9 Col 49 
 
 
 PREGNANCY 2:  Age became pregnant Years    
      
  Outcome of pregnancy Child kept by respondent 1  
   Child adopted 2  
   Pregnancy terminated 3  
   Miscarriage 4  
   Still birth 5  
  If other, specify: ____________ Currently pregnant 6  
  __________________________ Other 7  
   NA 9 
Col 52 
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 PREGNANCY 3:  Age became pregnant Years    
      
  Outcome of pregnancy Child kept by respondent 1  
   Child adopted 2  
   Pregnancy terminated 3  
   Miscarriage 4  
   Still birth 5  
  If other, specify: ____________ Currently pregnant 6  
  __________________________ Other 7  
   NA 9 Col 55 
 
 
 PREGNANCY 4:  Age became pregnant Years    
      
  Outcome of pregnancy Child kept by respondent 1  
   Child adopted 2  
   Pregnancy terminated 3  
   Miscarriage 4  
   Still birth 5  
  If other, specify: ____________ Currently pregnant 6  
  __________________________ Other 7  
   NA 9 
Col 58 
REC01 
 
 
IF MORE THAN 4 PREGNANCIES, ENTER 
DETAILS HERE   
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Biological Children 
 
B.2 a)  Total number of biological children    
  Number   
 
 b)  INTERVIEWER:  Complete the coding frame for all biological children of the 
respondent. 
 
  
Name of Child 
 
DOB 
Age 
(Years) 
 
Gender 
Legal 
Custody 
Physical 
Custody 
 
 1 (Eldest)          
 2          
 3          
 4          
 5 (Youngest)         
Col 60  
 
 
Coding:  Date of birth:  Code day, month, year. NA = 99. 
Child‟s age coded in whole years. NA = 99. 
Gender:  Female = 1; Male = 2; NA = 9. 
Legal custody:  Sole = 1; Shared = 2; None (ie, other parent has sole legal 
custody) = 3; NA = 9. 
Physical custody:  Sole = 1; Shared = 2; None (ie, no physical contact) = 3; 
NA = 9. 
 
 
 Record any additional information here: ____________________________________  
 _____________________________________________________________________  
 
 
B.3 Do all of these children have the same mother/father?    
  Yes 1  
  No 2 Col 61 
REC02 
 
 If no, please describe: ___________________________________________________  
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 _____________________________________________________________________  
Step or Non-biological Children  
 
B.4 Are you parenting or caring for any children who are not your own? 
(Include here all non-biological children) 
  
  Number   
 
 
B.5 Can you tell me the names and ages of each of these children?  Complete coding 
frame for non-biological children) 
 
  
Name of Child 
 
DOB 
Age 
(Years) 
 
Gender 
Relationship 
to child 
 
Custody 
 
 1 (Eldest)          
 2          
 3          
 4          
 5 (Youngest)         
Col 60 
 
 
Coding:  Date of birth:  Code day, month, year. NA = 99. 
Child‟s age coded in years, NA = 99. 
Gender:  Female = 1; Male =2; NA = 9. 
Relationship to child:  Adoptive parent = 1; Step/de facto step parent = 2; 
Family relation (eg, aunt/uncle) = 3; Foster parent = 4; Other = 5; NA = 9. 
Legal custody:  Yes = 1; No = 2; NA = 9. 
 
 
 
 Record any additional information here: ____________________________________  
 _____________________________________________________________________  
 _____________________________________________________________________  
 
 
B.6 Are any other people living with you at the moment?   
  Number   
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 Total number of people in the household?   
  Total number   
Col 64 
 
SECTION C. FAMILY FINANCES AND LIVING CONDITIONS 
 
Housing 
 
C.1 What kind of house are you living in at the moment?   
  Own house 1  
  Own flat 2  
  Rented house (private landlord) 3  
  Rented flat (private landlord) 4  
  State/council owned house 5  
  State/council owned flat 6  
  Single room or bedsit 7  
  Staying with other family members 8  
 Other, eg car, caravan, boat. Specify: _________________ 9  
 
C.2 How long have you lived here? Months    
 
C.3 How many places have you lived in the past 3 years? Number   
Col 69 
 
 
Family Finances 
 
C.4 Are you working (in paid employment) at the moment?    
 (If on maternity leave please note employment details)  Yes 1  
  No 2  
 
 
  137 
C.5 If yes, specify:   
 a) Occupation: ______________________________________________  
 b)  Industry: ________________________________________________  
 
 
 
c)  How many hours per week do you work? 
     If no work enter 00. 
Hours   
Col 72 
 
 
 d)  How much do you receive each week after 
tax?  (If not working enter 0‟s) 
Amount     Col 76 
REC03 
 
 
C.6 Are you in receipt of any of the following Social Welfare benefits? Yes No  
 Domestic Purposes Benefit 1 2  
 Unemployment Benefit / Community Wage 1 2  
 Sickness/Invalid‟s Benefit 1 2  
 Other Social Welfare Benefit. Specify: 1 2  
 
 
C.7 How much do you receive in benefit payments per week?    
  Amount     
 
 
C.8 Do you receive any Family Assistance payments (that are not already included 
above)? 
  
  
Amount/week     
 
 
C.9 Do you receive income from any other source, eg donations from parents, 
investment income, etc 
  
  Amount/week    
Col 17 
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IF NO COHABITING PARTNER ENTER 9‟s IN C.10 – C.15 
 
 
C.10 Is your partner working (in paid employment) at the moment?    
  Yes 1  
  No 2  
  NA 9 
Col 18 
 
 
C.11 If yes, specify:   
 a) Occupation: ______________________________________________  
 b)  Industry: ________________________________________________  
 
 
 c) How many hours per week does s/he work? Hours    
 
 
 d)  How much does s/he receive each week after tax?  (If not working enter 0‟s)    
  Amount     
Col 24 
 
 
C.12 Is your partner in receipt of any of the following Social 
Welfare benefits? 
 
Yes 
 
No 
 
NA 
 
 Domestic Purposes Benefit 1 2 9  
 Unemployment Benefit / Community Wage 1 2 9  
 Sickness/Invalid‟s Benefit 1 2 9  
 Other Social Welfare Benefit. Specify: 1 2 9 
Col 28 
 
C.13 How much does your partner receive in benefit payments per week?   
  Amount     
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C.14 Does your partner receive any Family Assistance payments (that are not 
already included above)? 
  
  
Amount/week     
 
C.15 Does s/he receive income from any other source, eg donations from parents, 
investment income, etc 
  
  
Amount/week    
Col 37 
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SECTION D. PREGNANCY 
 
D.1 How many weeks pregnant are you at the moment?   
  GA    
 
 
D.2 Were you trying to get pregnant?     
  Yes 1  
  Unsure 2  
  No 3 
Col 40 
 
 
D.3 What was your reaction when you first heard you were pregnant?   
  Delighted/very happy 1  
  Happy 2  
  Indifferent 3  
  Upset 4  
  Very upset 5  
 
 
D.4 What was your partner‟s reaction when you told him you were pregnant?   
  Delighted/very happy 1  
  Happy 2  
  Indifferent 3  
  Upset 4  
  Very upset 5  
  No partner 9 
Col 42 
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D.5 When did you first consult a doctor concerning your pregnancy?   
  Record weeks of pregnancy    
 
 
D.6 So far during your pregnancy, have you experienced any of the following 
problems or illnesses? 
  
 a)  Vaginal bleeding 0-3 months Yes 1  
   No 2  
      
  4-6 months Yes 1  
   No 2  
      
  7-9 months Yes 1  
   No 2  
   NA 9 
Col 47 
 
 b)  High blood pressure 0-3 months Yes 1  
   No 2  
   NA 9  
      
  4-6 months Yes 1  
   No 2  
   NA 9  
      
  7-9 months Yes 1  
   No 2  
   NA 9 
Col 50 
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 c) Psychiatric or emotional problems treated by a 
doctor eg depression 
0-3 months Yes 1  
 Specify: ________________________________  No 2  
      
  4-6 months Yes 1  
   No 2  
      
  7-9 months Yes 1  
   No 2  
   NA 9 
Col 53 
 
 
D.7 Who have you been seeing for antenatal care?   
 a)  Family doctor or GP  Yes 1  
   No 2  
      
 b)  Private specialist/Obstetrician  Yes 1  
   No 2  
      
 c)  Hospital clinic  Yes 1  
   No 2  
      
 d)  Midwife  Yes 1  
   No 2 
Col 57 
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Pregnancy Nutrition 
 
D.8 On average how many servings of the following would you have eaten per 
week during your pregnancy 
  
  Number  
 
a)  Fruit including fresh, frozen, canned, stewed 
(1 serving = 1 apple or 2 small apricots) 
   
 
  Number  
 
b)  Vegetables including fresh, frozen, canned 
(1 serving = 1 potato, ½ cup cooked vegetables, 1 cup salad greens) 
   
 
  Number  
 c)  Meat including beef, lamb, chicken, fish, shellfish    
 
  Number  
 d)  Bread or toast slices (number of slices)    
 
  Number  
 
e)  Pasta, rice, muesli, cereal 
(1 serving = 1 cup cooked rice/pasta/porridge/cornflakes or ½ cup 
   
 
muesli or 2 weetbix) 
  
 
  Number  
 f)  Milk (1 serving = 1 glass)    
 
  Number  
 g)  Eggs (1 serving = 1 egg)   
Col 71 
    REC 04 
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SECTION  E. DRUG USE DURING PREGNANCY 
 
 
E.1 Did you smoke cigarettes before or during your pregnancy?   
   No. of cigs 
per day 
 
  Before pregnancy    
  1
st
 3 months    
  2
nd
 3 months    
  3
rd
 3 months   
Col 12 
 
 
E.2 Did you smoke dope/cannabis before or during your pregnancy?   
   No. of 
joints per 
week 
 
  Before pregnancy    
  1
st
 3 months    
  2
nd
 3 months    
  3
rd
 3 months   
Col 20 
 
 
E.3 Did you drink alcohol before or during your pregnancy?   
   No. of 
drinks per 
week 
 
  Before pregnancy    
  1
st
 3 months    
  2
nd
 3 months    
  3
rd
 3 months   
Col 28 
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E.4 Did you use benzodiazepines before or during your pregnancy?   
   No. of times 
per  week 
 
  Before pregnancy    
  1
st
 3 months    
  2
nd
 3 months    
  3
rd
 3 months   
Col 36 
 
E.5 Did you use heroin or other opioids (excluding methadone) before or during 
your pregnancy? 
  
   No. of times 
per week 
 
  Before pregnancy    
  1
st
 3 months    
  2
nd
 3 months    
  3
rd
 3 months   
Col 44 
 
E.6 Did you use stimulants (eg amphetamines, speed, cocaine) before or during 
your pregnancy? 
  
     
  Before pregnancy    
  1
st
 3 months    
  2
nd
 3 months    
  3
rd
 3 months   
Col 52 
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SECTION F. MATERNAL WELLBEING 
(Edinburgh Postnatal Depression Scale, Cox et al., 1987) 
 
 
F.1 Right NOW Not at 
all 
Somewhat Moder
ately 
Very 
much 
 
 I feel calm 1 2 3 4  
 I am tense 1 2 3 4  
 I feel upset 1 2 3 4  
 I am relaxed 1 2 3 4  
 I feel confident 1 2 3 4  
 I am worried 1 2 3 4 Col 58 
 
 
F.2 During my PREGNANCY:  
Often 
 
Sometimes 
Hardly 
Ever 
 
Never 
 
 I was able to laugh and see the funny side of 
things 
 
1 
 
2 
 
3 
 
4 
 
 I looked forward with enjoyment to things 1 2 3 4  
 I blamed myself unnecessarily when things 
went wrong 
 
1 
 
2 
 
3 
 
4 
 
 I felt anxious or worried for no good reason 1 2 3 4  
 I felt scared or panicky for no very good 
reason 
 
1 
 
2 
 
3 
 
4 
 
 Things got on top of me 1 2 3 4  
 I was so unhappy that I had difficulty 
sleeping 
 
1 
 
2 
 
3 
 
4 
 
 I felt sad or miserable 1 2 3 4  
 I got so unhappy that I cried 1 2 3 4  
 I thought about harming myself 1 2 3 4 Col 68 
 
 
  147 
 
F.3 In the PAST TWO WEEKS:  
Often 
 
Sometimes 
Hardly 
Ever 
 
Never 
 
 I have been able to laugh and see the funny 
side of things 
 
1 
 
2 
 
3 
 
4 
 
 I have looked forward with enjoyment to 
things 
 
1 
 
2 
 
3 
 
4 
 
 I have blamed myself unnecessarily when 
things went wrong 
 
1 
 
2 
 
3 
 
4 
 
 I have been anxious or worried for no good 
reason 
 
1 
 
2 
 
3 
 
4 
 
 I have felt scared or panicky for no very 
good reason 
 
1 
 
2 
 
3 
 
4 
 
 Things have been getting on top of me 1 2 3 4  
 I have been so unhappy that I have had 
difficulty sleeping 
 
1 
 
2 
 
3 
 
4 
 
 I have felt sad or miserable 1 2 3 4  
 I have been so unhappy that I have been 
crying 
 
1 
 
2 
 
3 
 
4 
 
 The thought of harming myself has occurred 
to me. 
 
1 
 
2 
 
3 
 
4 Col 78 
      
REC 05 
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SECTION G. DRUG DEPENDENCE 
(DSM-IV questions from the Composite International Diagnostic Interview) 
 
Cigarettes 
 
G.1 Over the last 6 months have you smoked a cigarette or cigarettes?  If yes, how 
many cigarettes would you smoke per day? 
 
 
  Non-smoker 1  
  <1 per day 2  
  1-4 per day 3  
  5-9 per day 4  
  10-20 per day 5  
  21+ per day 6 Col 5 
IF RESPONDENT REPORTS SMOKING ASK G.2  
OTHERWISE ENDORSE THIS ITEM WITH 9‟s 
 
 
G.2 
 Doesn‟t 
Apply 
Applies 
Somewhat 
Def. 
Applies 
 
NA 
 
 If you can‟t get or have a cigarette do you 
feel tense, irritable, need a cigarette 
 
1 
 
2 
 
3 
 
9 
 
 Do you want a cigarette first thing in the 
morning 
 
1 
 
2 
 
3 
 
9 
 
 Do you have headaches or other physical 
symptoms when you can‟t get cigarettes 
 
1 
 
2 
 
3 
 
9 
 
 Have you more than once wanted to quit or 
cut down on smoking 
 
1 
 
2 
 
3 
 
9 
 
 Have you tried to quit or cut down on your 
smoking and found you couldn‟t 
 
1 
 
2 
 
3 
 
9 
 
 Can you go a day without having a 
cigarette 
 
1 
 
2 
 
3 
 
9 
 
 Do you think you are dependent on or 
addicted to cigarettes 
 
1 
 
2 
 
3 
 
9 
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 Have you often had periods of days when 
you smoked more than you intended 
 
1 
 
2 
 
3 
 
9 Col 13 
 Have you had to go outside of work or 
other places so that you could smoke 
 
1 
 
2 
 
3 
 
9 
 
 Have you increased the amount you smoke 
to get the same effect 
 
1 
 
2 
 
3 
 
9 
 
 Has smoking cigarettes ever caused a 
problem with your health 
 
1 
 
2 
 
3 
 
9 
 
 Have you ever been advised by a doctor to 
give up smoking because of your health 
 
1 
 
2 
 
3 
 
9 Col 17 
 
 
Alcohol 
 
G.3 Over the past month how often would you have drunk alcohol? 
 
 
  Never 1  
  Very occasionally (once or twice) 2  
  At least weekly 3  
  Almost every day 4 Col 18 
 
IF RESPONDENT HAS NEVER DRUNK ALCOHOL IN THE 
LAST MONTH ENTER 0‟s IN G.4 – G.5 
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G.4 On the last occasion you drank how much did you drink? 
INTERVIEWER:  Find out best „unit‟ eg glasses, 
etc in which to measure drinks and record for that 
unit. Enter 00 in other boxes 
  Number  
 Beer Glasses    
  Handles    
  Jugs    
  Standard bottles    
  Cans/stubbies   
 
  Flagons   
Col 30 
  Riggers    
 Low Alcohol Beer Glasses    
  Handles    
  Cans/stubbies    
 Spirits/Liqueurs Glasses    
  ½ Bottles    
  Bottles    
 Mixed Cocktails Glasses    
 Wine Glasses    
  Bottles    
 Wine Cooler Glasses   
 
  Bottles    
 Fortified Wine Glasses    
  Bottles    
  Flagons    
  151 
 Other, specify Glasses   Col 62 
 
 
G.5 What is the most you have drunk on any one occasion in the past month? Number  
 Beer Glasses    
  Handles    
  Jugs    
  Standard bottles    
  Cans/stubbies    
  Flagons    
  Riggers   Col 76 
     REC 06 
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 Low Alcohol Beer Glasses    
  Handles    
  Cans/stubbies    
 Spirits/Liqueurs Glasses    
  ½ Bottles    
  Bottles    
 Mixed Cocktails Glasses    
 Wine Glasses    
  Bottles    
 Wine Cooler Glasses    
  Bottles    
 Fortified Wine Glasses    
  Bottles    
  Flagons    
 Other, specify Glasses   Col 34 
 
 
Marijuana 
 
F.1 Have you ever used or tried smoking cannabis (marijuana, grass, dope 
etc)? 
  
 
  Yes 1  
  No 2 Col 35 
 
IF YES TO F.1 ASK F.2 - F.3  OTHERWISE 
ENDORSE THESE ITEMS WITH 9‟s AND ASK 
F.4 
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F.2 At the present time how often do you use cannabis? 
  
 
  Nearly every day 1  
  At least once a week 2  
  At least once a month 3  
  Less than once a month 4  
  Has only used once or twice 5  
  Not used cannabis 9 Col 36 
 
 
F.3 Over the last year has your use of cannabis resulted in any of the 
following 
 
Yes 
 
No 
 
NA 
 
 You being unable to work or meet other commitments because 
you were high 
 
1 
 
2 
 
9 
 
 Problems with your family 1 2 9  
 Problems with your friends 1 2 9  
 Problems with the Police 1 2 9  
 Problems with your husband/partner/boyfriend 1 2 9  
 Being in a situation where being high increased your chances of 
being hurt, having an accident 
 
1 
 
2 
 
9 
 
 You having a strong and irresistible desire to smoke cannabis 1 2 9  
 You wishing to stop or cut down on using cannabis but finding 
you couldn‟t 
 
1 
 
2 
 
9 
 
 Often using larger amounts of cannabis than you intended to 
when you started 
 
1 
 
2 
 
9 
 
 
 Using cannabis for longer than you intended to 1 2 9  
 Spending a great deal of time using cannabis or getting over its 
effects 
 
1 
 
2 
 
9 
 
 Having to use more to get the same effect 1 2 9  
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 Having withdrawal symptoms if you tried to stop or cut down on 
using cannabis (eg feeling sick, headaches etc) 
 
1 
 
2 
 
9 Col 49 
 Problems with your health 1 2 9  
 Psychological problems 1 2 9  
 Have you ever stolen goods or money in order to buy cannabis 1 2 9 
Col 52 
ASK ALL RESPONDENTS F.4 
 
 
F.4 Have you ever used or tried any of the following Yes No 
 Solvents - glue, petrol, etc 1 2  
 Sedatives – downers 1 2 
 
 Stimulants – uppers 1 2  
 Heroin/homebake 1 2  
 Morphine/MSTs 1 2 
 
 Cocaine 1 2 
 
 LSD, PCP, ecstasy 1 2  
 Other prescription medicine to get you high 1 2  
 Any other substance. Specify: 1 2 Col 61 
 
 IF RESPONDENT HAS USED ANY SUBSTANCE IN F.4 
ASK F.5  OTHERWISE ENDORSE THIS ITEM WITH 9 
 
F.5 At the present time (ie over the last month) how often do you use this 
drug (these drugs) 
  
 
  Nearly every day 1  
  At least once a week 2  
  At least once a month 3  
  Less than once a month 4  
  Has only used once or twice 5  
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  Not used drugs 9 Col 62 
SECTION  H. PERSONALITY 
 
Read each statement carefully, but don’t spend too much time deciding on the 
answer. 
 
Please answer every statement by circling either a T (true) or a F (false) after each 
question, even if you are not completely sure of the answer. 
 
Remember there are no right or wrong answers - just describe your own personal 
opinions and feelings. 
 
H.1 
 True False  
I often try new things just for fun and thrills, even if most people think 
it is a waste of time 
1 2  
I usually am confident that everything will go well even in situations 
that worry most people 
1 2  
I often feel that I am the victim of circumstances 1 2  
I can usually accept other people as they are, even when they are very 
different from me 
1 2  
I enjoy getting revenge on people who hurt me 1 2  
Often I feel that my life has little purpose or meaning 1 2  
I like to help find a solution to problems so that everyone comes out 
ahead 
1 2  
I could probably accomplish more than I do, but I don‟t see the point 
in pushing myself harder than is necessary to get by 
1 2  
I often feel tense and worried in unfamiliar situations, even when 
others feel there is little to worry about 
1 2  
I often do things based on how I feel at the moment without thinking 
about how they were done in the past 
1 2  
I usually do things my own way, rather than giving in to the wishes of 
other people 
1 2  
I generally don‟t like people who have different ideas from me 1 2  
I would do almost anything legal in order to become rich and famous, 
even if I would lose the trust of many old friends 
1 2  
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 True False  
I am much more reserved and controlled than most people 1 2  
I like to discuss my experiences and feelings openly with friends 
instead of keeping them to myself 
1 2 
Col 77 
REC 07 
I have less energy and get tired more quickly than most people 1 2  
I seldom feel free to choose what I want to do 1 2  
I often consider another person‟s feelings as much as my own 1 2  
I often avoid meeting strangers because I lack confidence with people 
I do not know 
1 2  
I like to please other people as much as I can 1 2  
I often wish that I was smarter than everyone else 1 2  
I am usually so determined that I continue to work long after other 
people have given up 
1 2  
I often wait for someone else to provide a solution to my problems 1 2  
I often spend money until I run out of cash or get into debt from using 
too much credit 
1 2  
Often I have unexpected flashes of insight or understanding while 
relaxing 
1 2  
I don‟t care very much whether other people like me or the way I do 
things 
1 2  
I usually try to get just what I want for myself because it is not 
possible to satisfy everyone anyway 
1 2  
I have no patience with people who don‟t accept my views 1 2  
I sometimes feel so connected to nature that everything seems to be 
part of one living organism 
1 2  
When I have to meet a group of strangers, I am more shy than most 
people 
1 2  
I am more sentimental than most people 1 2  
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 True False  
I seem to have a sixth sense that sometimes allows me to know what is 
going to happen 
1 2  
When someone hurts me in any way, I usually try to get even 1 2  
My attitudes are determined largely by influences outside my control 1 2 
Col 23 
I often wish I was stronger than everyone else 1 2  
I like to think about things for a long time before I make a decision 1 2  
I am more hard-working than most people 1 2  
I usually stay calm and secure in situations that most people would 
find physically dangerous 
1 2  
I do not think it is smart to help weak people who cannot help 
themselves 
1 2  
I cannot have any peace of mind if I treat other people unfairly, even if 
they are unfair to me 
1 2  
People will usually tell me how they feel 1 2  
Sometimes I have felt like I was part of something with no limits or 
boundaries in time or space 
1 2  
I sometimes feel a spiritual connection to other people that I cannot 
explain in words 
1 2  
I like it when people can do whatever they want without strict rules 
and regulations 
1 2  
I would probably stay relaxed and outgoing when meeting a group of 
strangers, even if I were told they are unfriendly 
1 2  
Usually I am more worried than most people that something might go 
wrong in the future 
1 2  
I usually think about all the facts in detail before I make a decision 1 2  
I often wish I had special powers like Superman 1 2  
Other people control me too much 1 2  
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 True False  
I like to share what I have learned with other people 1 2  
I am usually able to get other people to believe me, even when I know 
that what I am saying is exaggerated or untrue 
1 2  
Sometimes I have felt my life was being directed by a spiritual force 
greater than any human being 
1 2  
I have a reputation as someone who is very practical and does not act 
on emotion 
1 2 
Col 42 
I am strongly moved by sentimental appeals (like when asked to help 
crippled children) 
1 2  
 I usually push myself harder than most people do because I want to 
do as well as I possibly can 
1 2  
I have so many faults that I don‟t like myself very much 1 2  
I have too little time to look for long-term solutions for my problems 1 2  
I often cannot deal with problems because I just don‟t know what to 
do 
1 2  
I prefer spending money rather than saving it 1 2  
I can usually do a good job of stretching the truth to tell a funnier 
story or to play a joke on someone 
1 2  
If I am embarrassed or humiliated, I get over it very quickly 1 2  
It is extremely difficult for me to adjust to changes in my usual way of 
doing things because I get so tense, tired, or worried 
1 2  
I usually demand very good practical reasons before I am willing to 
change my old ways of doing things 
1 2  
I nearly always stay relaxed and carefree, even when nearly everyone 
else is fearful 
1 2  
I find sad songs and movies pretty boring 1 2  
Circumstances often force me to do things against my will 1 2  
I would rather be kind than get revenge when someone hurts me 1 2  
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 True False  
I often become so fascinated with what I‟m doing that I get lost in the 
moment--like I‟m detached from time and place 
1 2  
I do not think I have a real sense of purpose for my life 1 2  
I often feel tense and worried in unfamiliar situations, even when 
others feel there is no danger at all 
1 2  
I often follow my instincts, hunches, or intuition without thinking 
through all the details 
1 2  
Other people often think that I am too independent because I won‟t do 
what they want 
1 2 Col 61 
REC08 
I often feel a strong spiritual or emotional connection with all the 
people around me 
1 2  
I usually try to imagine myself in other people‟s shoes, so I can really 
understand them 
1 2  
Principles like fairness and honesty have little role in some aspects of 
my life 
1 2  
I am better at saving money than most people 1 2  
Even when most people feel it is not important, I often insist on things 
being done in a strict and orderly way 
1 2  
I feel very confident and sure of myself in almost all social situations 1 2  
My friends find it hard to know my feelings because I seldom tell 
them about my private thoughts 
1 2  
I like to imagine my enemies suffering 1 2  
I am more energetic and tire less quickly than most people 1 2  
I often stop what I am doing because I get worried, even when my 
friends tell me everything will go well 
1 2  
I often wish I was more powerful than everyone else 1 2  
Members of a team rarely get their fair share 1 2  
I don‟t go out of my way to please other people 1 2  
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 True False  
I am not shy with strangers at all 1 2  
I spend most of my time doing things that seem necessary but not 
really important to me 
1 2  
I don‟t think that religious or ethical principles about what is right and 
wrong should have much influence in business decisions 
1 2  
I often try to put aside my own judgments so that I can better 
understand what other people are experiencing 
1 2  
Many of my habits make it hard for me to accomplish worthwhile 
goals 
1 2  
I have made real personal sacrifices in order to make the world a 
better place--like trying to prevent war, poverty and injustice 
1 2 
Col 23 
I prefer to wait for someone else to take the lead in getting things done 1 2  
I usually respect the opinions of others 1 2  
My behaviour is strongly guided by certain goals that I have set for 
my life 
1 2  
It is usually foolish to promote the success of other people 1 2  
I usually like to stay cool and detached from other people 1 2  
I am more likely to cry at a sad movie than most people 1 2  
I recover more quickly than most people from minor illnesses or stress 1 2  
I often break rules and regulations when I think I can get away with it 1 2  
I need much more practice in developing good habits before I will be 
able to trust myself in many tempting situations 
1 2  
I wish other people didn‟t talk as much as they do 1 2  
Everyone should be treated with dignity and respect, even if they seem 
to be unimportant or bad 
1 2  
I like to make quick decisions so I can get on with what has to be done 1 2  
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 True False  
I am usually confident that I can easily do things that most people 
would consider dangerous (such as driving an automobile fast on a 
wet or icy road)  
1 2  
I like to explore new ways to do things 1 2  
I enjoy saving money more than spending it on entertainment or thrills 1 2  
I have had personal experiences in which I felt in contact with a divine 
and wonderful spiritual power 
1 2  
I have had moments of great joy in which I suddenly had a clear, deep 
feeling of oneness with all that exists 
1 2  
Most people seem more resourceful than I am 1 2  
I often feel like I am a part of the spiritual force on which all life 
depends 
1 2 
Col 42 
 Even when I am with friends, I prefer not to open up very much 1 2  
I think my natural responses now are usually consistent with my 
principles and long-term goals 
1 2  
I believe that all life depends on some spiritual order or power that 
cannot be completely explained 
1 2  
Often when I look at an ordinary thing, something wonderful happens-
-I get the feeling that I am seeing it fresh for the first time 
1 2  
I usually feel tense and worried when I have to do something new and 
unfamiliar 
1 2  
I often push myself to the point of exhaustion or try to do more than I 
really can 
1 2  
My will power is too weak to overcome very strong temptations, even 
if I know I will suffer as a consequence 
1 2  
I hate to see anyone suffer 1 2  
If I am feeling upset, I usually feel better around friends than when 
left alone 
1 2  
I wish I were better looking than everyone else 1 2  
I love the blooming of flowers in the spring as much as seeing an old 
friend again 
1 2  
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 True False  
I usually look at a difficult situation as a challenge or opportunity 1 2  
People involved with me have to learn how to do things my way 1 2  
I usually feel much more confident and energetic than most people, 
even after minor illnesses or stress 
1 2  
When nothing new is happening, I usually start looking for something 
that is thrilling or exciting 
1 2 Col 57 
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Control Family Extra Information. 
1. Have you or your child‟s biological father ever suffered from any of the following 
illnesses?  Code 9 if not known 
 
  Note: For mother, code only if illness occurred prior to this 
pregnancy 
  
     
  Mother   
   Yes No 
  Epilepsy 1 2 
  Diabetes 1 2 
  Depression 1 2 
  High blood pressure 1 2 
  Thyroid trouble 1 2 
  Anaemia 1 2 
  Psychiatric or mental illness 1 2 
            
 Col 11 
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2.  Father   
   Yes No NA 
  Epilepsy 1 2 9 
  Diabetes 1 2 9 
  Depression 1 2 9 
  High blood pressure 1 2 9 
  Thyroid trouble 1 2 9 
  Anaemia 1 2 9 
  Psychiatric or mental illness 1 2 9 
           
 Col 18
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LIFE EVENTS 
3. In the last year, have any of the following events occurred to you?  
INTERVIEWER:  IF “YES” ASK “HOW UPSET OR 
DISTRESSED WERE YOU BY THIS?” 
 
 
 Very 
Upset 
 
Upset 
Mildly 
Upset 
Not 
Upset 
No 
Event 
 
 Moved house 5 4 3 2 9  
 Took out a mortgage 5 4 3 2 9  
 Built a home or had one built 5 4 3 2 9  
 Remodelled a home 5 4 3 2 9  
 Increased financial problems from taking 
on a mortgage or purchasing a business 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Partner became unemployed 5 4 3 2 9  
 Partner changed his job 5 4 3 2 9  
 Partner took a cut in wage or salary 
without a demotion 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Respondent started a new job 5 4 3 2 9  
 Respondent took a cut in wage or salary 
without a demotion 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Someone stayed on in the household after 
he/she was expected to leave 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Serious family argument other than with 
spouse 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Family member other than partner or 
child died 
 
5 
 
4 
 
3 
 
2 
9  
 Close friend died 5 4 3 2 9  
 Had serious or prolonged disagreements 
with parents/in-laws 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Serious financial problems 5 4 3 2 9  
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 Suffered a financial loss or loss of 
property not related to work 
 
5 
 
4 
 
3 
 
2 9 Col 35 
 Foreclosure of mortgage or loan 5 4 3 2 9  
 Became engaged 5 4 3 2 9  
 Married 5 4 3 2 9  
 Relations with partner changed for the 
worse without separation or divorce 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Serious or prolonged arguments with 
partner/ex-partner if separated within year 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Divorce 5 4 3 2 9  
 Separation from partner 5 4 3 2 9  
 Reconciliation with partner (after divorce 
or legal separation) 
 
5 
 
4 
 
3 
 
2 
9  
 Robbed 5 4 3 2 9  
 Legal problems 5 4 3 2 9  
 Partner involved in court case 5 4 3 2 9  
 Injury (respondent) 5 4 3 2 9  
 Unable to get treatment for an illness or 
injury (respondent) 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Serious illness or accident of partner 5 4 3 2 9  
 Serious illness or accident (study child) 5 4 3 2 9  
 Serious illness or accident of child (other 
than survey child) 
 
5 
 
4 
 
3 
 
2 
 
9 
 
 Serious illness (other family members) 5 4 3 2 9  
 Miscarriage or still-birth 5 4 3 2 9  
 Pet died 5 4 3 2 9 Col 54 
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F.2 In the last year, have any other events occurred which have upset you or caused you 
distress?  Describe up to three such incidents and degree of distress caused. 
 
 Event 1:  _________________________________________ Very upset 5  
 _________________________________________________ Upset 4  
 _________________________________________________ Mildly upset 3  
 _________________________________________________ No event 1  
 
 Event 2:  _________________________________________ Very upset 5  
 _________________________________________________ Upset 4  
 _________________________________________________ Mildly upset 3  
 _________________________________________________ No event 1  
 
 Event 3:  _________________________________________ Very upset 5  
 _________________________________________________ Upset 4  
 _________________________________________________ Mildly upset 3  
 _________________________________________________ No event 1 Col 57 
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Appendix 5: Neonatal Abstinence Scoring Sheet Used in the Current Study 
 
  168 
 
  169 
Appendix 6: Cry wav Forms of the 20 Infants Analysed 
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